Bifunctional inhibitors of CBP / p300 proteins and androgen receptor
Heterobifunctional small molecules targeting CBP/p300 and AR offer a solution to overcome treatment resistance in advanced prostate cancer by dual inhibition, effectively treating cancer through bifunctional inhibition.
Patent Information
- Application Number
- PCT/US2026/026762
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-12-26
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current cancer treatments targeting the androgen receptor (AR) become ineffective in advanced prostate cancer with AR gene amplification, mutation, and alternate splicing, necessitating a need for safe and efficacious compounds that can dual inhibit CBP/p300 and AR to treat cancer and other diseases.
Development of heterobifunctional small molecules represented by Formulae (I)-(VII) and their pharmaceutically acceptable salts and solvates, which act as bifunctional inhibitors of CBP/p300 and AR, administered in a pharmaceutical composition to treat conditions like cancer.
The bifunctional inhibitors effectively inhibit both CBP/p300 and AR, providing therapeutic benefits in treating cancer by disrupting their functions and reducing tumor growth.
Smart Images

Figure US2026026762_12112026_PF_FP_ABST
Abstract
Description
BIFUNCTIONAL INHIBITORS OF CBP / P300 PROTEINS AND ANDROGEN RECEPTOR BACKGROUNDCross-Reference to Related ApplicationsThis application claims priority to and the benefit of U. S. Provisional Patent Application No. 63 / 799,890, filed on May 5, 2025, and Application No. 63 / 948,974, filed on December 26, 2025, each of which is incorporated by reference in its entirety.Field
[0001] The present disclosure provides bifunctional inhibitors of CREB -binding protein (CBP) and p300 proteins (collectively referred to as CBP / p300 proteins) and androgen receptor (AR). Bifunctional inhibitors of CBP / p300 and AR are useful for treating diseases, disorders, or conditions, for example, cancer, when administered to a subject.Background
[0002] CBP / p300 proteins are transcriptional co-activators that integrate and maintain various gene regulatory pathways and protein acetylation events with intrinsic histone acetyltransferase (HAT) activity. CBP / p300 proteins are involved in cell differentiation, apoptosis, and the cell cycle. For example, CBP / p300 inactivation inhibits the growth of prostate cancer cells and melanoma cells, see, e.g., Santer et al., Mol Cancer Ther 10(9); 1644-1655 (2011), and induces apoptosis and cell cycle arrest in leukaemia cells. Gao et al., PLoS ONE 8(2): e55481. https: / / doi.org / 10.1371 / joumal.pone.0055481. CBP and p300 also interact with an oncoprotein ETS translocation variant 1 (ETV1), a distinctive transcription factor that is overexpressed in most prostate cancers. In addition, p300 directly acetylates ETV1 and thereby enhances its stability, DNA-binding capacity, and transcriptional activity in vitro. Recent studies have demonstrated that ETV1 is a specific survival factor that cooperates with KIT in GISTs, and ETV1 was highly upregulated within tumor tissues in conjunction with KIT expression. CBP / p300 may play a vital role in tumorigenesis and progression of GISTs by regulating the functions of ETV1 and KIT-dependent pathways, serving as promising targets for antineoplastic therapy. See, e.g., Gu et al., Oncology Reports 36:2163-2110 (2016).The androgen receptor (AR) and its downstream signaling play a critical role in the development and progression of both localized and metastatic prostate cancer.Previous strategies that successfully target AR signaling have focused on blocking androgen synthesis by drugs such as abiraterone and inhibition of AR function by AR antagonists such as enzalutamide and apalutamide (ARN-509). Watson et al., Nat Rev Cancer. 2015, 15, 701-711. However, such agents become ineffective in advanced prostate cancer with AR gene amplification, mutation, and alternate splicing. Baibas et al., Elife. 2013, 2, e00499; Lottrup et al., J Clin Endocrinol Metab. 2013, 98, 2223-2229. But in most patients with CRPC, the AR protein continues to be expressed and tumors are still dependent upon AR signaling. Consequently, AR is an attractive therapeutic target for metastatic castration-resistant prostate cancer (mCRPC), see, e.g., Zhu et al., Nat Commun. 2018, 9, 500; Munuganti et al., Chem Biol. 2014, 27, 1476- 1485, and other diseases. Student et al., European Journal of Pharmacology 866: 172783 (2020).
[0003] There exists a need in the art for safe and efficacious compounds to treat cancer and other diseases wherein dual inhibition of CBP / p300 and AR provides a benefit.BRIEF SUMMARY
[0004] In one aspect, the present disclosure provides heterobifunctional small molecules represented by Formulae (I)-(VII), below, and the pharmaceutically acceptable salts and solvates thereof, and compounds of Table 1, and the pharmaceutically acceptable salts and solvates thereof. These compounds, and the pharmaceutically acceptable salts and solvates thereof, are collectively referred to herein as " Compounds of the Disclosure" or individually as a " Compound of the Disclosure." Compounds of the Disclosure are bifunctional inhibitors of CBP / p300 and AR and thus are useful in treating a disease, disorder, or condition c.g., cancer, wherein dual inhibition of CBP / p300 and AR function provides a therapeutic benefit to a subject.
[0005] In another aspect, the present disclosure provides a pharmaceutical composition comprising a Compound of the Disclosure and one or more pharmaceutically acceptable excipients.
[0006] In another aspect, the present disclosure provides a method of treating a condition or disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject. Thedisease or condition treatable by dual inhibition of CBP / p300 and AR is, for example, cancer.
[0007] In another embodiment, the present disclosure provides a Compound of the Disclosure for use in treating cancer in a subject in need thereof.
[0008] In another aspect, the present disclosure provides compounds represented by Formula (VIII), and the pharmaceutically acceptable salts and solvates thereof. Compounds having Formula (VIII) are synthetic intermediates that can be used, for example, to prepare Compounds of the Disclosure.
[0009] In another aspect, the present disclosure provides compounds represented by Formula (IX), and the pharmaceutically acceptable salts and solvates thereof. Compounds having Formula (IX) are synthetic intermediates that can be used, for example, to prepare Compounds of the Disclosure
[0010] In another aspect, present disclosure provides kits for carrying out the methods of the present disclosure.
[0011] In another aspect, the present disclosure provides methods of preparing Compounds of the Disclosure.
[0012] In another aspect, the present disclosure provides ternary complexes comprising an androgen receptor, a Compound of the Disclosure, and a CBP / p300 protein.BRIEF DESCRIPTION OF THE FIGURES
[0013] FIG. 1 is a set of line graphs depicting dose-response curves and IC50 of Kelly cells (left), NCI-H211 cells (middle), or MFM223 cells (right) treated with DALTAC-1 (Cpd. No. 85), CBPD-409, or p300i+ARi (n=3 biologically replicated wells).
[0014] FIG. 2 is a bar graph depicting antiproliferative effects (IC50 values) of DALTAC- 1 across different human normal and cancer cell lines following 5 days of treatment.
[0015] FIG. 3 is a bar graph depicting antiproliferative effects (IC50 values) of CBPD- 409 across different human normal and cancer cell lines following 5 days of treatment.
[0016] FIG. 4 is a set of line graphs depicting growth curves of LNCaP cells (left) or VCaP cells (right) treated with 100 nM DALTAC-1, combined p300i + ARi, or CBPD- 409 under washout or continuous treatment conditions, monitored using Incucyte Live- Cell Analysis (data represent mean ± standard deviation (SD), n=6 biologically replicated wells; statistical significance was assessed using two-way ANOVA).
[0017] FIG. 5 is an immunoblot analysis for p300, CBP, AR, and BRD4, with Cpd. No.85 in a cellular thermal shift assay in VCaP cells (left) or LNCaP cells (bottom); and a line graph of relative expression of the indicated proteins in vehicle (dimethyl sulfoxide, DMSO) or VCaP cells treated with Cpd. No. 85 (right).
[0018] FIG. 6 is a schematic illustrating the workflow of the ternary complex ELISA (left); and dose-response curves showing Cpd. Nos. 85, Nl, and N2 induced formation of the AR / p300 ternary complex (right; data represent mean ± SD; n=4 biologically replicated wells).
[0019] FIG. 7 is a bar graph depicting the quantification of AR-p300 PLA foci per cell (n = 20 cells; P values were calculated using a two-sided t-test).
[0020] FIG. 8 is a bar graph showing the relative viability of indicated mouse organoids (derived from respective GEMM models) treated with DMSO, 100 nM Cpd. No. 85, or 1000 nM Cpd. No. 85 for 7 days (P values were calculated using a two-sided t-test; n=4 biologically replicated wells).
[0021] FIG. 9 is a bar graph showing the relative viability of indicated human patient- derived xenograft (PDX) organoids treated with DMSO, 100 nM Cpd. No. 85, 1000 nM Cpd. No. 85, or 10000 nM Cpd. No. 85 for 14 days (P values were calculated using a two-sided t-test; n=6 biologically replicated wells).
[0022] FIG. 10 is a plot depicting tumor volume curves and weights in the VCaP-CRPC model treated with vehicle, Cpd. No. 85 (30mg / kg, ip, 5x / week during the first week, then 3x / week for an additional 3 weeks), Cpd. No. 85 (60 mg / kg, po, 5x / week during the first week, then 3x / week for an additional 3 weeks), or combination of p300i and ARi (30 mg / kg and 10 mg / kg respectively, po, 5x / week) (Data are mean ± standard error of the mean (SEM); n= 16 per group; P values were calculated using a two-sided t-test) (left); and a waterfall plot showing the change in tumor volume after 24 days of treatment from the VCaP-CRPC study (right).
[0023] FIG. 11 is a plot depicting tumor volume curves in the MDA-PCA-183 PDX model treated with vehicle or Cpd. No. 85 (30 mg / kg, ip, 5x / week during the first week, then 2x / wcck for an additional 4 weeks) (Data arc mean ± SEM; n = 8 in vehicle group and n=7 in Cpd. No. 85 treated group; P values were calculated using a two-sided t-test) (left); a waterfall plot showing the change in tumor volume after 35 days of treatment from the MDA-PCA-183 study (middle); and a Kaplan-Meier survival curve of MDA-PCA-183 PDX-bearing mice, with survival defined as the time for tumors to reach threefold the initial volume (right).DETAILED DESCRIPTIONI. Compounds of the Disclosure
[0024] In one embodiment, the disclosure provides a compound having Formula (I):CBPi—L—ARi,
[0025] or a pharmaceutically acceptable salt thereof, wherein:
[0026] CBPi is a monovalent radical of a CBP / p300 protein inhibitor;
[0027] ARi is a monovalent radical of an androgen receptor inhibitor; and
[0028] L is a covalent linker, i.e., a stable divalent radical, comprising 1-50 nonhydrogen atoms selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
[0029] In another embodiment, the disclosure provides a compound having Formula (II):
[0030] or a pharmaceutically acceptable salt thereof, wherein:
[0031] R1is selected from the group consisting of C1-C4 alkoxy, C1-C4 haloalkyl, and halo;
[0032] W is selected from the group consisting of =N- and =CH-;
[0033] R2is selected from the group consisting of hydrogen and C1-C4 alkyl;
[0034] m is 0, 1, 2, 3, or 4;
[0035] R3is selected from the group consisting of:
[0036] n = 0, 1 or 2;
[0037] X is selected from the group consisting of O, -NCH3and -CH2-;
[0038] U is selected from the group consisting of O, -NR3aand -CHR3a-; R3aat each occurrence is independently selected from the group consisting of hydrogen and C1-C4 alkyl;
[0039] R3bis selected from the group consisting of hydrogen, optionally substituted C1-C6alkyl, optionally substituted C3-C6cycloalkyl, and optionally substituted 4- to 8-membered heterocyclo;
[0040] R3Cis selected from the group consisting of hydrogen and optionally substituted Ci-C6alkyl; or
[0041] R3band R3ctaken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered heterocyclo;
[0042] R4is selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, and optionally substituted 4- to 8- membered heterocyclo;
[0043] V and Y are selected from the group consisting of -N= and -C(R5)=;
[0044] R5is selected from the group consisting of hydrogen, halo, cyano, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
[0045] R6is selected from the group consisting of hydrogen, halo, cyano, optionally substituted Ci-Ce alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted 4- to 8-membered heterocyclo, optionally substituted 5- to 9-membered heteroaryl, and -ORm;
[0046] Rmis selected from the group consisting of optionally substituted C1-C4 alkyl and optionally substituted C3-C6 cycloalkyl;
[0047] R12is selected from the group consisting of -C(=O)R12a, -C(=O)NR12bR12c, and -C(=O)OR12d;
[0048] R12ais selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl;
[0049] R12bis selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl;
[0050] R12Cis selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl; or
[0051] R12band R12Ctaken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered heterocyclo;
[0052] R12dis C1-C4 alkyl;
[0053] Z is absent; or
[0054] Z is selected from the group consisting of -O- and -N(Rla)-;
[0055] Ring A is -Cs cycloalkylenyl; and L1is -N(Rlb)-C(=O)-A, wherein the bond marked with an "A" is attached to Ring B; or
[0056] Ring A is 7- to 11 -membered spiroheterocyclenyl; and L1is absent; or
[0057] Ring A is 4- to 8-membered heterocyclenyl; and L1is absent; or
[0058] Ring A is 5- or 6-membered heteroarylenyl; and L1is:
[0059] wherein the bond marked with an is attached to Ring B;
[0060] Rlbis selected from the group consisting of hydrogen and C1-C4 alkyl;
[0061] Ring B is selected from the group consisting of optionally substituted arylenyl and optionally substituted 5- to 10-membered heteroarylenyl;
[0062] L2is -X1-X2-X3-X4-X5-*;
[0063] wherein the bond marked with an is attached to R3;
[0064] X1is absent; or
[0065] X1is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, C1-C4 alkylenyl, 3- to 8-membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 11 -membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0066] X2is absent; or
[0067] X2is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, Ci-Cs alkylenyl, 3- to 8-membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0068] X3is absent; or
[0069] X3is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, Ci-Cs alkylenyl, 3- to 11 -membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0070] X4is absent; or
[0071] X4is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, C1-C4 alkylenyl, 3- to 11 -membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0072] X5is absent; or
[0073] X5is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, C1-C4 alkylenyl, 3- to 8-membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl; and
[0074] each Rlais independently selected from the group consisting of hydrogen and C1-C4 alkyl.
[0075] In some embodiments, Compounds of the Disclosure are compounds having Formula (III):
[0076] or a pharmaceutically acceptable salt or solvate thereof,
[0077] wherein M1and M2are -C(CH3)2-; or M1and M2are --CH2CH2-.
[0078] In some embodiments, Compounds of the Disclosure are compounds having Formula (III), or a pharmaceutically acceptable salt thereof, wherein M1and M2are -C(CH3)2-.
[0079] In some embodiments, Compounds of the Disclosure are compounds having Formula (III), or a pharmaceutically acceptable salt thereof, wherein M1and M2are --CH2CH2-.
[0080] In some embodiments, Compounds of the Disclosure are compounds having Formula (II) or (III), or a pharmaceutically acceptable salt thereof, wherein Z is -O-.
[0081] In some embodiments, Compounds of the Disclosure are compounds having Formula (II) or (III), or a pharmaceutically acceptable salt thereof, wherein Z is -N(Rla)-.
[0082] In some embodiments, Compounds of the Disclosure are compounds having Formula (II) or (III), or a pharmaceutically acceptable salt thereof, wherein Rlais hydrogen or methyl.
[0083] In some embodiments, Compounds of the Disclosure are compounds having Formula (II) or (III), or a pharmaceutically acceptable salt thereof, wherein Rlais hydrogen.
[0084] In some embodiments, Compounds of the Disclosure are compounds having Formula (II) or (III), or a pharmaceutically acceptable salt thereof, wherein Rlais methyl.
[0085] In some embodiments, Compounds of the Disclosure are compounds having Formula (IV):
[0086] or a pharmaceutically acceptable salt or solvate thereof.
[0087] In some embodiments, Compounds of the Disclosure are compounds having Formula (II) or (IV), or a pharmaceutically acceptable salt thereof, wherein R2is methyl.
[0088] In some embodiments, Compounds of the Disclosure are compounds having Formula (V):(V),
[0089] or a pharmaceutically acceptable salt or solvate thereof.
[0090] In some embodiments, Compounds of the Disclosure are compounds having Formula (VI):(VI),
[0091] or a pharmaceutically acceptable salt or solvate thereof.
[0092] In some embodiments, Compounds of the Disclosure are compounds having Formula (VII):
[0093] or a pharmaceutically acceptable salt or solvate thereof.
[0094] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)- (VII), or a pharmaceutically acceptable salt thereof, wherein R1is selected from the group consisting of chloro, trifluoromethyl, and methoxy.
[0095] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R1is chloro.
[0096] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R1is tri fluoromethyl.
[0097] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R1is methoxy.
[0098] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R3is R3-l.
[0099] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R3is R3-2.
[0100] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R4is hydrogen.
[0101] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)- (VII), or a pharmaceutically acceptable salt thereof, wherein R4is optionally substituted C1-C4 alkyl.
[0102] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R4is selected from the group consisting of methyl, isopropyl, and
[0103] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R4is methyl.
[0104] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R4is isopropyl.
[0105] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R4is:
[0106] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R4is optionally substituted 4- to 8-membered heterocyclo.
[0107] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R4is selected from the group consisting of:
[0108] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)- (VII), or a pharmaceutically acceptable salt thereof, wherein R3is R3-3.
[0109] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R3is R3-4.
[0110] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R3is R3-5.
[0111] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)- (VII), or a pharmaceutically acceptable salt thereof, wherein R3is R3-6.
[0112] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is hydrogen.
[0113] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is halo.
[0114] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is bromo.
[0115] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is cyano. In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is optionally substituted Ci-Ce alkyl. In some embodiments, R6is a C1-C4 haloalkyl.
[0116] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is optionally substituted C3-C6 cycloalkyl.
[0117] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is -ORm. In some embodiments, Rmis optionally substituted C1-C4 alkyl. In some embodiments, Rmis optionally substituted C3-C6 cycloalkyl.
[0118] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is optionally substituted 5- or 6-membered heteroaryl.
[0119] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is:
[0120] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is optionally substituted 4 to 8-membered heterocyclo.
[0121] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R6is:
[0122] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R3aat each occurrence is independently selected from the group consisting of hydrogen and methyl.
[0123] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R3aat each occurrence is methyl.
[0124] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R3bis C1-C4 alkyl. In some embodiments, R3bis methyl. In some embodiments, R3cis hydrogen.
[0125] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R12is -C(=O)R12a. In some embodiments, R12ais C1-C4 alkyl. In some embodiments, R12ais methyl.
[0126] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R12is -C(=O)NR12bR12c. In some embodiments, R12bis C1-C4 alkyl. In some embodiments, R12bis methyl. In some embodiments, R12cis hydrogen.
[0127] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein Y is -N=.
[0128] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein Y is -C(R5)=.
[0129] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R5is selected from the group consisting of hydrogen, fluoro, chloro, bromo, cyano, C1-C4 alkyl, e.g., methyl, C1-C4 alkoxy, e.g., methoxy, and C1-C4 haloalkyl, e.g., -CHF2.
[0130] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein R5is -CHF2.
[0131] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted arylenyl.
[0132] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted phenylenyl.
[0133] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein Ring B is selected from the group consisting of:
[0134] wherein bond marked with an is attached to L2.
[0135] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted 5- to 10-membered heteroarylenyl.
[0136] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein Ring B is selected from the group consisting of:
[0137] wherein bond marked with an is attached to L2.
[0138] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is absent.
[0139] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is -O-.
[0140] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is -N(Rla)-.
[0141] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is -C(=O)-.
[0142] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is -CH=CH-.
[0143] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is -CC-.
[0144] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is C1-C4 alkylenyl.
[0145] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is 3- to 8-membered heteroalkylenyl.
[0146] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is C3-C8 cycloalkylenyl.
[0147] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is 4- to 11 -membered heterocyclenyl.
[0148] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is 7- to 11 -membered spiroheterocyclenyl.
[0149] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is arylenyl.
[0150] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X1is 5- to 9-membered heteroarylenyl.
[0151] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is absent.
[0152] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is -O-.
[0153] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is -N(Rla)-.
[0154] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is -C(=O)-.
[0155] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is -CH=CH-.
[0156] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is -C=C-.
[0157] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is C1-C8 alkylenyl.
[0158] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is 3- to 8-membered heteroalkylenyl.
[0159] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is C3-C8 cycloalkylenyl.
[0160] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is 4- to 8-membered heterocyclenyl.
[0161] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is arylenyl.
[0162] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X2is 5- to 9-membered heteroarylenyl.
[0163] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X3is absent.
[0164] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X3is -O-.
[0165] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X3is -N(Rla)-.
[0166] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is -C(=O)-.
[0167] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X3is -CH=CH-.
[0168] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is -C=C-.
[0169] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X3is C1-C8 alkylenyl.
[0170] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X3is 3- to 11 -membered heteroalkylenyl.
[0171] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X3is C3-C8 cycloalkylenyl.
[0172] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X3is 4- to 8 -membered heterocyclenyl.
[0173] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X is arylenyl.
[0174] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is 5- to 9-membered heteroarylenyl.
[0175] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is absent.
[0176] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is -O-.
[0177] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is -N(Rla)-.
[0178] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is -C(=O)-.
[0179] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is -CH=CH-.
[0180] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is -C=C-.
[0181] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is C1-C4 alkylenyl.
[0182] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is 3- to 11 -membered heteroalkylenyl.
[0183] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is C3-C8 cycloalkylenyl.
[0184] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is 4- to 8 -membered heterocyclenyl.
[0185] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is arylenyl.
[0186] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X4is 5- to 9-membered heteroarylenyl.
[0187] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is absent.
[0188] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is -O-.
[0189] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is -N(Rla)-.
[0190] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is -C(=O)-.
[0191] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is -CH=CH-.
[0192] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is -C=C-.
[0193] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is C1-C4 alkylenyl.
[0194] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is 3- to 8-membered heteroalkylenyl.
[0195] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is C3-C8 cycloalkylenyl.
[0196] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is 4- to 8-membered heterocyclenyl.
[0197] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is arylenyl.
[0198] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein X5is 5- to 9-membered heteroarylenyl.
[0199] In some embodiments, Compounds of the Disclosure are compounds having any one of Formulae (II)-(VII), or a pharmaceutically acceptable salt thereof, wherein L2is selected from the group consisting of:
[0200] wherein the bond marked with an is attached to R3.
[0201] In another embodiment, the present disclosure provides a compound having Formula (II), or a pharmaceutically acceptable salt thereof, selected from any one or more of the compounds of Table 1.Table 1
[0202] In another embodiment, the present disclosure provides a composition comprising a compound having any one of Formula (I)-(VII) and one or more pharmaceutically acceptable carriers.
[0203] In another embodiment, the present disclosure provides a ternary complex comprising an androgen receptor, a compound having any one of Formula (I)-(VII), or a pharmaceutically acceptable salt thereof, and a CBP / p300 protein.II. Synthetic Intermediates
[0204] In another embodiment, the disclosure provides compounds having Formula (VIII):
[0205] or a salt thereof, wherein:
[0206] R4is selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, and optionally substituted 4- to 8- membered heterocyclo;
[0207] Y is selected from the group consisting of -N= and -C(R5)=;
[0208] R5is selected from the group consisting of hydrogen, halo, cyano, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
[0209] R7is:
[0210] Ring C is selected from the group consisting of Cs-Cs cycloalkylenyl, 3- to 8- membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0211] R8is selected from the group consisting of hydrogen, halo, hydroxy, amino, -OCH3-CHO, and -C(=O)OR9;
[0212] R9is selected from the group consisting of hydrogen and C1-C6alkyl;
[0213] R12is selected from the group consisting of -C(=O)R12a, -C(=O)NR12hR12c, and -C(=O)OR12d;
[0214] R12ais selected from the group consisting of hydrogen, C1-C4 alkyl, and C3-C6 cycloalkyl;
[0215] R12bis selected from the group consisting of hydrogen, C1-C4 alkyl, and C3-C6 cycloalkyl;
[0216] R12Cis selected from the group consisting of hydrogen, C1-C4 alkyl, and C3-C6 cycloalkyl; or
[0217] R12band R12ctaken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered heterocyclo; and
[0218] R12dis C1-C4 alkyl.
[0219] In some embodiments, compounds having Formula (VIII) are useful as synthetic intermediates used to make compounds of Formulae (I)-(VII) disclosed herein.
[0220] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R4is hydrogen.
[0221] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R4is optionally substituted C1-C4 alkyl.
[0222] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R4is selected from the group consisting of methyl, isopropyl, and
[0223] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R4is optionally substituted 4- to 8-membered heterocyclo.
[0224] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R4is selected from the group consisting of:
[0225] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein Y is -N=.
[0226] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein Y is -C(R5)=.
[0227] In another embodiment, the disclosure provides compounds having Formula (VIII), wherein R3is hydrogen.
[0228] In another embodiment, the disclosure provides compounds having Formula (VIII), wherein R5is halo.
[0229] In another embodiment, the disclosure provides compounds having Formula (VIII), wherein R5is bromo.
[0230] In another embodiment, the disclosure provides compounds having Formula (VIII), wherein R5is cyano.
[0231] In another embodiment, the disclosure provides compounds having Formula (VIII), wherein R5is -CHF2.
[0232] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein Ring C is Ca-Cs cycloalkylenyl.
[0233] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein Ring C is 3- to 8-membered heterocyclenyl.
[0234] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein Ring C is phenylenyl.
[0235] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein Ring C is 5- to 9-membered heteroarylenyl.
[0236] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R8is hydrogen.
[0237] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R8is halo.
[0238] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R8is hydroxy.
[0239] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R8is amino.
[0240] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R8is -C=CH.
[0241] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R8is -CHO.
[0242] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R8is -C(=O)OR9.
[0243] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R9is hydrogen.
[0244] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R9is t-butyl.
[0245] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R7is selected from the group consisting of:
[0246] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R12is -C(=O)R12a.
[0247] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R12is -C(=O)NHR12a.
[0248] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R12is -C(=O)OR12a.
[0249] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R12ais C1-C4 alkyl.
[0250] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R12ais methyl.
[0251] In another embodiment, the disclosure provides compounds having Formula (VIII), or a salt thereof, wherein R7is selected from the group consisting of:
[0252] In another embodiment, the disclosure provides compounds having Formula (IX):
[0253] or a salt thereof, wherein:
[0254] R1is selected from the group consisting of C1-C4 alkoxy, C1-C4 haloalkyl, and halo;
[0255] W is selected from the group consisting of =N- and =CH-;
[0256] R2is selected from the group consisting of hydrogen and C1-C4 alkyl;
[0257] m is 0, 1, 2, 3, or 4;
[0258] Z is absent; or
[0259] Z is selected from the group consisting of -O- and -N(Rla)-;
[0260] Ring A is C4-Cs cycloalkylenyl; and L1is -N(Rlb)-C(=O)-A, wherein the bond marked with an "A" is attached to R10; or
[0261] Ring A is 7- to 11 -membered spiroheterocyclenyl; and L1is absent; or
[0262] Ring A is 4- to 8-membered heterocyclenyl; and L1is absent; or
[0263] Ring A is 5- or 6-membered heteroarylenyl; and L1is:
[0264] wherein the bond marked with an is attached to R10;
[0265] Rlbis selected from the group consisting of hydrogen and C1-C4 alkyl;
[0266] R10is:
[0267] Ring D is selected from the group consisting of optionally substituted aryl, optionally substituted 5- to 10-membered heteroaryl, and optionally substituted 7- to 11- membered spiroheterocyclenyl;
[0268] R11is absent; or
[0269] R11is selected from the group consisting of halo, hydroxy, amino, -N3, optionally substituted C1-C4 alkyl, C2-C3 alkynyl, -C(=O)OR1C, -N(Rla)C(=O)Rlc, optionally substituted 4- to 7-membered heterocyclo, -O- (optionally substituted 4- to 7-memberedheterocyclo), optionally substituted 7- to 11 -membered spiroheterocyclenyl, and boronic ester;
[0270] each Rlcis independently selected from the group consisting of hydrogen, C1-C4 alkyl, and optionally substituted C5-C6 aryl; and
[0271] each Rlais independently selected from the group consisting of hydrogen and C1-C4 alkyl.
[0272] In some embodiments, compounds having Formula (IX) are useful as synthetic intermediates used to make compounds of Formulae (I)-(VII) disclosed herein.
[0273] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein R1is halo.
[0274] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein R1is chloro.
[0275] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein R1is C1-C4 alkoxy.
[0276] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein R1is methoxy.
[0277] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein R1is C1-C4 haloalkyl.
[0278] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein W is =N-.
[0279] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein W is =CH-.
[0280] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein Z is absent.
[0281] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein Z is -O-.
[0282] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein Z is -N(Rla)-.
[0283] In some embodiments, the disclosure provides compounds having Formula (IX), wherein Rlais hydrogen or methyl.
[0284] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein m is 0.
[0285] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein m is 1, 2, 3, or 4.
[0286] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein m is 1.
[0287] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein m is 2.
[0288] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein m is 3.
[0289] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein m is 4.
[0290] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein R2is C1-C4 alkyl.
[0291] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein R2is methyl.
[0292] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein Ring A is C4-C8 cycloalkylenyl.
[0293] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein Ring A is 7- to 11 -membered spiroheterocyclenyl.
[0294] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein:
[0295] is selected from the group consisting of:
[0296] In some embodiments, the disclosure provides compounds having Formula (IX), or a salt thereof, wherein R10is selected from the group consisting of:
[0297] In some embodiments, the disclosure provides compounds having Formula (VIII) or (IX), wherein the compound is any one or more of the compounds disclosed herein as a synthetic intermediate, e.g., an " Intermediate" or " Int."
[0298] The compounds provided in this section, and the pharmaceutically acceptable salts and solvates thereof, are collectively referred to herein as " Compounds of the Disclosure" or individually as a " Compound of the Disclosure."III. Compositions of the Disclosure
[0299] The therapeutic methods and uses of the present disclosure can be accomplished by administering a Compound of the Disclosure as a neat compound or as a pharmaceutical composition. The present disclosure thus provides a pharmaceutical composition comprising (i) a Compound of the Disclosure; and (ii) one or more pharmaceutically acceptable carriers. In one embodiment, the pharmaceutical compositions of the present disclosure are sterile and contain no toxic, carcinogenic, or mutagenic compounds that would cause an adverse reaction when administered to a subject.
[0300] Pharmaceutically acceptable carriers include, but are not limited to, excipients, diluents, fillers, binders, buffers, stabilizers, solubilizers, disintegrants, lipids, suspensionagents, viscosity agents, lubricants, glidants, or other materials known in the art for use in pharmaceutical compositions and formulations, as suited to the particular dosage form desired. General considerations in the formulation and / or manufacture of pharmaceutical compositions can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
[0301] These pharmaceutical compositions of the present disclosure can be manufactured, for example, by conventional mixing, dissolving, granulating, emulsifying, encapsulating, entrapping, or lyophilizing techniques. The particular formulation depends upon the route of administration chosen. When a Compound of the Disclosure is administered orally the composition may be, for example, in the form of a tablet, capsule, powder, solution, or suspension. When administered by intravenous or subcutaneous injection, the composition may be, for example, in the form of a pyrogen-free, parenterally acceptable aqueous solution.
[0302] Pharmaceutical compositions of the present disclosure may comprise about 0.1% to about 95% of a Compound of the Disclosure, e.g., about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% of a Compound of the Disclosure.
[0303] The pharmaceutical compositions provided in this section are collectively referred to herein as " Compositions of the Disclosure" or individually as a " Composition of the Disclosure."IV. Therapeutic Methods and Uses
[0304] Compounds of the Disclosure are useful for treating or preventing diseases, disorders, or conditions in a subject in need thereof. Compounds of the Disclosure are particularly useful for treating or preventing a disease, disorder, or condition wherein dual inhibition of CBP / p300 and AR function provides a therapeutic benefit. In some embodiments, the disease, disorder, or condition is cancer.
[0305] Since Compounds of the Disclosure induce non-native AR / p300 interactions and effectively inhibit cancer cell growth by concurrently inhibiting both AR and p300 functions, diseases, disorders, or conditions mediated by CBP / p300 and AR can betreated or prevented by administering these compounds or pharmaceutical compositions comprising these compounds to a subject in need thereof. The present disclosure is thus directed generally to a method for treating or preventing a disease responsive to dual inhibition of CBP / p300 and AR function in a subject, e.g., an animal, e.g., a human, suffering from, or at risk of suffering from, the method comprising administering to the animal an effective amount of a Compound of the Disclosure.
[0306] In another embodiment, the Compounds of the Disclosure typically have IC50 (the drug concentration that results in 50% CBP / p300 and / or AR inhibition) values of less than 300 pM, e.g., less than 100 pM, less than 50 pM, less than 25 pM, and less than 5 pM, less than about 1 pM, less than about 0.5 pM, or less than about 0.1 pM. In some embodiments, Compounds of the Disclosure have IC50 values of less than about 0.1 pM. In some embodiments, Compounds of the Disclosure have IC50 values of less than about 0.5 pM. In some embodiments, Compounds of the Disclosure have IC50 values of less than about 0.01 pM.
[0307] In one embodiment, the present disclosure provides a method of treating a disease wherein dual inhibition of CBP / p300 and AR provides a therapeutic benefit in a subject, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject.
[0308] In another embodiment, the present disclosure provides a method of inhibiting CBP / p300 and AR in a cell of a subject, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject. In some embodiments, the subject has cancer.
[0309] In another embodiment, the present disclosure provides a method of treating cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject.
[0310] In another embodiment, the present disclosure provides a method of treating cancer in a subject in need thereof comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject in combination with one or more additional therapeutic agents. Therapeutic agents to treat cancer arc known in the art. See Section V below.
[0311] While not being limited to any specific theory or mechanism of action, in some embodiments, Compounds of the Disclosure treat cancer, at least in part, by dual inhibition of CBP / p300 and AR functions. Such compounds, referred to as Domain-ALTeration Chimeras (DALTACs), selectively miswire endogenous protein complexes by inducing non-functional domain-domain interactions between physiological partners. DALTACs function as chemical dominant-negatives, locking transcriptional regulators into inert conformations that disable complex activity. Compounds of the Disclosure are AR-p300 DALTAC compounds. By way of example, Cpd. No. 85 (DALTAC-1) exhibits superior inhibitory efficacy in AR-positive prostate cancer cells compared to combination treatment with an AR inhibitor and p300 bromodomain (BRD) inhibitor. DALTAC-1 also limits its action to AR-positive, p300-dependent cancer cells, highlighting its lineage-selective tumor inhibitory properties. Mechanistic analyses revealed that DALTAC-1 rewires the native N-terminal domain (NTD) of AR and p300 complex by enforcing neomorphic interactions between the AR ligand-binding domain (LBD) and the p300 BRD, leading to reprogramming of the p300 substrate spectrum. And, in contrast to p300 BRD inhibitors, DALTAC-1 rapidly eliminates histone H2B N- terminal multi-site acetylation (H2BNTac), the active enhancer mark, which is independent of p300 BRD activity, Luo et al., Nat Genet (2025). doi.org: 10.1038 / s41588- 025-02336-6, and disrupts the oncogenic program driven by AR and p300. Profiling of the chromatin landscape revealed an enhancement of AR-p300 co-occupancy at AR palindromic binding sites in DALTAC-1 treated cells, yet this is accompanied by disruption of the active AR neo-enhanceosome complex. In multiple preclinical models, DALTAC-1 inhibits tumor growth or induces tumor regression without causing overt toxicity. These findings establish AR-p300 DALTACs as promising therapeutic agents to selectively inhibit cancer cell growth by miswiring the native oncogenic protein complex.
[0312] In another embodiment, the cancer is any one or more of the cancers of Table A.Table A
[0313] In another embodiment, the cancer is a solid tumor. In another embodiment, the cancer is a carcinoma. In another embodiment, the cancer is a sarcoma. In anotherembodiment, the cancer is a lymphoma. In another embodiment, the cancer is a melanoma.
[0314] In another embodiment, the cancer is: (i) a bone tumor, e.g., adamantinoma, chondromas, chondroblastoma, chondrosarcoma, Ewing sarcoma, osteoblastoma, or osteosarcoma; (ii) a desmoid tumor; (iii) an endocrine tumor, e.g., adrenal tumors, carcinoid tumors, carney triad, multiple endocrine neoplasia (MEN), neuroendocrine tumors, paragangliomas / pheochromocytomas, thyroid carcinoma, or tumors of the pancreas; (iv) a genu cell tumor, e.g., ovarian tumors, teratoma, or testicular tumors; (v) a kidney (renal) tumor, e.g., malignant rhabdoid tumor or Wilms tumor; (vi) a liver tumor e.g., hepatoblastoma, hepatocellular carcinoma, or undifferentiated embryonal sarcoma of the liver (UESL); (vii) neuroblastoma; (viii) a rare tumor, e.g., adrenocortical carcinoma, melanoma, nasopharyngeal carcinoma, or odontogenic tumors; (ix) retinoblastoma: or (x) a soft tissue tumor, e.g., alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, dermatofibrosarcoma protuberans, epithelioid hemangioendothelioma, fibrosarcoma, hemangiopericytoma, juvenile nasopharyngeal angiofibroma (JNA), kaposiform hemangioendothelioma, leiomyosarcoma, liposarcoma, malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma, schwannoma (neurilemoma), Spitz tumors, or synovial sarcoma.
[0315] In another embodiment, the cancer a hematological cancer. Exemplary hematological cancers include, but are not limited to, the cancers listed in Table B.Table B
[0316] In another embodiment, the hematological cancer is acute lymphocytic leukemia, chronic lymphocytic leukemia (including B-cell chronic lymphocytic leukemia), or acute myeloid leukemia.
[0317] In another embodiment, the cancer is any one or more of the cancers of Table C.Table C
[0318] In another embodiment, the present disclosure provides a method of treating or preventing prostate cancer, e.g., localized prostate cancer, metastatic prostate cancer, or castration-resistant prostate cancer, in a subject in need thereof, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject.
[0319] In methods of the present disclosure, a therapeutically effective amount of a Compound of the Disclosure, formulated in accordance with pharmaceutical practice, e.g., as a Composition of the Disclosure, is administered to a subject, e.g., a human cancer patient, in need thereof. Whether such a treatment is indicated depends on the individual case and is subject to medical assessment (diagnosis) that takes into consideration signs, symptoms, and / or malfunctions that are present, the risks of developing particular signs, symptoms and / or malfunctions, and other factors.
[0320] A Compound of the Disclosure can be administered by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, intracistemal orintrathecal through lumbar puncture, transurethral, nasal, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and / or surgical implantation at a particular site) administration. Parenteral administration can be accomplished using a needle and syringe or using a high pressure technique. In one embodiment, a Compound of the Disclosure is orally administered to a subject. In another embodiment, a Compound of the Disclosure is parenterally administered, e.g., by injection or infusion.
[0321] The toxicity and therapeutic efficacy of the Compounds of the Disclosure can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the maximum tolerated dose (MTD) of a compound, which is defined as the highest dose that causes no toxicity in animals. The dose ratio between the maximum tolerated dose and therapeutic effects, e.g., inhibiting of tumor growth, is the therapeutic index. The dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
[0322] A therapeutically effective amount of a Compound of the Disclosure required for use in therapy varies with the nature of the disease, disorder, or condition being treated, the length of time that activity is desired, and the age and the disease, disorder, or condition of the subject, and ultimately is determined by the attendant physician. Dosage amounts and intervals can be adjusted individually to provide plasma levels of the bifunctional inhibitor of CBP / p300 and AR that are sufficient to maintain the desired therapeutic effects. In some embodiments, a total dose of about 0.005 to about 10000 milligrams of a Compound of the Disclosure is administered to the subject per day. The desired total dose can be administered to a subject in a single dose or as multiple doses administered at appropriate intervals, for example as two, three, four or more subdoses per day. Multiple subdoses per day may be desired or required.
[0323] In some embodiments, a Compound of the Disclosure or Composition of the Disclosure is administered to the subject once a day. In some embodiments, a Compound of the Disclosure or Composition of the Disclosure is administered to the subject twice a day. In some embodiments, a Compound of the Disclosure or Composition of the Disclosure is administered to the subject three times a day. In some embodiments, aCompound of the Disclosure or Composition of the Disclosure is administered to the subject four times a day.
[0324] A Compound of the Disclosure or Composition of the Disclosure used in a method of the present disclosure can be administered to a subject in an amount of about 0.005 to about 10000 milligrams per dose, e.g., about 1 to about 5000 milligrams per dose, about 1 to about 1000 milligrams per dose, about 1 to about 500 milligrams per dose, about 1 to about 250 milligrams per dose, about 1 to about 100 milligrams per dose, or about 1 to about 50 milligrams per dose. For example, a Compound of the Disclosure can be administered, per dose, in an amount of about 0.005, about 0.05, about 0.5, about 1, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500. or about 1000 milligrams. All doses between 0.005 and 10000 milligrams are contemplated in the therapeutic methods and uses of the present disclosure.
[0325] The dosage of a Compound of the Disclosure or Composition of the Disclosure can be from about 1 ng / kg to about 200 mg / kg, e.g., about 1 pg / kg to about 100 mg / kg, or about 1 mg / kg to about 50 mg / kg. For example, the dosage may be about 1 pg / kg, about 10 pg / kg, about 25 pg / kg, about 50 pg / kg, about 75 pg / kg, about 100 pg / kg, about 125 pg / kg, about 150 pg / kg, about 175 pg / kg, about 200 pg / kg, about 225 pg / kg, about 250 pg / kg, about 275 pg / kg, about 300 pg / kg, about 325 pg / kg, about 350 pg / kg, about 375 pg / kg, about 400 pg / kg, about 425 pg / kg, about 450 pg / kg, about 475 pg / kg, about 500 pg / kg, about 525 pg / kg, about 550 pg / kg, about 575 pg / kg, about 600 pg / kg, about 625 pg / kg, about 650 pg / kg, about 675 pg / kg, about 700 pg / kg, about 725 pg / kg, about 750 pg / kg, about 775 pg / kg, about 800 pg / kg, about 825 pg / kg, about 850 pg / kg, about 875 pg / kg, about 900 pg / kg, about 925 pg / kg, about 950 pg / kg, about 975 pg / kg, about 1 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 60 mg / kg, about 70 mg / kg, about 80 mg / kg, about 90 mg / kg, about 100 mg / kg, about 125 mg / kg, about 150 mg / kg, about 175 mg / kg, about 200 mg / kg, or more. The above dosages are exemplary of the average case, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this disclosure. In practice, the physician determines the actual dosing regimen that ismost suitable for an individual subject, which can vary with the age, weight, response, etc. of the particular subject.
[0326] The disclosure also provides the following particular method of treatment embodiments.
[0327] Embodiment 1. A method of treating or preventing cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure or Composition of the Disclosure to the subject.
[0328] Embodiment 2. The method of Embodiment 1, wherein the cancer is selected from any one or more of the cancers of Table A and / or Table B.
[0329] Embodiment 3. The method of Embodiment 1, wherein the cancer is selected from any one or more of the cancers of Table C, e.g., the cancer is prostate cancer.
[0330] Embodiment 4. The method of any one of Embodiments 1-3, for treating cancer in the subject.
[0331] Embodiment 5. The method of any one of Embodiments 1-3, for preventing cancer in the subject.
[0332] Embodiment 6. A kit for carrying out the method of any one of Embodiments 1-5, the kit comprising a Compound of the Disclosure or Composition of the Disclosure and instructions on how to administer the compound or composition to the subject.
[0333] The disclosure also provides the following particular use-limited product embodiments.
[0334] Embodiment 1. A Compound of the Disclosure or Composition of the Disclosure for use in treating or preventing cancer in a subject in need thereof.
[0335] Embodiment 2. The compound or composition of Embodiment 1, wherein the cancer is selected from any one or more of the cancers of Table A and / or Table B.
[0336] Embodiment 3. The compound or composition of Embodiment 1, wherein the cancer is selected from any one or more of the cancers of Table C, e.g., the cancer is prostate cancer.
[0337] Embodiment 4. The compound or composition of any one of Embodiments 1-3, for treating cancer in the subject.
[0338] Embodiment 5. The compound or composition of any one of Embodiments 1-3, for preventing cancer in the subject.
[0339] The disclosure also provides the following particular use-limited process embodiments.
[0340] Embodiment 1. Use of Compound of the Disclosure or Composition of the Disclosure in the manufacture of a medicament for treating or preventing cancer in a subject in need thereof.
[0341] Embodiment 2. The use of Embodiment 1, wherein the cancer is selected from any one or more of the cancers of Table A and / or Table B.
[0342] Embodiment 3. The use of Embodiment 1, wherein the cancer is selected from any one or more of the cancers of Table C, e.g., the cancer is prostate cancer.
[0343] Embodiment 4. The use of any one of Embodiments 1-3, for treating cancer in the subject.
[0344] Embodiment 5. The use of any one of Embodiments 1-3, for preventing cancer in the subject.V. Additional Therapeutic Agents
[0345] In one embodiment, a Compound of the Disclosure is administered as a single agent to treat a disease, disorder, or condition, e.g., cancer.
[0346] In another embodiment, a Compound of the Disclosure is administered in combination with one or more additional therapeutic agents to treat a disease, disorder, or condition. A Compound of the Disclosure and the additional therapeutic agent(s) can be administered simultaneously or sequentially to achieve the desired effect. The Compound of the Disclosure and additional therapeutic agent(s) can also be administered as a single pharmaceutical composition or separate pharmaceutical compositions. In one embodiment, the Compound of the Disclosure and additional therapeutic agent(s) are administered as separate pharmaceutical compositions.
[0347] The additional therapeutic agent(s) is / are administered in an amount to provide the desired therapeutic effect. The effective dosage range for each additional therapeutic agent is generally known in the art, and the additional therapeutic agent(s) is / are administered to subject in need thereof within such established ranges.
[0348] A Compound of the Disclosure and the additional therapeutic agent(s) can be administered together as a single-unit dose or separately as multi-unit doses, wherein the Compound of the Disclosure is administered before the additional therapeutic agent(s) orvice versa. One or more doses of the Compound of the Disclosure and / or one or more doses of the additional therapeutic agent(s) can be administered.VI. Kits
[0349] In another embodiment, the disclosure provides a kit comprising a Compound of the Disclosure and a label with instructions for how to use the Compound of the Disclosure to treat a disease, disorder, or condition, e.g., cancer, in a subject in need thereof.
[0350] In another embodiment, the disclosure provides a kit comprising Composition of the Disclosure and a label with instructions for how to use the Composition of the Disclosure to treat a disease, disorder, or condition, e.g., cancer, in a subject in need thereof.
[0351] In another embodiment, the disclosure provides a kit for carrying out the methods of the present disclosure, the kit comprising a Compound of the Disclosure and a label with instructions for how to use the Compound of the Disclosure to treat a disease, disorder, or condition, e.g., cancer, in a subject in need thereof.
[0352] In another embodiment, the label is approved by at least one regulatory health agency, e.g., the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), the China Food and Drug Administration (CFDA), or the Japanese Ministry of Health Labor and Welfare (MHLW).
[0353] In another embodiment, the kit further comprises one or more additional therapeutic agents.VII. Definitions
[0354] The term "disease, disorder, or condition" denotes disturbances and / or anomalies that are regarded as being pathological conditions or functions, and that can manifest themselves in the form of particular signs, symptoms, and / or malfunctions. Compounds of the Disclosure are CBP / p300 and / or AR inhibitors and thus can be used, for example, to treat or prevent diseases, disorders, or conditions wherein CBP / p300 and / or AR inhibition provides a benefit.
[0355] The term "a disease, disorder, or condition wherein CBP / p300 and / or AR inhibition provides a benefit" and the like pertains to a disease, disorder, or condition in which CBP / p300 and / or AR is important or necessary, e.g., for the onset, progress,expression of that disease, disorder, or condition, or a disease, disorder, or condition which is known to be treated by a CBP / p300 and / or AR inhibitor. An example of such a disease, disorder, or condition includes, but is not limited to, cancer. One of ordinary skill in the art is readily able to determine whether a compound treats or prevents a disease mediated by CBP / p300 and / or AR for any particular cell type, for example, using in vitro, in vivo, and ex vivo assays that assess the activity of particular compounds.
[0356] As used herein, the terms "treat," "treating," "treatment," and the like refer to eliminating, reducing, or ameliorating a disease, disorder, or condition, e.g., cancer, and / or symptoms associated therewith. Although not precluded, treating a disease does not require that the disease, disorder, or condition, or symptoms associated therewith be completely eliminated. The term "treat" and synonyms contemplate administering a therapeutically effective amount of a Compound of the Disclosure and optionally one more additional therapeutic agents to a subject need of such treatment. The treatment can be orientated symptomatically, for example, to suppress symptoms. It can be effected over a short period, be oriented over a medium term, or can be a long-term treatment, for example within the context of a maintenance therapy.
[0357] As used herein, the terms "prevent," "preventing," and "prevention" refer to a method of preventing the onset of a disease and / or its attendant symptoms or barring a subject from acquiring a disease. As used herein, "prevent," "preventing," and "prevention" also include delaying the onset of a disease and / or its attendant symptoms and reducing a subject's risk of acquiring a disease. The terms "prevent," "preventing" and "prevention" may include "prophylactic treatment," which refers to reducing the probability of redeveloping a disease, disorder, or condition, or of a recurrence of a previously-controlled disease, disorder, or condition, in a subject who does not have, but is at risk of or is susceptible to, redeveloping a disease or a recurrence of the disease.
[0358] The term "therapeutically effective amount" and the like as used herein refers to an amount of a Compound of the Disclosure and, optionally, other active ingredient(s) that is / are sufficient, when administered according to a method of the present disclosure, to efficaciously deliver the active ingredient(s) for the treatment of a disease of interest to a subject in need thereof. In the case of a cancer or other proliferation disorders, the therapeutically effective amount of the agent may reduce, e.g., retard to some extent or stop, unwanted cellular proliferation; reduce the number of cancer cells; reduce the tumor size, e.g., reduce tumor size by about 2%, about 5%, about 10%, about 15%, about 20%,about 25%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% or more; inhibit, e.g., retard to some extent or stop, cancer cell infiltration into peripheral organs; inhibit, e.g., retard to some extent or stop, tumor metastasis; inhibit, to some extent, tumor growth; and / or relieve, to some extent, one or more of the symptoms associated with the cancer. To the extent the administered compound or composition prevents growth and / or kills existing cancer cells, it may be cytostatic and / or cytotoxic.
[0359] The term "container" means any receptacle and closure therefore suitable for storing, shipping, dispensing, and / or handling a pharmaceutical product.
[0360] The term "package insert" means information accompanying a pharmaceutical product that provides a description of how to formulate and / or administer the product, along with the safety and efficacy data required to allow the physician, pharmacist, and patient to make an informed decision regarding use of the product. The package insert generally is regarded as the "label" for a pharmaceutical product.
[0361] " Concurrent administration," "administered in combination," "simultaneous administration," and similar phrases mean that two or more agents are administered concurrently to the subject being treated. By "concurrently," it is meant that each agent is administered either simultaneously or sequentially in any order at different points in time. However, if not administered simultaneously, it is meant that they are administered to a subject in a sequence and sufficiently close in time so as to provide the desired therapeutic effect and can act in concert. For example, a Compound of the Disclosure can be administered at the same time or sequentially in any order at different points in time as one or more additional therapeutic agents. A Compound of the Disclosure and an additional therapeutic agent can be administered separately, in any appropriate form and by any suitable route. When a Compound of the Disclosure and an additional therapeutic agent are not administered concurrently, it is understood that they can be administered in any order to a subject in need thereof. For example, a Compound of the Disclosure can be administered before, e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before, concomitantly with, or after, e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after, the administration of the additional therapeutic agent to the subject. In some embodiments,a Compound of the Disclosure and an additional therapeutic agent are administered less than 15 minutes apart, less than 30 minutes apart, less than 1 hour apart, less than 2 hours apart, less than 3 hours apart, less than 4 hours apart, less than 5 hours apart, less than 6 hours apart, less than 12 hours apart, less than 24 hours apart, or less than 48 hours apart. In some embodiments, the active agents of the combination therapy are administered at about 1 minute to about 24 hours apart.
[0362] The term "halo" as used herein by itself or as part of another group refers to a radical of the formula -Cl (chloro), -F (fluoro), -Br (bromo), or -I (iodo). In some embodiments the halo is -F. In some embodiments, the halo is -Cl. In some embodiments, the halo is -Br.
[0363] The term "nitro" as used herein by itself or as part of another group refers to a radical of the formula -NO2.
[0364] The term "cyano" as used herein by itself or as part of another group refers to a radical of the formula -CN.
[0365] The term "hydroxy" as herein used by itself or as part of another group refers to a radical of the formula -OH.
[0366] The term "amino" as used herein by itself or as part of another group refers to a radical of the formula -NRaRb, wherein Raand Rbare independently hydrogen, optionally substituted alkyl, e.g., haloalkyl, (hydroxy)C2-C4 alkyl, (alkoxy)C2-C4 alkyl, (amino)C2- C4 alkyl, (aryl)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, or (heteroaryl)alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, the amino is -NH2, i.e., an amino wherein Raand Rbare both hydrogen. In some embodiments, the amino is an "alkylamino," i.e., an amino wherein Rais Ci-Ce alkyl and Rbis hydrogen. In one embodiment, Rais C1-C4 alkyl. Non-limiting exemplary alkylamino groups include -N(H)CH3 and -N(H)CH2CH3. In some embodiments, the amino is a "dialkylamino," i.e., an amino whereinRaand Rbare each independently C1-C6 alkyl. In one embodiment, Raand Rbare each independently C1-C4 alkyl. Non-limiting exemplary dialkylamino groups include -N(CH3)2 and -N(CH3)CH2CH(CH3)2.
[0367] The term "alkyl" as used herein by itself or as part of another group refers to a straight- or branched-chain unsubstituted aliphatic hydrocarbon radical containing one to twelve carbon atoms, i.e., a C1-C12 alkyl, or the number of carbon atoms designated, e.g., a C1-C3 alkyl such as methyl, ethyl, propyl, and isopropyl; a C1-C4 alkyl such as methyl,ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl; and so on. In some embodiments, the alkyl is a Ci-Ce alkyl. In some embodiments, the alkyl is a C1-C4 alkyl. In some embodiments, the alkyl is a C1-C3 alkyl. In some embodiments, the alkyl is a C2-C4 alkyl. Non-limiting exemplary C1-C12 alkyl groups include methyl, i.e., -CH3, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, iso-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, and decyl.
[0368] The term "optionally substituted alkyl" as used herein by itself or as part of another group refers to an alkyl that is either unsubstituted or substituted with one or more, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroarylsulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroarylcarbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)RJ; -N(R‘)S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy,
[0369] wherein:
[0370] Rhis hydrogen or alkyl;
[0371] R1is hydrogen or alkyl;
[0372] Rjis alkoxy, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl;
[0373] Rkis amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl; and
[0374] Rmis optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, optionally substituted heteroaryl, carboxamido, or carbonyl.
[0375] In some embodiments, the optionally substituted alkyl has four substituents. In some embodiments, the optionally substituted alkyl has three substituents. In some embodiments, the optionally substituted alkyl has two substituents. In some embodiments, the optionally substituted alkyl has one substituent. In some embodiments,the optionally substituted alkyl is unsubstituted. In some embodiments, the optionally substituted alkyl is an optionally substituted Ci-Ce alkyl. In some embodiments, the optionally substituted alkyl is an optionally substituted C1-C4 alkyl.
[0376] In some embodiments, the optionally substituted alkyl is a "(hydroxyl) alkyl," i.e., an alkyl substituted with one or two hydroxy groups. In some embodiments, the alkyl is a Ci-Ce alkyl and thus the resulting (hydroxy) alkyl is referred to as a "(hydroxy)Ci-Ce alkyl." In some embodiments, the alkyl is a C1-C4 alkyl and thus the resulting (hydroxy)alkyl is referred to as a "(hydroxy)Ci-C4 alkyl." In some embodiments, the hydroxyalkyl is a monohydroxyalkyl, e.g., a C1-C4 alkyl substituted with one hydroxy group. In some embodiments, the hydroxyalkyl is a dihydroxyalkyl, i.e., a C1-C4 substituted with two hydroxy groups. Non-limiting exemplary (hydroxyl)alkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, such as 1 -hydroxy ethyl, 2-hydroxyethyl, 1,2-dihydroxy ethyl, 2-hydroxypropyl, 3 -hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy- 1 -methylpropyl, and l,3-dihydroxyprop-2- yi.
[0377] In some embodiments, the optionally substituted alkyl is a "haloalkyl," i.e., an alkyl substituted by one or more fluorine, chlorine, bromine, and / or iodine atoms. In some embodiments, the alkyl is substituted by one, two, or three fluorine and / or chlorine atoms. In some embodiments, the alkyl is substituted by one, two, or three fluorine atoms. In some embodiments, the alkyl is a C1-C4 alkyl and thus the resulting haloalkyl is thus referred to as a " C1-C4 haloalkyl." Non-limiting exemplary haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1 -difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4, 4, 4- trifluorobutyl, and tri chloromethyl.
[0378] In some embodiments, the optionally substituted alkyl is an "(amino)alkyl" i.e., an alkyl substituted with one amino group. In some embodiments, the amino group is -NH2. In some embodiments, the amino group is an alkylamino. In some embodiments, the amino group is a dialkylamino In some embodiments, the alkyl is a Ci-Ce alkyl and thus the resulting (amino)alkyl is thus referred to as a "(amino)Ci-C6 alkyl." In some embodiments, the alkyl is a C1-C4 alkyl and thus the resulting (amino)alkyl is thus referred to as a "(amino)Ci-C4 alkyl." Non-limiting exemplary (amino)alkyl groups include -CH2NH2, -CH2CH2N(H)CH3, -CH2CH2N(CH3)2,CH2N(H)cyclopropyl, -CH2N(H)cyclobutyl, -CH2N(H)cyclohexyl, -CH2CH2CH2N(H)C H2Ph and -CH2CH2CH2N(H)CH2(4-CF3-Ph).
[0379] In some embodiments, the optionally substituted alkyl is an"(alkoxy)alkyl," i.e., an alkyl substituted with one alkoxy group. In some embodiments, the alkoxy group is a Ci-C6alkoxy. In some embodiments, the alkoxy group is a C1-C4 alkoxy. In some embodiments, the alkyl group is a Ci-Ce alkyl. In some embodiments, the alkyl group is a C1-C4 alkyl. In some embodiments, the alkoxy is a C1-C4 alkoxy and the alkyl is a Ci- C4 alkyl and thus the resulting (alkoxy)alkyl is referred to as a "(C1-C4 alkoxy)Ci-C4 alkyl." Non-limiting exemplary alkoxy alkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sec-butoxymethyl, and pentyloxymethyl.
[0380] In some embodiments, the optionally substituted alkyl is a "(cycloalkyl)alkyl," i.e., an alkyl substituted with one or two optionally substituted cycloalkyl groups. In some embodiments, the cycloalkyl is an optionally substituted C3-C6 cycloalkyl. In some embodiments, the alkyl is a Ci-Ce alkyl. In some embodiments, the alkyl is a C1-C4 alkyl. In some embodiments, the alkyl is a Ci or C2 alkyl. In some embodiments, the alkyl is substituted with one optionally substituted cycloalkyl group. In some embodiments, the alkyl is substituted with two optionally substituted cycloalkyl groups. Non-limiting exemplary (cycloalkyl)alkyl groups include:
[0381] In some embodiments, the optionally substituted alkyl is a "(heterocyclo)alkyl," i.e., an alkyl substituted with one, two, or three optionally substituted heterocyclo groups. In some embodiments, the alkyl is substituted with one optionally substituted 5- to 8-membered heterocyclo group. In some embodiments, alkyl is a Ci-Ce alkyl. In some embodiments, alkyl is a C1-C4 alkyl. In some embodiments, alkyl is a C1-C3 alkyl. The optionally substituted heterocyclo group can be linked to the alkyl group through a carbon or nitrogen radical. Non-limiting exemplary (heterocyclo)alkyl groups include:
[0382] In some embodiments, the optionally substituted alkyl is an "(aryl)alkyl," i.e., an alkyl substituted with one, two, or three optionally substituted aryl groups. In some embodiments, the alkyl is substituted with one optionally substituted aryl group. In some embodiments, the alkyl is substituted with two optionally substituted aryl groups. In some embodiments, the aryl is an optionally substituted phenyl or optionally substituted naphthyl. In some embodiments, the aryl is an optionally substituted phenyl. In some embodiments, the alkyl is a Ci-Ce alkyl. In some embodiments, the alkyl is a C1-C4 alkyl. In some embodiments, the alkyl is a Ci or C2 alkyl. Non-limiting exemplary (aryl)alkyl groups include benzyl, phenethyl, -CHPI12, -C(H)CH3Ph and -CH(4-F-Ph)2.
[0383] In some embodiments, the optionally substituted alkyl is a "(heteroaryl)alkyl," i.e., an alkyl substituted with one or two optionally substituted heteroaryl groups. In one embodiment, the alkyl group is substituted with one optionally substituted 5- to 14- membered heteroaryl group. In some embodiments, the alkyl group is substituted with two optionally substituted 5- to 14-membered heteroaryl groups. In some embodiments, the alkyl group is substituted with one optionally substituted 5- to 9-membered heteroaryl group. In another embodiment, the alkyl group is substituted with two optionally substituted 5- to 9-membered heteroaryl groups. In some embodiments, the alkyl group is substituted with one optionally substituted 5- or 6-membered heteroaryl group. In some embodiments, the alkyl group is substituted with two optionally substituted 5- or 6-membered heteroaryl groups. In some embodiments, the alkyl group is a Ci-Ce alkyl. In some embodiments, the alkyl group is a C1-C4 alkyl. In some embodiments, the alkyl group is a Ci or C2 alkyl. Non-limiting exemplary (heteroaryl)alkyl groups include:
[0384] The term "heteroalkyl" as used herein by itself or part of another group refers to an unsubstituted straight- or branched-chain aliphatic hydrocarbon radical containingfrom three to sixteen chain atoms, i.e., 3- to 16-membered heteroalkyl, or the number of chain atoms designated, wherein at least one -CH2- is replaced with at least one of -O-, - N(H)-, -N(CI-C4 alkyl)-, or -S-. The -O-, -N(H)-, -N(CI-C4 alkyl)-, or -S- can independently be placed at any position of the aliphatic hydrocarbon chain so long as each -O-, -N(H)-, -N(CI-C4 alkyl)-, and -S- group is separated by at least two -CH2- groups. In some embodiments, one -CH2- group is replaced with one -O- group. In some embodiments, two -CH2- groups are replaced with two -O- groups. In some embodiments, three -CH2- groups are replaced with three -O- groups. In some embodiments, one -CH2- group is replaced with one -N(H)- group. In some embodiments, two -CH2- groups are replaced with two - N(H)- groups. Non-limiting exemplary heteroalkyl groups include -CH2OCH3, -CH2OCH2CH2CH3, -CH2CH2CH- 2OCH3, -CH2CH2OCH2CH2OCH2CH3, - CH2CH2OCH2CH2OCH2CH2OCH2CH3, and - CH2OCH2CH2OH,.
[0385] The term "alkenyl" as used herein by itself or as part of another group refers to an alkyl group containing one, two, or three carbon-to-carbon double bonds. In some embodiments, the alkenyl group is a C2-C6 alkenyl group containing one or two carbon- to-carbon double bonds. In some embodiments, the alkenyl group is a C2-C4 alkenyl group containing one carbon-to-carbon double bond. Non-limiting exemplary alkenyl groups include ethenyl, i.e., -CH=CH2, propenyl, isopropenyl, butenyl,.scc-bulenyl, pentenyl, and hexenyl.
[0386] The term "optionally substituted alkenyl" as used herein by itself or as part of another refers to an alkenyl that is either unsubstituted or substituted with one or more, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl) alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroarylsulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroarylcarbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)RJ; N(R')S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or(aryl)alkyloxy, wherein Rh, R1, RJ, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0387] In some embodiments, the optionally substituted alkenyl has four substituents. In some embodiments, the optionally substituted alkenyl has three substituents. In some embodiments, the optionally substituted alkenyl has two substituents. In some embodiments, the optionally substituted alkenyl has one substituent. In some embodiments, the optionally substituted alkenyl is unsubstituted. Non-limiting exemplary optionally substituted alkenyl groups include -CH=CHCH3 and - CH2CH=CHCH3;
[0388] In some embodiments, the optionally substituted alkenyl is an "(aryl)alkenyl," i.e., an alkenyl substituted with one, two, or three optionally substituted aryl groups. In some embodiments, the alkenyl is substituted with one optionally substituted aryl group. In some embodiments, the alkenyl is substituted with two optionally substituted aryl groups. In some embodiments, the aryl is an optionally substituted phenyl or optionally substituted naphthyl. In some embodiments, the aryl is an optionally substituted phenyl. In some embodiments, the alkenyl is a C2-C6 alkyl. In some embodiments, the alkenyl is a C2-C4 alkyl. In some embodiments, the alkenyl is a C2 alkyl. Non-limiting exemplary (aryl) alkenyl groups include -CH=CHPh.
[0389] The term "alkynyl" as used herein by itself or as part of another group refers to an alkyl containing one, two, or three carbon- to-carbon triple bonds. In some embodiments, the alkynyl is a C2-C6 alkynyl containing one or two carbon-to-carbon triple bonds. In some embodiments, the alkynyl is a C2-C4 alkynyl containing one carbon-to-carbon triple bond. Non-limiting exemplary alkynyl groups include ethynyl, i.e., -C=CH, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.
[0390] The term "optionally substituted alkynyl" as used herein by itself or as part of another group refers to an alkynyl that is either unsubstituted or substituted with one or more, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy) alkyl, (cycloalkyl) alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroarylsulfonyl; carbonyl,e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroarylcarbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)RJ; N(R')S(=0)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, RJ, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0391] In some embodiments, the optionally substituted alkynyl has four substituents. In some embodiments, the optionally substituted alkynyl has three substituents. In some embodiments, the optionally substituted alkynyl has two substituents. In some embodiments, the optionally substituted alkynyl has one substituent. In some embodiments, the optionally substituted alkynyl is unsubstituted. Non-limiting exemplary optionally substituted alkynyl groups include -C=CPh and -CH(Ph)C=CH.
[0392] The term "cycloalkyl" as used herein by itself or as part of another group refers to a saturated and partially unsaturated, e.g., containing one or two double bonds, monocyclic, bicyclic, or tricyclic unsubstituted aliphatic hydrocarbon radical, that may include fused, bridged, or spirocyclic systems, containing three to twelve carbon atoms, i.e., a C3-C12 cycloalkyl, or the number of carbons designated. In some embodiments, the cycloalkyl is bicyclic, i.e., it has two rings. In some embodiments, the cycloalkyl is monocyclic, i.e., it has one ring. In some embodiments, the cycloalkyl is a C3-C8 cycloalkyl. In some embodiments, the cycloalkyl is a C3-C6 cycloalkyl, i.e., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, Non-limiting exemplary C3-12 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, and spiro[3.3]heptane.
[0393] The term "optionally substituted cycloalkyl" as used herein by itself or as part of another group refers to a cycloalkyl that is either unsubstituted or substituted with one or more, e.g., one. two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroarylsulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroarylcarbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)R';N(R')S(=0)2Rk; or -OR111, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, RJ, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0394] In some embodiments, the optionally substituted cycloalkyl has four substituents.In some embodiments, the optionally substituted cycloalkyl has three substituents. In some embodiments, the optionally substituted cycloalkyl has two substituents. In some embodiments, the optionally substituted cycloalkyl has one substituent. In some embodiments, the optionally substituted cycloalkyl is unsubstituted. The term cycloalkyl includes groups wherein one or more -CH2- groups in the ring is replaced with one or more -C(=O)- groups. The term optionally substituted cycloalkyl also includes cycloalkyl groups having fused optionally substituted aryl groups or fused optionally substituted heteroaryl groups such as:
[0395] Non-limiting exemplary optionally substituted cycloalkyl groups include:
[0396] The term "heterocyclo" as used herein by itself or as part of another group refers to a saturated and partially unsaturated, e.g., containing one or two double bonds, monocyclic, bicyclic, or tricyclic radical, that may include fused, bridged, or spirocyclic systems, containing three to eighteen ring members, i.e., a 3- to 18-membered heterocyclo, comprising carbon atoms and one, two, three, or four heteroatoms. Each heteroatom is independently oxygen, sulfur, or nitrogen. Each sulfur atom is independently oxidized to give a sulfoxide or sulfone. The term heterocyclo includes groups wherein one or more -CH2- groups is replaced with one or more -C(=O)- groups and / or -C(=S)- groups, including cyclic ureido groups such as imidazolidinyl-2-one, cyclic amide groups such as pyrrolidin-2-one or piperidin-2-one, and cyclic carbamate groups such as oxazolidinyl-2-one. The term heterocyclo also includes groups having fused optionally substituted aryl or optionally substituted heteroaryl groups such as indoline, indolin-2-one, 2,3-dihydro-lH-pyrrolo[2,3-c]pyridine, 2,3,4,5-tetrahydro-lH- benzo[d] azepine, or l,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one.
[0397] In some embodiments, the heterocyclo is a 4- to 8-membered cyclic radical containing one ring and one or two oxygen atoms, e.g., tetrahydrofuran or tetrahydropyran, or one or two nitrogen atoms, e.g., pyrrolidine, piperidine, or piperazine, or one oxygen and one nitrogen atom, e.g., morpholine, and, optionally, one -CH2- group is replaced with one -C(=O)- group, e.g., pyrrolidin-2-one or piperazin-2-one. In some embodiments, the heterocyclo is a 5- to 8-membered cyclic radical containing one ring and one or two nitrogen atoms and, optionally, one -CH2- group is replaced with one -C(=O)- group.
[0398] In some embodiments, the heterocyclo is a 5- to 8-membered cyclic radical nitrogen atoms, one -CH2- group replaced a -C(=O)- group and one CH2- group replaced a -C(=S)- group, e.g., 2-thioxoimidazolidin-4-one. In some embodiments, the heterocyclo is a 5- or 6-membered cyclic radical containing one ring and one or two nitrogen atoms and, optionally, one -CH2- group is replaced with one -C(=O)- group. In some embodiments, the heterocyclo is an 8- to 12-membered cyclic radical containing two rings and one or two nitrogen atoms. The heterocyclo can be linked to the rest of the molecule through any available carbon or nitrogen radical. Non-limiting exemplary heterocyclo groups include:
[0399] The term "optionally substituted heterocyclo" as used herein by itself or part of another group refers to a heterocyclo that is either unsubstituted or substituted with one or more, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroarylsulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroarylcarbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)RJ; -N(R')S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy,heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, RJ, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0400] In some embodiments, the optionally substituted heterocyclo has four substituents. In some embodiments, the optionally substituted heterocyclo has three substituents. In some embodiments, the optionally substituted heterocyclo has two substituents. In some embodiments, the optionally substituted heterocyclo has one substituent. In some embodiments, the optionally substituted heterocyclo is unsubstituted. Non-limiting exemplary optionally substituted heterocyclo groups include:
[0401] In some embodiments, the heterocyclo group is a spiroheterocyclo. The term "spiroheterocyclo" as used herein by itself or part of another group refers to an optionally substituted heterocyclo group containing seven to eighteen ring members, or the number of ring members designated, wherein:
[0402] (i) a first and second ring are connected through a quaternary carbon atom, i.e., a spirocarbon;
[0403] (ii) the first ring is an optionally substituted mono- or bicyclic heterocyclo containing a nitrogen atom; and
[0404] (iii) the second ring is either:
[0405] (a) an optionally substituted mono- or bicyclic cycloalkyl; or
[0406] (b) an optionally substituted mono- or bicyclic heterocyclo containing a nitrogen atom.
[0407] In one embodiment, the first ring is an optionally substituted monocyclic 4- to 9- membered heterocyclo containing a nitrogen atom. In another embodiment, the second ring is an optionally substituted monocyclic C3-8 cycloalkyl. In another embodiment, the second ring is a monocyclic C3-8 cycloalkyl substituted with a hydroxy group. In another embodiment, the second ring is an optionally substituted monocyclic 4- to 9-membered heterocyclo containing a nitrogen atom. Non-limiting exemplary spiroheterocyclo groups include:
[0408] The term "aryl" as used herein by itself or as part of another group refers to an aromatic radical having six to fourteen carbon atoms, i.e., C6-C14 aryl. Non-limiting exemplary aryl groups include phenyl (abbreviated as " Ph"), naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. In some embodiments, the aryl group is phenyl or naphthyl. In some embodiments, the aryl group is phenyl.
[0409] The term "optionally substituted aryl" as used herein by itself or as part of another group refers to aryl that is either unsubstituted or substituted with one, two, three, four, or five substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroarylsulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroarylcarbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)RJ; N(R')S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, RJ, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0410] In some embodiments, the optionally substituted aryl is an optionally substituted phenyl. In some embodiments, the optionally substituted phenyl has four substituents. In some embodiments, the optionally substituted phenyl has three substituents. In some embodiments, the optionally substituted phenyl has two substituents. In some embodiments, the optionally substituted phenyl has one substituent. Non-limitingexemplary optionally substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3 -methylphenyl, 3 -methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl, 3,5-dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, 3-chloro- 4-fluorophenyl, and 2-phenylpropan-2-amine. The term optionally substituted aryl includes aryl groups having fused optionally substituted cycloalkyl groups or fused optionally substituted heterocyclo groups. Non-limiting exemplary fused aryl groups include:
[0411] The term "heteroaryl" as used herein by itself or as part of another group refers to a monocyclic and bicyclic aromatic radical having 5 to 14 fourteen ring members, i.e., a 5- to 14- membered heteroaryl, comprising one, two, three, or four heteroatoms. Each heteroatom is independently oxygen, sulfur, or nitrogen. In some embodiments, the heteroaryl has three heteroatoms. In some embodiments, the heteroaryl has two heteroatoms. In some embodiments, the heteroaryl has one heteroatom. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl has 5 ring atoms, e.g., thienyl, a 5-membered heteroaryl having four carbon atoms and one sulfur atom. In some embodiments, the heteroaryl has 6 ring atoms, e.g., pyridyl, a 6-membered heteroaryl having five carbon atoms and one nitrogen atom. Non-limiting exemplary heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, P-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl,isoxazolyl, furazanyl, and phenoxazinyl. In some embodiments, the heteroaryl is chosen from thienyl, e.g., thien-2-yl and thien-3-yl, furyl, e.g., 2-furyl and 3-furyl, pyrrolyl, e.g., lH-pyrrol-2-yl and lH-pyrrol-3-yl), imidazolyl, e.g., 2H-imidazol-2-yl and 2H-imidazol- 4-yl, pyrazolyl, e.g., lH-pyrazol-3-yl, lH-pyrazol-4-yl, and lH-pyrazol-5-yl, pyridyl, e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl, pyrimidinyl, e.g., pyrimidin-2-yl, pyrimidin-4-yl, and pyrimidin-5-yl, thiazolyl, e.g., thiazol-2-yl, thiazol-4-yl, and thiazol- 5-yl, isothiazolyl, e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl, oxazolyl, e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl, and isoxazolyl, e.g., isoxazol-3-yl, isoxazol-4- yl, and isoxazol-5-yl. The term heteroaryl also includes N-oxides. A non-limiting exemplary N-oxide is pyridyl N-oxide.
[0412] The term "optionally substituted heteroaryl" as used herein by itself or as part of another group refers to a heteroaryl that is either unsubstituted or substituted with one or more substituents, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroarylsulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroarylcarbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)Rj; -N(R‘)S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, RJ, Rk, and Rmare as defined in connection with optionally substituted alkyl. The term optionally substituted heteroaryl includes heteroaryl groups having fused optionally substituted cycloalkyl groups or fused optionally substituted heterocyclo groups. Non-limiting exemplary fused heteroaryl groups include:
[0413] In some embodiments, the optionally substituted heteroaryl has four substituents.In some embodiments, the optionally substituted heteroaryl has three substituents. In some embodiments, the optionally substituted heteroaryl has two substituents. In someembodiments, the optionally substituted heteroaryl has one substituent. In some embodiments, the optionally substituted heteroaryl is unsubstituted. Any available carbon or nitrogen atom can be substituted. The term optionally substituted heteroaryl includes heteroaryl groups having fused optionally substituted cycloalkyl groups or fused optionally substituted heterocyclo groups. Non-limiting exemplary optionally substituted heteroaryl groups include:
[0414] The term "alkoxy" as used herein by itself or as part of another group refers to an alkyl attached to a terminal oxygen radical, i.e., a radical of the formula -OR111, wherein Rmis an alkyl. In some embodiments, the alkyl is a Ci-Ce alkyl, and thus the resulting alkoxy is referred to as a " Ci-Ce alkoxy." In some embodiments, the alkyl is a C1-C4 alkyl group and thus the resulting alkoxy is referred to as a " C1-C4 alkoxy." Non-limiting exemplary alkoxy groups include methoxy, ethoxy, and tert-butoxy.
[0415] The term "haloalkoxy" as used herein by itself or as part of another group refers to a haloalkyl attached to a terminal oxygen radical, i.e., a radical of the formula -ORm, wherein Rmis a haloalkyl. In some embodiments, the haloalkyl is a Ci-Ce haloalkyl and thus the resulting haloalkoxy is referred to as a " Ci-Ce haloalkoxy." In some embodiments, the haloalkyl is a C1-C4 haloalkyl and thus the resulting haloalkoxy is referred to as a " C1-C4 haloalkoxy." Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy.
[0416] The term "aryloxy" as used herein by itself or as part of another group refers to an optionally substituted aryl attached to a terminal oxygen radical, i.e., a radical of the formula -ORm, wherein Rmis an optionally substituted aryl. In some embodiments, the optionally substituted aryl is an optionally substituted phenyl. A non-limiting exemplary aryloxy group is PhO-.
[0417] The term "heteroaryloxy" as used herein by itself or as part of another group refers to an optionally substituted heteroaryl attached to a terminal oxygen radical, i.e., a radical of the formula -ORm, wherein Rmis an optionally substituted heteroaryl. In some embodiments, the optionally substituted heteroaryl is an optionally substituted 5- to 10- membered heteroaryl. A non-limiting exemplary aryloxy group is pyridyl-O-.
[0418] The term "(aryl)alkyloxy" as used herein by itself or as part of another group refers to an (aryl)alkyl attached to a terminal oxygen radical, i.e., a radical of the formula -ORm, wherein Rmis an (aryl)alkyl. In some embodiments, the aryl group is an optionally substituted phenyl. In some embodiments, the alkyl group is a C1-C4 alkyl and thus the resulting (aryl)alkyloxy is referred to as a "(aryl)Ci-C4 alkyloxy." Non-limiting exemplary aralkyloxy groups include PhCH2O- and Ph-CH2CH2-.
[0419] The term "alkylthio" as used herein by itself or as part of another group refers to an alkyl group attached to a terminal sulfur radical. In some embodiments, the alkyl group is a C1-C4 alkyl group and thus the resulting alkylthio is referred to as a " C1-C4 alkylthio." Non-limiting exemplary alkylthio groups include -SCH3, and -SCH2CH3.
[0420] The term "sulfonyl" as used herein by itself or as part of another group refers to refers to a radical of the formula -S(=O)2R°, wherein R° is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl.
[0421] In some embodiments, the sulfonyl is an "alkylsulfonyl," i.e., a -S(=O)2- group substituted with one optionally substituted alkyl group. In some embodiments, the sulfonyl group is substituted with a C1-C4 alkyl group and thus the resulting alkylsulfonyl group is referred to as a " C1-C4 alkylsulfonyl." A non-limiting exemplary alkylsulfonyl group is -S(=O)2CH3.
[0422] In some embodiments, the sulfonyl is a "cycloalkylsulfonyl," i.e., a -S(=O)2- group substituted with one optionally substituted cycloalkyl group. In some embodiments, the sulfonyl group is substituted with optionally substituted C3-C6 cycloalkyl group and thus the resulting cycloalkylsulfonyl group is referred to as a " C3-C6 cycloalkylsulfonyl." A non-limiting exemplary cycloalkylsulfonyl group is - S (=O)2-cyclohexyl.
[0423] In some embodiments, the sulfonyl is a "heterocyclosulfonyl," i.e., a -S(=O)2- group substituted with one optionally substituted heterocyclo group. In some embodiments, the sulfonyl group is substituted with an optionally substituted 4- to8-membered heterocyclo group and thus the resulting heterocyclosulfonyl group is referred to as a "4- to 8-membered heterocyclosulfonyl." A non-limiting exemplary heterocyclosulfonyl group is:
[0424] In some embodiments, the sulfonyl is an "arylsulfonyl," i.e., a -S(=O)2- group substituted with one optionally substituted aryl group. In some embodiments, the sulfonyl group is substituted with one optionally substituted phenyl and thus the resulting arylsulfonyl is referred to as a "phenylsulfonyl. " A non-limiting exemplary arylsulfonyl group is -S(=O)2Ph.
[0425] In some embodiments, the sulfonyl is a "heteroarylsulfonyl," i.e., a -S(=O)2- group substituted with an optionally substituted heteroaryl group. In some embodiments, the sulfonyl group is substituted with an optionally substituted 5- to 10-membered heteroaryl group and thus the resulting heteroarylsulfonyl is referred to as a "5- to 10- membered heteroaryl sulfonyl." A non-limiting exemplary heteroarylsulfonyl group is:
[0426] The term "carbonyl" as used herein by itself or as part of another group refers to refers to a radical of the formula -C(=O)R°, wherein R° is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl.
[0427] In some embodiments, the carbonyl is an "alkylcarbonyl," i.e., a -C(=O)- group substituted with one optionally substituted alkyl group. In some embodiments, the carbonyl group is substituted with a C1-C4 alkyl group and thus the resulting alkylcarbonyl group is referred to as a " C1-C4 alkylcarbonyl." A non-limiting exemplary alkylcarbonyl group is -C(=O)CH3.
[0428] In some embodiments, the carbonyl is a "cycloalkylcarbonyl," i.e., a -C(=O)- group substituted with one optionally substituted cycloalkyl group. In some embodiments, the carbonyl group is substituted with optionally substituted C3-C6 cycloalkyl group and thus the resulting cycloalkylcarbonyl group is referred to as a " C3-C6 cycloalkylcarbonyl." A non- limiting exemplary cycloalkylcarbonyl group is - C(=O)cyclohexyl.
[0429] In some embodiments, the carbonyl is a "heterocyclocarbonyl," i.e., a -C(=O)- substituted with one optionally substituted heterocyclo group. In some embodiments, the carbonyl group is substituted with an optionally substituted 4- to 8-membered heterocyclo group and thus the resulting heterocyclocarbonyl group is referred to as a "4- to 8-membered heterocyclocarbonyl." A non-limiting exemplary heterocyclocarbonyl group is:
[0430] In some embodiments, the carbonyl is an "arylcarbonyl," i.e., a -C(=O)- group substituted with one optionally substituted aryl group. In some embodiments, the carbonyl group is substituted with one optionally substituted phenyl and thus the resulting arylcarbonyl is referred to as a "phenylcarbonyl." A non- limiting exemplary arylcarbonyl group is -C(=O)Ph.
[0431] In some embodiments, the carbonyl is a "heteroarylcarbonyl," i.e., a -C(=O)- group substituted with an optionally substituted heteroaryl group. In some embodiments, the carbonyl group is substituted with an optionally substituted 5- to 10-membered heteroaryl group and thus the resulting heteroarylcarbonyl is referred to as a "5- to 10- membered heteroarylcarbonyl." A non-limiting exemplary heteroarylcarbonyl group is:
[0432] The term "carboxamido" as used herein by itself or as part of another group refers to a radical of formula -C(=O)NRcRd, wherein Rcand Rdare independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, and optionally substituted heteroaryl; or Rcand Rdtaken together with the nitrogen to which they are attached form an optionally substituted heterocyclo group. In some embodiments, Rcand Rdare each independently hydrogen, Ci-Ce alkyl, or optionally substituted aryl. Non-limiting exemplary carboxamido groups include -C(=O)NH2, -C(=O)N(H)CH3, and -C(=O)N(H)Ph.
[0433] The term "sulfonamide" as used herein by itself or as part of another group refers to a radical of the formula -S(=O)2NReRf, wherein Reand Rfare independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted cycloalkyl, optionally heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl; or Reand Rftaken together with the nitrogen to which they are attached form an optionally substituted heterocyclo group. Non-limiting exemplary sulfonamide groups include -S(=O)2NH2, -S(=O)2N(H)CH3, and - S(=O)2N(H)Ph.
[0434] The term "carboxyl" as used herein by itself or as part of another group refers to a radical of the formula -C(=O)ORg, wherein Rgis hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl. Non-limiting exemplary carboxyl groups include -C(=O)OH and -C(=O)OtBu.
[0435] The term "alkylenyl" as used herein by itself or part of another group refers to a divalent form of an optionally substituted alkyl group. In some embodiments, the alkylenyl is a divalent form of an optionally substituted C1-C12 alkyl, i.e., an optionally substituted C1-C12 alkylenyl, or the number of carbon atoms designated, e.g., an optionally substituted C1-C3 alkylenyl such as -CH2-, --CH2CH2-, -CH2-CH2CH2-. In some embodiments, the alkylenyl is a divalent form of an optionally substituted C1-C10 alkyl, i.e., an optionally substituted C1-C10 alkylenyl. In some embodiments, the alkylenyl is a divalent form of an optionally substituted C1-C8 alkyl, i.e., an optionally substituted C1-C8 alkylenyl. In some embodiments, the alkylenyl is a divalent form of an unsubstituted C1-C6 alkyl, i.e., a C1-C6 alkylenyl. In some embodiments, the alkylenyl is a divalent form of an unsubstituted C1-C4 alkyl, i.e., a C1-C4 alkylenyl. Non-limiting exemplary alkylenyl groups include -CH2-, -CH2CH2-, -CH(Ph)-, -CH(Ph)CH2-, -CH2-CH2CH2-, - CH(Ph)CH2CH2-, -CH2(CH2)2CH2-, -CH2(CH2)3CH2-, and -CH2(CH2)4CH2-.
[0436] The term "heteroalkylenyl" as used herein by itself or part of another group refers to a divalent form of a heteroalkyl group. In some embodiments, the heteroalkylenyl is a divalent form of a 3- to 16-membered heteroalkyl, i.e., an optionally substituted C3-C16 heteroalkylenyl, or the number of chain atoms atoms designated. In some embodiments, the heteroalkylenyl is a divalent form of a C3-C10 heteroalkyl, i.e., a C3-C10 heteroalkylenyl. In some embodiments, the alkylenyl is a divalent form of an optionally substituted C3-C8 heteroalkyl, i.e., an optionally substituted C3-C8 heteroalkylenyl. In some embodiments, the alkylenyl is a divalent form of a C3-C6 heteroalkyl, i.e., a C3-C6 heteroalkylenyl. In another embodiment, the heteroalkylenyl is a radical of the formula -(CH2CH2O)zz-, wherein zz is 1, 2, 3, 4, or 5. Non-limiting exemplaryheteroalkylenyl groups include -CH2CH2O-, -CH2OCH2-, -CH2CH2OCH2CH2O-, - CH2OCH2-CH2CH2-, and -CH2CH2OCH2CH2OCH2CH2O-.
[0437] The term "cycloalkylenyl" as used herein by itself or part of another group refers to a divalent form of an optionally substituted cycloalkyl group. In some embodiments, the cycloalkylenyl is a divalent form of an optionally substituted C3-C12 cycloalkyl, i.e., a C1-C12 cycloalkylenyl, or the number of carbons designated. In some embodiments, the cycloalkylenyl is a divalent form of an optionally substituted C3-C8 cycloalkyl, i.e., an optionally substituted C3-C8 cycloalkylenyl. In some embodiments, the cycloalkylenyl is a divalent form of an optionally substituted monocyclic C5 or C6 cycloalkyl. Nonlimiting exemplary cycloalkylenyl groups include:
[0438] The term "arylenyl" as used herein by itself or part of another group refers to a divalent form of an optionally substituted arylenyl group. In some embodiments, the arylenyl is substituted with one, two, or three substituents. In some embodiments, the arylenyl is substituted with one or two substituents. In some embodiments, the arylenyl is substituted with one substituent. In some embodiments, the arylenyl is unsubstituted. In some embodiments, the arylenyl is a divalent form of an optionally substituted naphthyl group. Non-limiting exemplary arylenyl groups include:
[0439] In some embodiments, the arylenyl is a divalent form of an optionally substituted phenyl group, i.e., a phenylenyl group. The term "phenylenyl" as used herein by itself or part of another group refers to a divalent form of an optionally substituted phenyl group. In some embodiments, the phenylenyl is substituted with one, two, or three substituents. In some embodiments, the phenylenyl is substituted with one or two substituents. In some embodiments, the phenylenyl is substituted with one substituent. In some embodiments, the phenylenyl is unsubstituted. Non-limiting exemplary phenylenyl groups include:
[0440] The term "heterocyclenyl" as used herein by itself or part of another group refers to a divalent form of an optionally substituted heterocyclo group. In some embodiments, the heterocyclenyl is a divalent form of an optionally substituted 4- to 14-membered heterocyclo group, i.e., an optionally substituted 4- to 14-membered heterocyclenyl, or the number of carbons designated. In some embodiments, the heterocyclenyl is a divalent form of an optionally substituted 4- to 10-membered heterocyclo group, i.e., an optionally substituted 4- to 10-membered heterocyclenyl. In some embodiments, the heterocyclenyl is a divalent form of an optionally substituted 4- to 8-membered heterocyclo group, i.e., an optionally substituted 4- to 8-membered heterocyclenyl. In some embodiments, the heterocyclenyl is a divalent form of an unsubstituted 4- to 6- membered heterocyclo group, i.e., a 4- to 6-membered heterocyclenyl. In some embodiments, the heterocyclenyl is a divalent form of an optionally substituted azetidine. In some embodiments, the heterocyclenyl is a divalent form of an optionally substituted piperidinyl. In some embodiments, the heterocyclenyl is a divalent form of an optionally substituted piperazinyl. Non-limiting exemplary heterocyclenyl groups include:
[0441] In some embodiments, the heterocyclenyl is a spiroheterocyclenyl. The term "spiroheterocyclenyl" as used herein by itself or part of another group refers to a divalent form of a spiroheterocyclo. In some embodiments, the spiroheterocyclenyl is a 7- to 11- membered spiroheterocyclo. Non-limiting exemplary spiroheterocyclenyl groups include:
[0442] The term "heteroarylenyl" as used herein by itself or part of another group refers to a divalent form of an optionally substituted heteroaryl group. In some embodiments, the heteroarylenyl is a divalent form of an optionally substituted 5- to 9-membered heteroaryl, e.g., a 5- to 9-membered heteroarylenyl, or the number of members designated. In some embodiments, the heteroarylenyl is an optionally substituted 5-membered heteroarylenyl, e.g., heteroarylenyl derived from thiophene or pyrazole. In some embodiments, the hetero arylenyl is an optionally substituted 6-membered heteroarylenyl, e.g., heteroarylenyl derived from pyridine. In some embodiments, the heteroarylenyl is an optionally substituted bicyclic 9-membered heteroarylenyl. In some embodiments, the heteroarylenyl is unsubstituted. Exemplary non-limiting heteroarylenyl groups include:
[0443] The term "boronic ester" as used herein by itself or part of another group refers to -B(ORp)(ORq), wherein Rpand Rqare each independently selected from optionally substituted alkyl, or Rpand Rqtogether with the oxygen atoms to which they are attached form an optionally substituted 5- to 7-membered heterocyclyl. In some embodiments, the boronic ester is boronic pinacol ester having the following structure:
[0444] In some embodiments, L of Formula (I) or L2of Formula (II- VII) comprises a combination of stable covalent bonds comprising 1-50 non-hydrogen atoms, e.g., 1-45 non-hydrogen atoms, 1-40 non-hydrogen atoms, 1-35 non-hydrogen atoms, 1-30 nonhydrogen atoms, 1-25 non-hydrogen atoms, 1-20 non-hydrogen atoms, 1-15 nonhydrogen atoms, or 1-10 non-hydrogen atoms, wherein the non-hydrogen atoms are selected from the group consisting of C, N, O, and S. Stable covalent bonds include, but are not limited to, carbon-carbon bonds, carbon-nitrogen bonds, nitrogen-nitrogen bonds, carbon-sulfur bonds, and carbon-oxygen bonds, and single, double, triple, and aromatic bonds.
[0445] The chemical structure of L of Formula (I) or L2of Formula (II- VII) is delimited by principles of chemical bonding known to those skilled in the art. Accordingly, for example, each of X1, X2, X3, X4, and X3is selected so as to comply with established principles of chemical bonding and to give linkers that are not inherently unstable and / or would not be known to be unstable under typical isolation / purification conditions and / or physiological conditions to one of ordinary skill in the art. For example, in some embodiments, L2comprises: (i) no oxygen-oxygen bonds, e.g., -X'-X2- cannot be -O-O-; (ii) no more than two consecutive non-aromatic nitrogen-nitrogen bonds and / or nitrogenoxygen bonds, e.g., -X1-X2-X3- cannot be -N(Rla)-N(Rla)-N(Rla)- or -N(Rla)-O-N(Rla)-; (iii) no more than two consecutive -C(=O)- groups, e.g., -X^X^X3- cannot be -C(=O)- C(=O)-C(=O)-; (iv) no more than two consecutive -C=C- groups, e.g., -X1-X2-X3- cannot be -C=C-C=C-C=C-; and so on, thereby avoiding inherently unstable compounds.
[0446] In another embodiment, L2is -X1-X2-X3-X4-*, i.e., -X3- is absent.
[0447] In another embodiment, L2is -X1-X2-X3-*, i.e., -X4- and -X3- are absent.
[0448] In another embodiment, L2is -X^X2-*, i.e., -X3-, -X4-, and -X3- are absent.
[0449] In another embodiment, L2is - X1-*, i.e., -X2-, -X3-, -X4-, and -X5- are absent.
[0450] In another embodiment, L2is a bond, i.e., -X1-, -X2-, -X3-, -X4-, and -X3- are absent.
[0451] In another embodiment, -X2is a 7- to 11 -membered spiroheterocyclenyl
[0452] In another embodiment, -X3- or -X4- is a 7- to 11-membered spiroheterocyclenyl.
[0453] The term "optionally substituted" as used herein means that substitution is optional and thus it is possible for the designated atom or group to be unsubstituted. In the event the designated atom or group is substituted then such substitution means that at least one hydrogen atom on the designated atom or group is replaced with at least one non-hydrogen atom, provided that the normal valency of the designated atom or group is not exceeded and the substitution results in a stable compound. Optional substituents may include, but are not limited to, the following atoms and groups, halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl) alkyl, (heterocyclo) alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroarylsulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroarylcarbonyl; carboxamido; sulfonamide; carboxyl;N(Rh)C(=O)R'; -N(R')S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl) alkyloxy,
[0454] wherein:
[0455] Rhis hydrogen or alkyl;
[0456] R1is hydrogen or alkyl;
[0457] RJis alkoxy, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl;
[0458] Rkis amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl; and
[0459] Rmis optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, optionally substituted heteroaryl, carboxamido, or carbonyl.
[0460] The term "stable compound" refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture and subsequent formulation into an efficacious therapeutic agent.
[0461] The present disclosure encompasses any of the Compounds of the Disclosure being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as2H (or deuterium (D)),3H,nC,13C,14C,15N,18O,17O,31P,32P,35S,18F, and36C1, respectively, e.g.,3H,nC, and14C. In one embodiment, provided is a composition wherein substantially all of the atoms at a position within the Compound of the Disclosure are replaced by an atom having a different atomic mass or mass number. In another embodiment, provided is a composition wherein a portion of the atoms at a position within the Compound of the disclosure are replaced, i.e., the Compound of the Disclosure is enriched at a position with an atom having a different atomic mass or mass number. In some embodiments, one or more hydrogen atom are replaced with one or more deuterium atoms. Isotopically-labelled Compounds of the Disclosure can be prepared by methods known in the art.
[0462] Compounds of the Disclosure may contain one or more asymmetric carbon atoms and thus may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. The present disclosure encompasses the use of all such possible forms including racemic and resolved forms and mixtures thereof. Individual enantiomers of a chiral Compound of the Disclosure can be separated according to methods known in the art in view of the present disclosure. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers. All tautomers are also encompassed by the present disclosure.
[0463] As used herein, the term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
[0464] The term "chiral center" or "asymmetric carbon atom" refers to a carbon atom to which four different groups are attached.
[0465] The terms "enantiomer" and "enantiomeric" refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction.
[0466] The term "racemic" refers to an optically inactive mixture of equal parts of enantiomers. In one embodiment, Compounds of the Disclosure are racemic.
[0467] The term "absolute configuration" refers to the spatial arrangement of the atoms of a chiral molecular entity (or group) and its stereochemical description, e.g., R or S.
[0468] The stereochemical terms and conventions used in the specification are meant to be consistent with those described in Pure & Appl. Chem ri / ?:2193 (1996), unless otherwise indicated.
[0469] The term "enantiomeric excess" or "ee" refers to a measure for how much of one enantiomer is present compared to the other. For a mixture of R and. S' enantiomers, the percent enantiomeric excess is defined as | R - S | *100, where R and 5 are the respective mole or weight fractions of enantiomers in a mixture such that R + S = 1. With knowledge of the optical rotation of a chiral substance, the percent enantiomeric excess is defined as ([a]Obs / [a]max)*100, where [a]Obs is the optical rotation of the mixture of enantiomers and [a]max is the optical rotation of the pure enantiomer. Determination of enantiomeric excess is possible using a variety of analytical techniques, including NMR spectroscopy, chiral column chromatography, or optical polarimetry.
[0470] The term "pharmaceutically acceptable earner" as used herein refers to a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic and thus acceptable for veterinary and / or human pharmaceutical or therapeutic use. Pharmaceutically acceptable carriers include, but are not limited to, any excipient, diluent, filler, binder, buffer, stabilizer, solubilizer, disintegrant, lipid, stabilizer, suspension agent, viscosity agent, lubricant, glidant, or other material well known in the art for use in pharmaceutical formulations.
[0471] The term "excipient" as used herein refers to any and all solvents, diluents or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. General considerations in formulation and / or manufacture can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), andRemington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
[0472] Non-limiting exemplary excipients include, but are not limited to, any non-toxic, inert solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as excipients include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as com starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as Tween 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol: and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. As would be appreciated by one of skill in this art, the excipients may be chosen based on what the composition is useful for. For example, with a pharmaceutical composition, the choice of the excipient will depend on the route of administration, the agent being delivered, time course of delivery of the agent, etc., and can be administered to humans and / or to animals, orally, rectally, parenterally, intracisternally, intravaginally, intranasally, intraperitoneally, topically (as by powders, creams, ointments, or drops), buccally, or as an oral or nasal spray. In some embodiments, a Compound of the Disclosure administered orally or parenterally.
[0473] Non-limiting exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
[0474] Non-limiting exemplary granulating and / or dispersing agents include potato starch, com starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked polyvinylpyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
[0475] Non-limiting exemplary surface active agents and / or emulsifiers include natural emulsifiers, e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin, colloidal clays, e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate), long chain amino acid derivatives, high molecular weight alcohols, e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, and polyvinyl alcohol, carbomers, e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxy vinyl polymer, carrageenan, cellulosic derivatives, e.g., carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and methylcellulose, sorbitan fatty acid esters, e.g., polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan (Tween 60), polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60), sorbitan tristearate (Span 65), glyceryl monooleate, and sorbitan monooleate (Span 80), polyoxyethylene esters, e.g., polyoxyethylene monostearate (Mytj 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol, sucrose fatty acid esters, polyethylene glycol fatty acid esters, e.g., Cremophor, polyoxyethylene ethers,, e.g., polyoxyethylene lauryl ether (Brij 30), poly( vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cctylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and / or combinations thereof. Exemplary binding agents include starch,, e.g., cornstarch and starch paste, gelatin, sugars, e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc., natural and synthetic gums, e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks,carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, etc., and / or combinations thereof.
[0476] Non-limiting exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
[0477] Non-limiting exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
[0478] Non-limiting exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof, e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like, citric acid and salts and hydrates thereof, e.g., citric acid monohydrate, fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
[0479] Non-limiting exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
[0480] Non-limiting exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
[0481] Non-limiting exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid. Other preservatives include tocopherol, tocopherol acetate,deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, NeoIone, Kathon, and Euxyl. In certain embodiments, the preservative is an anti-oxidant. In other embodiments, the preservati ve is a chelating agent.
[0482] Non-limiting exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, etc., and combinations thereof.
[0483] Non-limiting exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.
[0484] A pharmaceutically acceptable composition of the present disclosure may further comprise a polymer. Non-limiting exemplary polymers include cellulosic polymers and copolymers, for example, cellulose ethers such as methylcellulose (MC), hydroxyethylcellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), methylhydroxyethylcellulose (MHEC), methylhydroxypropylcellulose (MHPC), carboxymethyl cellulose (CMC) and its various salts, including, c.g., the sodium salt, hydroxycthylcarboxymcthylccllulosc (HECMC) and its various salts, carboxymethylhydroxyethylcellulose (CMHEC) and its various salts, other polysaccharides and polysaccharide derivatives such as starch, dextran, dextran derivatives, chitosan, and alginic acid and its various salts, carageenan, varoius gums, including xanthan gum, guar gum, gum arabic, gum karaya, gum ghatti, konjacand gum tragacanth, glycosaminoglycans and proteoglycans such as hyaluronic acid and its salts, proteins such as gelatin, collagen, albumin, and fibrin, other polymers, for example, polyhydroxyacids such as polylactide, polyglycolide, polyl(lactide-co- glycolide) and poly(.epsilon.-caprolactone-co-glycolide)-, carboxyvinyl polymers and their salts e.g., carbomer, polyvinylpyrrolidone (PVP), polyacrylic acid and its salts, polyacrylamide, polyacrylic acid / acryl amide copolymer, polyalkylene oxides such as polyethylene oxide, polypropylene oxide, poly(ethylene oxide-propylene oxide), and a pluronic polymer, polyoxy ethylene (polyethylene glycol), polyanhydrides, polyvinyl alcohol, polyethyleneamine and polypyrridine, polyethylene glycol (PEG) polymers, such as PEGylated lipids, e.g., PEG-stearate, l,2-Distearoyl-sn-glycero-3- Phosphoethanolamine-N-(Methoxy(Polyethylene glycol)- 1000], 1,2-Distearoyl-sn- glycero-3-Phosphoethanolamine-N-(Methoxy (Polyethylene glycol)-2000], and 1,2- Distearoyl-sn-glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethyleneglycol)-5000]), copolymers and salts thereof.
[0485] A pharmaceutically acceptable composition of the present disclosure may further comprise an emulsifying agent. Non-limiting exemplary emulsifying agents include a polyethylene glycol (PEG), a polypropylene glycol, a polyvinyl alcohol, a poly-N-vinyl pyrrolidone and copolymers thereof, poloxamer nonionic surfactants, neutral water- soluble polysaccharides, e.g., dextran, Ficoll, celluloses, non-cationic poly(meth)acrylates, non-cationic polyacrylates, such as poly (meth) acrylic acid, and esters amide and hydroxy alkyl amides thereof, natural emulsifiers, e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin, colloidal clays, e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate), long chain amino acid derivatives, high molecular weight alcohols, e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, and polyvinyl alcohol, carbomers, e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxy vinyl polymer, carrageenan, cellulosic derivatives, e.g., carboxymcthylccllulosc sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and methylcellulose, sorbitan fatty acid ester, e.g., polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan (Tween 60), polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monopalmitate (Span 40),sorbitan monostearate (Span 60), sorbitan tristearate (Span 65), glyceryl monooleate, sorbitan monooleate (Span 80), polyoxyethylene esters, e.g., polyoxyethylene monostearate (Myrj 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol, sucrose fatty acid esters, polyethylene glycol fatty acid esters, e.g., Cremophor, polyoxyethylene ethers, e.g., polyoxyethylene lauryl ether (Brij 30), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and / or combinations thereof. In certain embodiments, the emulsifying agent is cholesterol.
[0486] Pharmaceutically acceptable liquid compositions of the present disclosure may include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition a Compound of the Disclosure, the liquid composition may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, e.g., cottonseed, groundnut, com, germ, olive, castor, and sesame oils, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0487] Pharmaceutically acceptable injectable compositions of the present disclosure may be, for example, injectable aqueous or oleaginous suspensions that may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be an injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents for pharmaceutical or cosmetic compositions that may be employed are water, Ringer's solution, U. S. P. and isotonic sodium chloride solution. In addition, sterile, fixed oils arc conventionally employed as a solvent or suspending medium. Any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. In certain embodiments, the particles are suspended in a carrier fluid comprising 1% (w / v) sodium carboxymethyl cellulose and0.1% (v / v) Tween 80. The injectable composition can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0488] Pharmaceutically acceptable compositions of the present disclosure for rectal or vaginal administration may be, for example, in the form of suppositories which can be prepared by mixing the particles with suitable non-irritating excipients or earners such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the particles.
[0489] Pharmaceutically acceptable solid compositions of the present disclosure may be, for example, capsules, tablets, pills, powders, and granules. In such solid compositions, the particles are mixed with at least one excipient and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0490] Tablets, capsules, pills, and granules comprising a Compound of the Disclosure can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in softand hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0491] Pharmaceutically acceptable compositions for topical or transdermal administration include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The Compound of the Disclosure is admixed with an excipient and any needed preservatives or buffers as may be required. The ointments, pastes, creams, and gels may contain, in addition to the Compound of the Disclosure, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.
[0492] Pharmaceutically acceptable powders and sprays may contain, in addition to the Compound of the Disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
[0493] The term "about," as used herein, includes the recited number ± 10%. Thus, "about 10" means 9 to 11.
[0494] As used herein, the term "and / or" is to be taken as specific disclosure of each of the two specified features or components with or without the other, thus, the term "and / or" as used in a phrase such as " A and / or B" herein is intended to include " A and B," " A or B," " A" (alone), and " B" (alone). Likewise, the term "and / or" as used in a phrase such as " A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C: A or B; A or C; B or C; A and B; A and C; B and C: A (alone); B (alone); and C (alone).
[0495] The use of the terms "a", "an", "the", and similar referents in the context of describing the disclosure (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated. Recitation of ranges of values herein merely are intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The use of any and all examples, or exemplary language, e.g., "such as," provided herein, is intended to better illustrate the disclosure and is not a limitation on the scope of the disclosure unless otherwise claimed. No language in thespecification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.
[0496] The word "comprising" is used in a manner consistent with its open-ended meaning, that is, to mean that a given product, composition, or process can optionally also have additional features or elements beyond those expressly described. It is understood that wherever embodiments are described with the language "comprising," otherwise analogous embodiments described in terms of "consisting of" and / or "consisting essentially of" are also contemplated and within the scope of this disclosure.
[0497] Pharmaceutically acceptable and solvates, e.g., hydrates, of the Compounds of the Disclosure can also be used in the methods disclosed herein.
[0498] The present disclosure encompasses the preparation and use of pharmaceutically acceptable salts of Compounds of the Disclosure. Pharmaceutically acceptable salts of Compounds of the Disclosure can be prepared during the final isolation and purification of the compounds or separately by reacting the compound with a suitable acid or base. Pharmaceutically acceptable salts of Compounds of the Disclosure can be acid addition salts formed with acceptable acids. Examples of acids which can be employed to form salts include inorganic acids such as nitric, boric, hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Non-limiting examples of salts of compounds of the disclosure include, but are not limited to, the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, 2-hydroxyethansulfonate, phosphate, hydrogen phosphate, acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerolphosphate, hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate, maleate, ascorbate, isethionate, salicylate, methanesulfonate, mesitylenesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, paratoluenesulfonate, undecanoate, lactate, citrate, tartrate, gluconate, methanesulfonate, ethanedisulfonate, benzene sulfonate, and p-tolucncsulfonatc salts. In addition, available amino groups present in the compounds of the disclosure can be quatemized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates: decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.- I ll -
[0499] The present disclosure encompasses the preparation and use of solvates of Compounds of the Disclosure. The term "solvate" as used herein is a combination, physical association and / or solvation of a compound of the present disclosure with a solvent molecule such as, e.g., a disolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to compound of the present disclosure is about 2:1, about 1:1 or about 1:2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. Thus, "solvate" encompasses both solution-phase and isolatable solvates. Compounds of the Disclosure can be present as solvated forms with a solvent, such as water, methanol, and ethanol, and it is intended that the disclosure includes both solvated and unsolvated forms of Compounds of the Disclosure.
[0500] One type of solvate is a hydrate. A "hydrate" relates to a particular subgroup of solvates where the solvent molecule is water. Preparation of solvates is known in the art. See, for example, M. Caira et al, J. Pharmaceut. Sci., 93(3) 601-611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by van fonder et al., AAPS Pharm. Sci. lech., 5(1)'. Article 12 (2004), and A. L. Bingham et al., Chem. Commun. 603-604 (2001). A typical, non-limiting, process of preparing a solvate would involve dissolving a Compound of the Disclosure in a desired solvent (organic, water, or a mixture thereof) at temperatures above 20°C to about 25 °C, then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
[0501] In light of the foregoing, any reference to Compounds of the Disclosure appearing in the present disclosure includes such compounds as well as pharmaceutically acceptable salts, hydrates, or solvates thereof.VIII. Particular Embodiments
[0502] The present disclosure provides the following particular embodiments.
[0503] Embodiment 1. A compound having Formula (I):CPBi— L-ARi (j),
[0504] or a pharmaceutically acceptable salt thereof, wherein:
[0505] CBPi is a monovalent radical of a CBP / p300 protein inhibitor;
[0506] ARi is a monovalent radical of an androgen receptor inhibitor; and
[0507] L is a covalent linker, i.e., a stable divalent radical, comprising 1-50 nonhydrogen atoms selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
[0508] Embodiment 2. A compound having Formula (II):(II),
[0509] or a pharmaceutically acceptable salt thereof, wherein:
[0510] R1is selected from the group consisting of C1-C4 alkoxy, C1-C4 haloalkyl, and halo;
[0511] W is selected from the group consisting of =N- and =CH-;
[0512] R2is selected from the group consisting of hydrogen and C1-C4 alkyl;
[0513] m is 0, 1, 2, 3, or 4;
[0514] R3is selected from the group consisting of:
[0100] n = 0, 1 or 2;
[0101] X is selected from the group consisting of O, -NCH3and -CH2-;
[0515] U is selected from the group consisting of O, -NR3aand -CHR3a-; R3aat each occurrence is independently selected from the group consisting of hydrogen and C1-C4 alkyl;
[0516] R3bis selected from the group consisting of hydrogen, optionally substituted C1-C6alkyl, optionally substituted C3-C6cycloalkyl, and optionally substituted 4- to 8-membered heterocyclo;
[0517] R3Cis selected from the group consisting of hydrogen and optionally substituted Ci-C6alkyl; or
[0518] R3band R3ctaken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered heterocyclo;
[0519] R4is selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, and optionally substituted 4- to 8- membered heterocyclo;
[0520] V and Y are selected from the group consisting of -N= and -C(R5)=;
[0521] R5is selected from the group consisting of hydrogen, halo, cyano, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
[0522] R6is selected from the group consisting of hydrogen, halo, cyano, optionally substituted Ci-Ce alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted 4- to 8-membered heterocyclo, optionally substituted 5- to 9-membered heteroaryl, and -ORm;
[0523] Rmis selected from the group consisting of optionally substituted C1-C4 alkyl and optionally substituted C3-C6 cycloalkyl;
[0524] R12is selected from the group consisting of -C(=O)R12a, -C(=O)NR12bR12c, and -C(=O)OR12d;
[0525] R12ais selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl;
[0526] R12bis selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl;
[0527] R12Cis selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl; or
[0528] R12band R12Ctaken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered heterocyclo;
[0529] R12dis C1-C4 alkyl;
[0530] Z is absent; or
[0531] Z is selected from the group consisting of -O- and -N(Rla)-;
[0532] Ring A is -Cs cycloalkylenyl; and L1is -N(Rlb)-C(=O)-A, wherein the bond marked with an "A" is attached to Ring B; or
[0533] Ring A is 7- to 11 -membered spiroheterocyclenyl; and L1is absent; or
[0534] Ring A is 4- to 8-membered heterocyclenyl; and L1is absent; or
[0535] Ring A is 5- or 6-membered heteroarylenyl; and L1is:
[0537] wherein the bond marked with an is attached to Ring B;
[0538] Rlbis selected from the group consisting of hydrogen and C1-C4 alkyl;
[0539] Ring B is selected from the group consisting of optionally substituted arylenyl and optionally substituted 5- to 10-membered heteroarylenyl;
[0540] L2is -X1-X2-X3-X4-X5-*;
[0541] wherein the bond marked with an is attached to R3;
[0542] X1is absent; or
[0543] X1is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -OC-, C1-C4 alkylenyl, 3- to 8-membered heteroalkylenyl, Cs-Cs cycloalkylenyl, 4- to 11 -membered helerocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0544] X2is absent; or
[0545] X2is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, Ci-Cs alkylenyl, 3- to 8-membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0546] X3is absent; or
[0547] X3is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, Ci-Cs alkylenyl, 3- to 11 -membered heteroalkylenyl, C3-C8 cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0548] X4is absent; or
[0549] X4is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, C1-C4 alkylenyl, 3- to 11 -membered heteroalkylenyl, C3-C8 cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0550] X5is absent; or
[0551] X5is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, C1-C4 alkylenyl, 3- to 8-membered heteroalkylenyl, C,3-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl; and
[0552] each Rlais independently selected from the group consisting of hydrogen and C1-C4 alkyl.
[0553] Embodiment 3. The compound of Embodiment 2, or a pharmaceutically acceptable salt thereof, having Formula (III):
[0554] wherein M1and M2are -C(CH3)2-; or M1and M2are --CH2CH2-.
[0555] Embodiment 4. The compound of Embodiments 2 or 3, or a pharmaceutically acceptable salt thereof, wherein Z is -O-.
[0556] Embodiment 5. The compound of Embodiments 2 or 3, or a pharmaceutically acceptable salt thereof, wherein Z is -N(Rla)-.
[0557] Embodiment 6. The compound of Embodiment 3, or a pharmaceutically acceptable salt thereof, wherein Rlais hydrogen or methyl.
[0558] Embodiment?. The compound of Embodiment 2, or a pharmaceutically acceptable salt thereof, having Formula (IV):(IV).
[0559] Embodiment 8. The compound of Embodiments 2 or 7, or a pharmaceutically acceptable salt thereof, wherein R2is methyl.
[0560] Embodiment 9. The compound of Embodiment 2, or a pharmaceutically acceptable salt thereof, having Formula (V):
[0561] Embodiment 10. The compound of Embodiment 2, or a pharmaceutically acceptable salt thereof, having Formula (VI):
[0562] Embodiment 11. The compound of Embodiment 2, or a pharmaceutically acceptable salt thereof, having Formula (VII):
[0563] Embodiment 12. The compound of any one of Embodiments 2-11, or a pharmaceutically acceptable salt thereof, wherein R1is selected from the group consisting of chloro, trifluoromethyl, and methoxy.
[0564] Embodiment 13. The compound of Embodiment 12, or a pharmaceutically acceptable salt thereof, wherein R1is chloro.
[0565] Embodiment 14. The compound of Embodiment 12, or a pharmaceutically acceptable salt thereof, wherein R1is trifluoromethyl.
[0566] Embodiment 15. The compound of any one of Embodiments 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-l.
[0567] Embodiment 16. The compound of any one of Embodiments 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-2.
[0568] Embodiment 17. The compound of Embodiments 15 or 16, or a pharmaceutically acceptable salt thereof, wherein R4is hydrogen.
[0569] Embodiment 18. The compound of Embodiments 15 or 16, or a pharmaceutically acceptable salt thereof, wherein R4is optionally substituted C1-C4 alkyl.
[0570] Embodiment 19. The compound of Embodiment 18, or a pharmaceutically acceptable salt thereof, wherein R4is selected from the group consisting of methyl, isopropyl, and
[0571] Embodiment 20. The compound of Embodiments 15 or 16, or a pharmaceutically acceptable salt thereof, wherein R4is optionally substituted 4- to 8- membered heterocyclo.
[0572] Embodiment 21. The compound of Embodiment 20, or a pharmaceutically acceptable salt thereof, wherein R4is selected from the group consisting of:
[0573] Embodiment 22. The compound of any one of Embodiments 2-14, or a pharmaceutically acceptable salt thereof, wherein R is R3-3.
[0574] Embodiment 23. The compound of any one of Embodiments 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-4.
[0575] Embodiment 24. The compound of any one of Embodiments 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-5.
[0576] Embodiment 25. The compound of any one of Embodiments 2-14, or a pharmaceutically acceptable salt thereof, wherein R is R3-6.
[0577] Embodiment 26. The compound of any one of Embodiments 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is hydrogen.
[0578] Embodiment 27. The compound of any one of Embodiments 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is halo.
[0579] Embodiment 28. The compound of any one of Embodiments 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is cyano.
[0580] Embodiment 29. The compound of any one of Embodiments 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is optionally substituted 5- or 6- membered heteroaryl.
[0581] Embodiment 30. The compound of Embodiment 29, or a pharmaceutically acceptable salt thereof, wherein R6is:
[0582] Embodiment 31. The compound of any one of Embodiments 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is optionally substituted 4 to 8- membered heterocyclo.
[0583] Embodiment 32. The compound of Embodiment 31, or a pharmaceutically acceptable salt thereof, wherein R6is:
[0584] Embodiment 33. The compound of any one of Embodiments 23-32, or a pharmaceutically acceptable salt thereof, wherein R3aat each occurrence is independently selected from the group consisting of hydrogen and methyl.
[0585] Embodiment 34. The compound of Embodiment 33, or a pharmaceutically acceptable salt thereof, wherein R3aat each occurrence is methyl.
[0586] Embodiment 35. The compound of any one of Embodiments 15-34, or a pharmaceutically acceptable salt thereof, wherein R12is -C(=O)R12a.
[0587] Embodiment 36. The compound of any one of Embodiments 15-34, or a pharmaceutically acceptable salt thereof, wherein R12is -C(=O)NHR12a.
[0588] Embodiment 37. The compound of Embodiments 35 or 36, or a pharmaceutically acceptable salt thereof, wherein R12ais C1-C4 alkyl.
[0589] Embodiment 38. The compound of Embodiment 37, or a pharmaceutically acceptable salt thereof, wherein R12ais methyl.
[0590] Embodiment 39. The compound of any one of Embodiments 15-38, or a pharmaceutically acceptable salt thereof, wherein Y is -N=.
[0591] Embodiment 40. The compound of any one of Embodiments 15-38, or a pharmaceutically acceptable salt thereof, wherein Y is -C(R5)=.
[0592] Embodiment 41. The compound of Embodiment 40, or a pharmaceutically acceptable salt thereof, wherein R5is -CHF2.
[0593] Embodiment 42. The compound of any one of Embodiments 2-41, or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted arylenyl.
[0594] Embodiment 43. The compound of Embodiment 42, or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted phenylenyl.
[0595] Embodiment 44. The compound of Embodiment 42, or a pharmaceutically acceptable salt thereof, wherein Ring B is selected from the group consisting of:
[0596] wherein bond marked with an is attached to L2.
[0597] Embodiment 45. The compound of any one of Embodiments 2-41, or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted 5- to 10-membered heteroarylenyl.
[0598] Embodiment 46. The compound of Embodiment 45, or a pharmaceutically acceptable salt thereof, wherein Ring B is selected from the group consisting of:
[0599] wherein bond marked with an is attached to L2.
[0600] Embodiment 47. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is absent.
[0601] Embodiment 48. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -O-.
[0602] Embodiment 49. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -N(Rla)-.
[0603] Embodiment 50. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -C(=O)-.
[0604] Embodiment 51. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -CH=CH-.
[0605] Embodiment 52. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -C=C-.
[0606] Embodiment 53. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is C1-C4 alkylenyl.
[0607] Embodiment 54. The compound any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is 3- to 8-membered heteroalkylenyl.
[0608] Embodiment 55. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is C3-C8cycloalkylenyl.
[0609] Embodiment 56. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is 4- to 11 -membered heterocyclenyl.
[0610] Embodiment 57. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is arylenyl.
[0611] Embodiment 58. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is 5- to 9-membered heteroarylenyl.
[0612] Embodiment 59. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is absent.
[0613] Embodiment 60. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -O-.
[0614] Embodiment 61. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -N(Rla)-.
[0615] Embodiment 62. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -C(=O)-.
[0616] Embodiment 63. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -CH=CH-.
[0617] Embodiment 64. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -C=C-.
[0618] Embodiment 65. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is C1-C8 alkylenyl.
[0619] Embodiment 66. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is 3- to 8-membered heteroalkylenyl.
[0620] Embodiment 67. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is C3-C8cycloalkylenyl.
[0621] Embodiment 68. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is 4- to 8-membered heterocyclenyl.
[0622] Embodiment 69. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is arylenyl.
[0623] Embodiment 70. The compound of any one of Embodiments 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is 5- to 9-membered heteroarylenyl.
[0624] Embodiment 71. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is absent.
[0625] Embodiment 72. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is -O-.
[0626] Embodiment 73. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is -N(Rla)-.
[0627] Embodiment 74. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X5is -C(=O)-.
[0628] Embodiment 75. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is -CH=CH-.
[0629] Embodiment 76. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X5is -C=C-.
[0630] Embodiment 77. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is C1-C8 alkylenyl.
[0631] Embodiment 78. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is 3- to 11-membered heteroalkylenyl.
[0632] Embodiment 79. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is C3-C8 cycloalkylenyl.
[0633] Embodiment 80. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is 4- to 8-membered heterocyclenyl.
[0634] Embodiment 81. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is arylenyl.
[0635] Embodiment 82. The compound of any one of Embodiments 2-70, or a pharmaceutically acceptable salt thereof, wherein X5is 5- to 9-membered heteroarylenyl.
[0636] Embodiment 83. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is absent.
[0637] Embodiment 84. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -O-.
[0638] Embodiment 85. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -N(Rla)-.
[0639] Embodiment 86. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -C(=O)-.
[0640] Embodiment 87. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -CH=CH-.
[0641] Embodiment 88. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -C=C-.
[0642] Embodiment 89. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is C1-C4 alkylenyl.
[0643] Embodiment 90. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is 3- to 11-membered heteroalkylenyl.
[0644] Embodiment 91. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is C3-C8cycloalkylenyl.
[0645] Embodiment 92. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is 4- to 8-membered heterocyclenyl.
[0646] Embodiment 93. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is arylenyl.
[0647] Embodiment 94. The compound of any one of Embodiments 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is 5- to 9-membered heteroarylenyl.
[0648] Embodiment 95. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X is absent.
[0649] Embodiment 96. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is -O-.
[0650] Embodiment 97. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is -N(Rla)-.
[0651] Embodiment 98. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is -C(=O)-.
[0652] Embodiment 99. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is -CH=CH-.
[0653] Embodiment 100. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is -C=C-.
[0654] Embodiment 101. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is C1-C4 alkylenyl.
[0655] Embodiment 102. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is 3- to 8-membered heteroalkylenyl.
[0656] Embodiment 103. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is C3-C8cycloalkylenyl.
[0657] Embodiment 104. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is 4- to 8-membered heterocyclenyl.
[0658] Embodiment 105. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is arylenyl.
[0659] Embodiment 106. The compound of any one of Embodiments 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is 5- to 9-membered heteroarylenyl.
[0660] Embodiment 107. The compound of any one of Embodiments 2-46, or a pharmaceutically acceptable salt thereof, wherein L2is selected from the group consisting of:
[0661] wherein the bond marked with an is attached to R3.
[0662] Embodiment 108. The compound of Embodiment 1, or a pharmaceutically acceptable salt thereof, wherein the compound is any one or more of the compounds of Table 1.
[0663] Embodiment 109, The compound of Embodiment 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
[0664] Embodiment 110. A pharmaceutical composition comprising the compound of any one of Embodiments 1-109, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
[0665] Embodiment 111. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of any one of Embodiments 1-109, or a pharmaceutically acceptable salt or solvate thereof.
[0666] Embodiment 112. The method of Embodiment 111, wherein the cancer is any one or more of the cancers of Tables A, B, and / or C, e.g., the cancer is prostate cancer.
[0667] Embodiment 113. The method of Embodiments 111 or 112 further comprising administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of cancer.
[0668] Embodiment 114. A kit comprising the compound of any one of Embodiments 1-109, or a pharmaceutically acceptable salt or solvate thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt or solvate thereof, to a subject having cancer.
[0669] Embodiment 115. The kit of Embodiment 114, wherein the cancer is any one or more of the cancers of Tables A, B, and / or C, e.g., the cancer is prostate cancer.
[0670] Embodiment 116. A method of inhibiting CBP / P300 proteins and androgen receptors within a cell of a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of any one of Embodiments 1-109, or a pharmaceutically acceptable salt or solvate thereof.
[0671] Embodiment 117. A compound having Formula (VIII):
[0672] or a salt thereof, wherein:
[0673] R4is selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, and optionally substituted 4- to 8- membered heterocyclo;
[0674] Y is selected from the group consisting of -N= and -C(R5)=;
[0675] R3is selected from the group consisting of hydrogen, halo, cyano, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
[0677] Ring C is selected from the group consisting of C3-C8cycloalkylenyl, 3- to 8- membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;
[0678] R8is selected from the group consisting of hydrogen, halo, hydroxy, amino, -C=CH, -CHO, and -C(=O)OR9;
[0679] R9is selected from the group consisting of hydrogen and C1-C6alkyl;
[0680] R12is selected from the group consisting of -C(=O)R12a, -C(=O)NHR12a, and -C(=O)OR12a; and
[0681] R12ais selected from the group consisting of hydrogen and C1-C4 alkyl.
[0682] Embodiment 118. The compound of Embodiment 117, or a salt thereof, wherein R4is hydrogen.
[0683] Embodiment 119. The compound of Embodiment 117, or a salt thereof, wherein R4is optionally substituted C1-C4 alkyl.
[0684] Embodiment 120. The compound of Embodiment 119, or a salt thereof, wherein R4is selected from the group consisting of methyl, isopropyl, and
[0685] Embodiment 121. The compound of Embodiment 117, or a salt thereof, wherein R4is optionally substituted 4- to 8-membered heterocyclo.
[0686] Embodiment 122. The compound of Embodiment 121, or a salt thereof, wherein R4is selected from the group consisting of:
[0687] Embodiment 123. The compound of any one of Embodiments 117-122, or a salt thereof, wherein Y is -N=.
[0688] Embodiment 124. The compound of any one of Embodiments 117-122, or a salt thereof, wherein Y is -C(R5)=.
[0689] Embodiment 125. The compound of Embodiment 124, or a salt thereof, wherein R5is hydrogen.
[0690] Embodiment 126. The compound of Embodiment 124, or a salt thereof, wherein R5is halo.
[0691] Embodiment 127. The compound of Embodiment 124, or a salt thereof, wherein R5is cyano.
[0692] Embodiment 128. The compound of Embodiment 124, or a salt thereof, wherein R5is -CHF2.
[0693] Embodiment 129. The compound of any one of Embodiments 117-124, or a salt thereof, wherein Ring C is Cs-Cs cycloalkylenyl.
[0694] Embodiment 130. The compound of any one of Embodiments 117-124, or a salt thereof, wherein Ring C is 3- to 8-membered heterocyclenyl.
[0695] Embodiment 131. The compound of any one of Embodiments 117-124, or a salt thereof, wherein Ring C is phenylenyl.
[0696] Embodiment 132. The compound of any one of Embodiments 117-124, or a salt thereof, wherein Ring C is 5- to 9-membered heteroarylenyl.
[0697] Embodiment 133. The compound of any one of Embodiments 117-132, or a salt thereof, wherein R8is hydrogen.
[0698] Embodiment 134. The compound of any one of Embodiments 117-132, or a salt thereof, wherein R8is halo.
[0699] Embodiment 135. The compound of any one of Embodiments 117-132, or a salt thereof, wherein Rsis hydroxy.
[0700] Embodiment 136. The compound of any one of Embodiments 117-132, or a salt thereof, wherein R8is amino.
[0701] Embodiment 137. The compound of any one of Embodiments 117-132, or a salt thereof, wherein R8is -C=CH.
[0702] Embodiment 138. The compound of any one of Embodiments 117-132, or a salt thereof, wherein R8is -CHO.
[0703] Embodiment 139. The compound of any one of Embodiments 117-132, or a salt thereof, wherein R8is -C(=O)OR9.
[0704] Embodiment 140. The compound of Embodiment 139, or a salt thereof, wherein R9is hydrogen.
[0705] Embodiment 141. The compound of Embodiment 139, or a salt thereof, wherein R9is t-butyl.
[0706] Embodiment 142. I’he compound of Embodiment 117, or a salt thereof, wherein R7is selected from the group consisting of:
[0707] Embodiment 143. The compound of Embodiment 117, or a salt thereof, wherein R7is selected from the group consisting of:
[0708] Embodiment 144. The compound of any one of Embodiments 117-143, or a salt thereof, wherein R12is -C(=O)R12a.
[0709] Embodiment 145. The compound of any one of Embodiments 117-143, or a salt thereof, wherein R12is -C(=O)NHR12a.
[0710] Embodiment 146. The compound of Embodiments 144 or 145, of a salt thereof, wherein R12ais C1-C4 alkyl.
[0711] Embodiment 147. The compound of Embodiment 146, or a salt thereof, wherein R12ais methyl.
[0712] Embodiment 148. A compound having Formula (IX):
[0713] or a salt thereof, wherein:
[0714] R1is selected from the group consisting of C1-C4 alkoxy, C1-C4 haloalkyl, and halo;
[0715] W is selected from the group consisting of =N- and =CH-;
[0716] R2is selected from the group consisting of hydrogen and C1-C4 alkyl;
[0717] m is 0, 1, 2, 3, or 4;
[0718] Z is absent; or
[0719] Z is selected from the group consisting of -O- and -N(Rla)-;
[0720] Ring A is C4-C8 cycloalkylenyl; and L1is -N(Rlb)-C(=O)-A, wherein the bond marked with an "A" is attached to R10; or
[0721] Ring A is 7- to 11 -membered spiroheterocyclenyl; and L1is absent; or
[0722] Ring A is 4- to 8-membered heterocyclenyl; and L1is absent; or
[0723] Ring A is 5- or 6-membered heteroarylenyl; and L1is:
[0724] wherein the bond marked with an is attached to R10;
[0725] Rlbis selected from the group consisting of hydrogen and C1-C4 alkyl;
[0726] R10is:
[0727] Ring D is selected from the group consisting of optionally substituted aryl, optionally substituted 5- to 10-membered heteroaryl, and optionally substituted 7- to 11- membered spiroheterocyclenyl;
[0728] R11is absent; or
[0729] R11is selected from the group consisting of halo, hydroxy, amino, -N3, optionally substituted C1-C4 alkyl, C2-C3 alkynyl, -C(=O)ORlc, -N(Rla)C(=O)Rlc, optionally substituted 4- to 7-membered heterocyclo, -O- (optionally substituted 4- to 7-membered heterocyclo), optionally substituted 7- to 11 -membered spiroheterocyclenyl, and boronic ester;
[0730] each Rlcis independently selected from the group consisting of hydrogen, C1-C4 alkyl, and optionally substituted C5-C6 aryl; and
[0731] each Rlais independently selected from the group consisting of hydrogen and C1-C4 alkyl.
[0732] Embodiment 149. The compound of Embodiment 148, or a salt thereof, wherein R1is halo.
[0733] Embodiment 150. The compound of Embodiment 149, or a salt thereof, wherein R1is chloro.
[0734] Embodiment 151. The compound of Embodiment 148, or a salt thereof, wherein R1is C1-C4 alkoxy.
[0735] Embodiment 152. The compound of Embodiment 151, or a salt thereof, wherein R1is methoxy.
[0736] Embodiment 153. 1’he compound of Embodiment 148, or a salt thereof, wherein R1is C1-C4 haloalkyl.
[0737] Embodiment 154. The compound of any one of Embodiments 148-153, or a salt thereof, wherein W is =N-.
[0738] Embodiment 155. The compound of any one of Embodiments 148-153, or a salt thereof, wherein W is =CH-.
[0739] Embodiment 156. The compound of any one of Embodiments 148-155, or a salt thereof, wherein Z is absent.
[0740] Embodiment 157. The compound of any one of Embodiments 148-155, or a salt thereof, wherein Z is -O-.
[0741] Embodiment 158. The compound of any one of Embodiments 148-155, or a salt thereof, wherein Z is -N(Rla)-.
[0742] Embodiment 159. The compound of Embodiment 158, wherein Rlais hydrogen or methyl.
[0743] Embodiment 160. The compound of any one of Embodiments 148-159, or a salt thereof, wherein m is 0.
[0744] Embodiment 161. The compound of any one of Embodiments 148-159, or a salt thereof, wherein m is 1, 2, 3, or 4.
[0745] Embodiment 162. The compound of Embodiment 161, or a salt thereof, wherein R2is C1-C4 alkyl.
[0746] Embodiment 163. The compound of Embodiment 162, or a salt thereof, wherein R2is methyl.
[0747] Embodiment 164. The compound of any one of Embodiments 148-163, or a salt thereof, wherein Ring A is C4-C8 cycloalkylenyl.
[0748] Embodiment 165. The compound of any one of Embodiments 148-163, or a salt thereof, wherein Ring A is 7- to 11-membered spiroheterocyclenyl.
[0749] Embodiment 166. The compound of any one of Embodiments 148-165, or a salt thereof, wherein:
[0750] is selected from the group consisting of:
[0751] Embodiment 167. The compound of any one of Embodiments 148-166, or a salt thereof, wherein R10is selected from the group consisting of:EXAMPLESIntermediate EXAMPLE 1General Procedure for Synthesis of Intermediates 4, 7, 9 and 10
[0752] Reagents and conditions: (a) Cs2CO3, DMF, 70-80°C, 8h; (b) TFA, DCM; (c) AC2O, DIPEA, DCM, 15 min; (d) RuPhos Pd G2, RuPhos, t-BuONa, N2, 1,4-dioxane, 100°C, overnight; (e) NBS, DCM, 0°C; (0 Pd(OAc)2, Pph3, K2CO3, Dioxane: H2O (5:2), 100 °C, N2, 3h; (g) TFA, DCM.tert-Butyl-3-iodo-l-(tetrahydro-2H-pyran-4-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3- c]pyridine-5-carboxylate (Int 2)
[0753] CS2CO3 (1.4 g, 4.3 mmol) and tetrahydro-2H-pyran-4-yl mcthancsulfonatc (283 mg, 1.57 mmol) were added to a solution of tert-butyl 3-iodo-6,7-dihydro-lH- pyrazolo[4,3-c]pyridine-5(4H)carboxylate (500 mg, 1.43 mmol) in DMF (3 mL). The mixture was heated to 90 °C for 12 h under an argon atmosphere. After cooling to rt, the mixture was filtered, then diluted with DCM (10 mL), and washed with brine (2 x 10 mL). The organic layer was concentrated in vacuo. The crude residue was purified by silica gel chromatography (hexanes / EtOAc). The product eluted at 50% hexanes: 50% EtOAc to give the title compound (345 mg, 0.8 mmol, 56%) as a white solid. The structural data corresponds to intermediate 2.rH NMR (400 MHz, DMSO-d6) 54.30 (dq, J = 11.4, 5.8, 4.4 IIz, III), 4.11 (d, J = 4.7 Hz, 211), 3.94 (dd, J = 11.4, 4.3 IIz, 211), 3.60 (dt, J = 8.9, 5.7 Hz, 2H), 3.47-3.37 (m, 2H), 2.72 (t, J = 5.8 Hz, 2H), 2.04-1.88 (m, 2H), 1.78 (d, J = 11.7 Hz, 2H), 1.42 (s, 9H). ESI-MS calculated for C16H24IN3O3: 433.29, LCMS m / z (M + H)+found 434.11.3-Iodo-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridine (Intermediate 3)
[0754] Trifluoroacetic acid (2 mL) was added dropwise at 0 °C to a solution of tert-butyl 3-iodo-l-(tetrahydro-2H-pyran-4-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5- carboxylate (0.34 g, 0.79 mmol) in DCM (2 mL). The mixture was stirred at room temperature (rt) for 2 h and afforded Intermediate 3 in a 100% yield (0.26 g, 0.79 mmol). l-(3-Iodo-l-(tetrahydro-2H-pyran-4-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5- yl)ethan-l-one (Intermediate 4)Intermediate 4
[0755] A solution of Intermediate 2 (0.26 g, 0.79 mmol) was evaporated in vacuo, and the residue was redissolved in DCM (3 mL). The mixture was cooled to 0 °C before the dropwise addition of triethylamine (0.29 mL, 2.0 mmol) and acetic anhydride (0.15 mL, 1.6 mmol). The mixture was stirred at rt for an additional 1 h. The reaction was quenched with water (6 mL). The organic layer was dried over anhydrous Na2SC>4, filtered, and concentrated in vacuo. The crude residue was purified by silica gel flash chromatography (DCM / MeOH). The title compound (0.23 g, 0.63 mmol) eluted at 10% MeOH: 90% DCM as a light-yellow solid, giving a yield of 80%. The structure of the product was confirmed by ’ll NMR & LCMS. 'l l NMR (400 MHz, CDC13) 5 4.42 (s, 1H), 4.26 (s, 1H), 4.11 (dd, J = 11.4, 5.0 Hz, 2H), 3.90 (t, J = 5.8 Hz, 1H), 3.49 (td,.1 = 12.1, 2.2 Hz, 2H), 2.81-2.68 (m, 2H), 2.29 (qd, J = 12.4, 4.7 Hz, 2H), 2.20 (s, 3H), 2.10 (s, 2H), 1.82 (d, J = 12.8 Hz, 2H). ESLMS calculated for C13H18IN3O2 is 375.21. LCMS M / Z (M + H)+found 376.20.1 -(3-(7 -(difluoromethyl)-3,4-dihydroquinolin- 1 (2H)-yl)- 1 -(tetrahydro-2H-pyran-4-yl)- l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 6)
[0756] A mixture of Intermediate 4 (2.0 g, 1.0 equiv), 7-(difluoromethyl)-l,2,3,4- tetrahydroquinoline 5 (1.4 g, 1.2 equiv), RuPhos Pd G2 (828 mg, 0.2 equiv), RuPhos (500 mg, 0.2 equiv), and t-BuONa (2.3 g, 4.5 equiv) in dioxane (40 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 110 °C for 12 h. LC-MS showed Intermediate 4 was completely consumed, and a main peak with desired MS was formed. The mixture was cooled, diluted with DCM, filtered through Celite, the filter cake was washed with DCM, and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (0-100% EtOAc / n-hexane) togive Intermediate 6 as a light yellow foam (1.7 g, yield = 74%):!H NMR (400 MHz, DMSO- e) 57.12 (d, J = 7.7 Hz, 1H), 6.79 (d, J = 7.7 Hz, 1H), 6.81 (td, J = 56.4, 9.7 Hz, 1H), 6.64 (d, J= 6.3 Hz, 1H), 4.29 (dq, J = 11.3, 6.3, 5.5 Hz, 1H), 4.10 (d, J = 12.4 Hz, 2H), 3.95 (d, J = 11.6 Hz, 2H), 3.73 (dt, J = 18.4, 5.7 Hz, 2H), 3.58 (q, J = 5.3 Hz, 2H), 3.46 (t, J = 11.8 Hz, 3H), 2.91 - 2.72 (m, 5H), 2.08 (s, 2H), 2.02 - 1.92 (m, 5H), 1.82 (d, 7= 12.7 Hz, 2H).l-(3-(6-bromo-7-(difluoromethyl)-3,4-dihydroquinolin-l(2H)-yl)-l-(tetrahydro-2H- pyran-4-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate
[0757] To a solution of Intermediate 6 (1.7 g, 1.0 cquiv) in DCM (30 mL) was added NBS (667 mg, 0.95 equiv) in portions under ice bath condition. 2 h later, the reaction mixture was diluted with DCM, washed with aq. N 328203 followed by brine, dried over Na2SOi, and concentrated under reduced pressure to remove the solvent. The crude product was purified by flash column chromatography (0-5% MeOH / DCM) to give Intermediate 7 as light yellow solid (1.75 g, yield = 87%); ’ll NMR (400 MHz, DMSO- d6) 5 7.35 (s, 1H), 6.94 (td, J = 54.8, 8.3 Hz, 1H), 6.83 (d, 7 = 8.0 Hz, 1H), 4.30 (q, 7 = 5.9, 4.0 Hz, 1H), 4.16 (d, 7 = 14.2 Hz, 2H), 4.00 - 3.90 (m, 2H), 3.72 (dt, 7 = 19.0, 5.8 Hz, 2H), 3.61 - 3.52 (m, 2H), 3.45 (t, J= 12.1 Hz, 2H), 2.90 - 2.72 (m, 4H), 2.57 (s, 3H), 2.00 - 1.90 (m, 4H), 1.86 - 1.77 (m, 2H).tert-butyl 5-( 1 -(5-acetyl- 1 -(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH- pyrazolo[4,3-c]pyridin-3-yl)-7-(di fluoromethyl)- 1,2,3, 4-tetrahydroquinolin-6- yl)picolinate (Intermediate 9a)
[0758] A solution of Intermediate 7 (180mg, 1.0 eq), tert-butyl 5-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)picolinate (129 mg, 1.2 eq), Pd(OAc)2 (7.9 mg, 0.1 eq), Ppto (18.5 mg, 0.2 eq), and K2CO3 (97 mg, 2 eq), in Dioxan: H2O (5:2). The mixture was evacuated and backfilled with argon (3 cycles). The reaction mixture was then heated at 100 °C for 4 h. Monitor the reaction through TLC until the reaction was completed. Then the reaction solvent was evaporated under reduced pressure and purified by silica gel column chromatography to afford compound Intermediate 9a. LC- MS m / z [M+H]+608.30.
[0759] Intermediates 9b-9n were synthesized with procedures similar to that of Intermediate 9a.5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)picolinic acid (Intermediate 10a)
[0760] Intermediate 9a (0.27 g) was dissolved in DCM (4mL) and TFA (1 mL) was added at it. The mixture was stirred at it for 4 h. Monitor the reaction through TLC until the reaction was completed. Then the reaction solvent was evaporated under reduced pressure to give the crude product Intermediate 10a, which was used for the next step without further purification. LC-MS m / z [M+H]+552.23.
[0761] Intermediates 10b- lOh were synthesized with a similar procedure to that of Intermediate 10a.Intermediate EXAMPLE 2General procedure for Intermediate 11
[0762] Reagents and conditions: (a) Pd / C, H2, MeOH; reflux, overnight; (b) TFA, DCM, rt.
[0763] A solution of Intermediate 9n (200 mg) in MeOH (10 mL), Pd / C 5% (20 mg) was added, The reaction mixture was stirred at 50 °C under hydrogen atmosphere for overnight. Monitor the reaction through LC-MS until the reaction was completed. The reaction solvent was filtered through celite and evaporated under reduced pressure. The above crude product was dissolved in DCM (4mL) and TFA (2 mL) was added at rt. The mixture was stirred at rt for 4 h. Monitor the reaction through TLC until the reaction was completed. Then the reaction solvent was evaporated under reduced pressure to give the crude product Intermediate 11, which was used for the next step without further purification. LC-MS m / z [M+H]+649.31.Intermediate EXAMPLE 3General procedure for Intermediates 12 and 13
[0764] Reagents and conditions: (a) piperazine, XPhos Pd G3, Z-BuONa, 1,4-dioxane, 100 °C; (b) Formic acid, DCC, Et3N, Pd(AcO)2, Xantphos, DMF,100 °C.1 -(3-(7 -(difluoromethyl)-6-(piperazin- 1 -yl)-3,4-dihydroquinolin- 1 (2H)-yl)- 1 -(tetrahydro- 2H-pyran-4-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 12)
[0765] A solution of Intermediate 7 (200 mg, 1.0 equiv), piperazine (168 mg, 5 equiv), RuPhos Pd G3 (33 mg, 0.1 equiv), and Z-BuONa (113 g, 3 equiv) in dioxane (30 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 100 °C for 6 h. LC-MS showed 7 was completely consumed, and a main peak with desired MS was formed. The mixture was cooled, diluted with DCM, filtered through Celite, the filter cake was washed with DCM, and the filtrate was concentrated under reduced pressure.The residue was purified by pre-HPLC to give Intermediate 12.!H NMR (400 MHz, DMSO-d6) 57.14 (td, J = 55.6, 6.1 Hz, 1H),7. O1 (s, 1H), 6.74 (d, J = 8.1 Hz, 1H), 4.33 - 4.23 (m, 1H), 4.13 (d, J = 17.9 Hz, 2H), 3.99 - 3.90 (m, 2H), 3.72 (dt, J = 20.8, 5.8 Hz, 2H), 3.56 (q, J = 5.7 Hz, 2H), 3.51 - 3.39 (m, 3H), 3.24 (t, J = 4.9 Hz, 4H), 2.97 (t, J = 4.9 Hz, 4H), 2.90 - 2.80 (m, 4H), 2.08 (s, 3H), 1.99 - 1.92 (m, 4H), 1.81 (d, J = 14.4 Hz, 2H).l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin- 3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinoline-6-carboxylic acid (Intermediate 13)
[0766] A solution of Intermediate 7 (200 mg, 1.0 equiv), formic acid (62.5 mg, 5 equiv), Pd(OAc)2 (4.4 mg, 0.1 equiv), Xantphos (22.5 mg, 0.2 equiv), DCC (16 mg, 0.43 equiv) EhN (78 mg, 3 equiv) in DMF (3 mL) was degassed and purged 2 times with N2, and then the mixture was stirred at 100 °C for 8 h. LC-MS showed Intermediate 7 was completely consumed, and a main peak with desired MS was formed. The mixture was cooled, filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by pre-HPLC to give Intermediate 13. LC- MS m!z [M+H]+475.21.Intermediate EXAMPLE 4General procedure for Intermediates 16, 18 and 20
[0767] Reagents and conditions: (a) RuPhos Pd G2, RuPhos, t-BuONa, N2,l,4-dioxane, 100 °C; (b) NBS, DCM, 0°C; (c) Pd(OAc)2, Pph3, K2CO3, Dioxane: H2O (5:2), 100 °C, N2, 3h; (d) TFA, DCM.
[0768] Intermediate 15 was synthesized by following a similar procedure as that of Intermediate 6 (yield, 45%). 'll NMR (400 MHz, DMSO-rf6) 8 7.82 (d, J = 4.8 Hz, 1H), 7.77 (d, J = 18.1 Hz, 1H), 7.06 (d, J = 4.8 Hz, 1H), 4.29 (tq, J = 11.2, 4.3 Hz, 1H), 4.18 (d, J = 9.9 Hz, 2H), 3.96 (dd, J = 11.1, 4.7 Hz, 2H), 3.74 (dt, J = 19.1, 5.9 Hz, 2H), 3.57 (dt, J = 11.2, 5.4 Hz, 2H), 3.50 - 3.4 (m, 2H), 2.90 - 2.70 (m, 4H), 2.08 (s, 2H), 2.02 - 1.91 (m, 5H), 1.88 - 1.77 (m, 2H).
[0769] Intermediate 16 was synthesized by following a similar procedure as that of Intermediate 7. 'll NMR (400 MHz, DMSO-6) 87.54 (d, J= 19.6 Hz, 1H), 7.25 (s, 1H), 4.28 (d, J = 4.5 Hz, 1H), 4.19 (d, J = 12.7 Hz, 2H), 3.95 (dd, J = 10.9, 4.7 Hz, 2H), 3.74 (dt, J = 18.6, 5.8 Hz, 2H), 3.60 - 3.51 (m, 2H), 2.89 - 2.70 (m, 4H), 2.08 (s, 3H), 2.01 - 1.97 (m, 2H), 1.94 (q, J = 5.7, 5.0 Hz, 4H), 1.86 - 1.77 (m, 2H).
[0770] Intermediate 18 was synthesized by following a similar procedure as that of Intermediate 9a.£II NMR (400 MHz, DMSOA6) 8 10.00 (d,. / = 0.7 Hz, III), 9.40 (dd, J = 2.2, 0.8 Hz, 1H), 8.54 (dd, J = 8.4, 2.1 Hz. 1H), 7.99 - 7.90 (m, 3H), 4.38 - 4.28 (m, 1H), 4.25 (d, J = 12.6 Hz, 2H), 4.00 - 3.93 (m, 2H), 3.77 (dt, J = 18.8, 5.8 Hz, 2H), 3.69 - 3.59 (m, 2H), 3.51 - 3.43 (m, 3H), 2.96 - 2.83 (m, 4H), 2.09 (s, 2H), 2.06 - 1.96 (m, 4H), 1.89 - 1.80 (m, 2H).
[0771] Intermediate 20 was synthesized by following a similar procedure as that of Intermediate 10a. LC-MS m / z [M+H]+503.23.Intermediate EXAMPLE 5
[0772] (a)[l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (10 mol %), NaHCO3 (2 equiv), and methyl 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)picolinate (1.5 equiv), dioxanc / IPO, 106 °C, 37%: (b) Xphos (10 mol %), Xphos pre-catalyst (G2) (10 mol %), KOAc (2.5 equiv), and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2- dioxaborolane) (3 equiv), dioxane / IFO. 106 °C, 56%; (c) l-(3-iodo-l-(tetrahydro-2H- pyran-4-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)cthan-l-onc (1 equiv), methyl 5-(8-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoquinolin-3-yl)picolinate (1.26 equiv), Xphos (10 mol %), Xphos pre-catalyst (G2) (10 mol %), Cs2CO3 (3 equiv), dioxane / H2O, 60 °C, 50%; and (d) LiOH (5 equiv), THF / MeOH / H2O, 50 °C, 100%.Methyl 5-(8-chloroisoquinolin-3-yl)picolinate (Intermediate 23)
[0773] NaHCCh (346 mg, 4.12 mmol), 7V-methyl-5-(4, 4,5, 5 -tetramethyl- 1,3,2- dioxaborolan-2-yl)picolinamide (813 mg, 3.09 mmol), and [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (151 mg, 0.206 mmol) were added to a solution of 3-bromo-8-chloro-isoquinoline (500 mg, 2.06 mmol) in 1,4- dioxane (5 mL) and water (1.25 mL). The mixture was heated to 106 °C for 3 h by microwave irradiation. After cooling the reaction to rt, the mixture was concentrated in vacuo. EtOAc (50 mL) was added, and the mixture was washed with water (30 mL x 2) and brine (30 mL). The organic layer was dried over anhydrous Na2SC>4, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (EtOAc / DCM). The product eluted at 63% EtOAc: 37% DCM to give the title compound (Intermediate 23) (230.7 mg, 38%) as a white solid.rH NMR (400 MHz, CDCL) 8 9.56 (s,lH), 9.27 (s,lH), 8.44 (dd, 1H), 8.08-8.02 (d, 2H), 7.69 (d, 1H), 7.50-7.47 (dd, 2H), 3.84 (s, 3H). ESLMS calculated for C16H11CIN2O2 is 298.73. LCMS M / Z (M + H)+found 299.16.methyl 5-(8-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoquinolin-3-yl)picolinate (Intermediate 24)
[0774] 2-(Dicyclohcxylphosphino)-2',4',6'-triisopropylbiphcnyl (24 mg, 0.05 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-tri-z-propyl-l, T-biphenyl)(2'-amino-l, T- biphenyl-2-yl) palladium(ll) (39.3 mg, 0.05 mmol), KOAc (125 mg, 1.27 mmol), and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (383 mg, 1.51 mmol) were added to a solution of methyl 5-(8-chloroisoquinolin-3-yl)picolinate (150 mg, 0.5 mmol) in 1,4-dioxane (7 mL). The mixture was heated to 106 °C for 1 h by microwave irradiation. After cooling to rt, the mixture was concentrated in vacuo. EtOAc (50 mL) was added, and the mixture was washed with water (40 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by silica gel flash chromatography (EtOAc / DCM). Intermediate 24 eluted at 52% EtOAc: 48% DCM (110 mg, 0.28 mmol) as a brown solid, affording 56% yield? H NMR (400 MHz, CDCI3) 6 10.30 (s, 1H), 9.50 (s, 1H), 8.68-8.66 (dd, 1H), 8.32-8.30(dd, 1H), 8.25-8.23 (dd, 1H) 8.20 (s, 1H), 8.05-8.03 (d, 1H), 7.79-7.75 (dd, 1H), 4.08 (s, 3H), 1.47 (s, 12H).Methyl 5-(8-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)isoquinolin-3-yl)picolinate (Intermediate 25)
[0775] 2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (13.6 mg, 0.03 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-tri-z-propyl- 1, 1 '-biphenyl)(2'-amino- 1,1'- biphenyl-2-yl) palladium(II) (22 mg, 0.03 mmol), and CS2CO3 (279 mg, 0.86 mmol) were added to a solution of l-(3-iodo-l-(tetrahydro-2H-pyran-4-yl)-l,4,6,7-tetrahydro-577- pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (107 mg, 0.28 mmol) and methyl 5-(8-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)isoquinolin-3-yl)picolinate (141 mg, 0.36 mmol) in 1,4-dioxane (3 mL) and water (0.75 mL). The reaction mixture was heated to 60 °C for 2 h by microwave irradiation. After cooling to rt, the mixture was filtered and concentrated in vacuo. EtOAc (50 mL) was added, and the mixture was washed with water (2 x 40 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by silica gel flash chromatography (EtOAc / DCM / MeOH) to give Intermediate 25 (73 mg, 0.14 mmol) as a white solid, giving 50% yield. ’ll NMR (400 MHz, DMSO-A) 5 10.02 (d, J = 1.1 Hz, 1H), 9.54 (d, J= 2.2 Hz, 1H), 8.77 (dd, J= 8.2, 2.2 Hz, 1H), 8.73 (d, 7= 0.9 Hz, 1H), 8.20 (d, J = 8.2 Hz, 1H), 8.08 (d, J = 8.2 Hz, 1H), 7.97-7.87 (m, 1H), 7.72 (ddd, 7= 26.3, 7.2, 1.1 Hz, 1H), 4.59 (d, 7= 3.4 Hz, 2H), 4.48 (tq, 7= 11.3, 3.9 Hz, 1H), 4.03 (dd, 7 = 11.3, 4.9 Hz, 2H), 3.93 (s, 3H), 3.84 (dt, 7= 14.3, 5.9 Hz, 2H), 3.58-3.47 (m, 2H), 2.98 (t, 7= 5.8 Hz, 1H), 2.85 (t, 7= 5.7 Hz, 1H), 2.17 (td, 7= 12.1, 5.0 Hz, 2H), 2.11 (s, 3H), 2.03 (s, 1H), 2.00-1.91 (m, 2H). ESI-MS calculated for C29H29N5O4is 511.58. LCMS M / Z (M + H)+found 512.36.5-(8-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)isoquinolin-3-yl)picolinic acid (Intermediate 26)
[0776] LiOH (17 mg, 0.71 mmol) was added to a solution of methyl 5-(8-(5-acetyl-l- (tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c|pyridin-3- yl)isoquinolin-3-yl)picolinate (73 mg, 0.14 mmol) in THF (0.75 mL), MeOH (0.25 mL), and H2O (1.5 mL). The reaction mixture was heated to 50 °C for 4 h. After cooling to rt, a few drops of TFA were added to the mixture. The mixture was then purified by reverse phase chromatography (15-75% MeCN / 0.1%TFA in H2O in 60 min-60 mL), and Intermediate 26 eluted at 26% (44 mg, 0.14 mmol) as a white solid in 100% yield.!H NMR (400 MHz, DMSO-Je) 8 10.02 (s, 1H), 9.53 (s, 1H), 8.78 (d, J= 8.5 Hz, 1H), 8.73 (s, 1H), 8.21 (d,. / = 8.3 Hz, 1H), 8.08 (d,. / = 8.4 Hz, 1H), 7.94 (d,. / = 8.9 Hz, 1H), 7.72 (dd, J= 27.1, 7.1 Hz, 1H), 4.59 (s, 2H), 4.49 (d, J= 12.2 Hz, 1H), 4.03 (d, J= 11.3 Hz, 2H), 3.83 (q, J= 7.4, 5.9 Hz, 2H), 3.53 (t, J = 12.0 Hz, 2H), 2.98 (s, 1H), 2.86 (s, 1H), 2.21-2.08 (m, 5H), 2.03 (s, 1H), 1.97 (d, J= 12.3 Hz, 3H). ESI-MS calculated for C28H27N5O4 is 497.56. LCMS M / Z (M + H)+found 498.31.Intermediate EXAMPLE 6General procedure for Intermediates 33, 35 and 39d
[0777] Reagents and conditions: (a) TFA, DCM; (b)Ac2O, DIPEA, DCM; DCM, NBS, 0°C; (c) KOH, THF / H2O (2:1), rt; (d) 3,4-dihydro-2H-pyran, PTSA, THE, 60 °C; (e) Dioxane, Ruphos pd G2, Ruphos, t-B / / ONa, I00°C, N2, overnight; (f) NBS, DCM, 0°C; (g)3 M HCl / MeOH, rt; (h) Pd(OAc)2, Pph3, K2CO3, Dioxan: H2O (5:2), 100 °C, N2, 3h; (i) TFA, DCM; (j) Cs2CO3, DMF, 70-80°C, 8h; (k) DIBAL-H (25% in toluene), DCM, -78 °C, 40% yield.l,l'-(3-iodo-6,7-dihydro-2H-pyrazolo[4,3-c]pyridine-2,5(4H)-diyl)bis(ethan-l-one) and 1, l'-(3-iodo-6,7 -dihydro- 1 H-pyrazolo[4,3-c]pyridine- 1,5(4H)-diyl)bis(ethan- 1 -one) (Intermediate 28)
[0778] To a solution of tert-butyl 3-iodo- 1,4,6, 7-tetrahydro-5H-pyrazolo[4,3-c]pyridine- 5-carboxylate 1 (2.5 g, 1.0 equiv) in DCM (30 mL) was added TFA (10 mL). The reaction was stirred at rt for 4 hrs, then the mixture was concentrated under reduced pressure. The residue was dissolved in DCM (30 mL), and the solution was cooled to 0°C. DIPEA (6.2 mL, 5.0 equiv) was added, followed by AC2O (1.8 mL, 2.5 equiv), after which the reaction was warmed to rt and kept stirring for 20 h. The reaction mixture was diluted with DCM, washed with brine, dried over IsfeSCU, and concentrated under reduced pressure to remove the solvent. The resulting crude product was purified by flash column chromatography (0-5% MeOH / DCM) to give l,l'-(3-iodo-6,7-dihydro-lH- pyrazolo[4,3-c]pyridine- l,5(4H)-diyl)bis(ethan- l-one) and 1,l'-(3-iodo-6,7-dihydro-2H- pyrazolo[4,3-c]pyridine-2,5(4H)-diyl)bis(ethan-l-one) (Intermediate 28) as a white solid (2.2 g, 92% yield): LC-MS m / z [M+H]+334.04; ’ll NMR (400 MHz, Chlorofomi-d) 5 4.46-4.22 (m, 2H), 3.88-3.65 (m, 2H), 3.20-3.07 (m, 2H), 2.67 (s, 3H), 2.19 (s, 3H). l-(3-iodo-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate
[0779] To a solution of Intermediate 28 (3.4 g, 1.0 equiv) in THF / H2O (40 mL / 20 mL) was added KOH (2.9 g, 5.0 equiv), and the reaction was stirred at rt for 3 h. Then the solvent was removed under reduced pressure, and the residue was dissolved in water, neutralized with 2 N aq. HC1 to pH 8-9, extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na2SO4, and concentrated to give l-(3- iodo-l,4,6,7-tetrahydro-5H-pyrazolo[4,3- pyridin-5-yl)ethan-l-one (Intermediate 29) as a white solid (2.7 g, 91% yield): LC-MS m / z [M+H]+291.89; ’ll NMR (400 MHz, Melhanol-d) 5 12.97 (s, 1H), 4.22 (s, 2H), 3.76-3.60 (m, 2H), 2.77-2.54 (m, 2H), 2.13- 2.05 (m, 3H).l-(3-iodo-2-(tetrahydro-2H-pyran-2-yl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5- yl)ethan- 1 -one and 1 -(3-iodo- 1 -(tetrahydro-2H-pyran-2-yl)- 1,4,6,7 -tetrahydro-5H- pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 30)
[0780] To a solution of Intermediate 29 (3.7 g, 1.0 equiv) and 3,4-dihydro-2H-pyran (3.5 mL, 3.0 equiv) in THF (60 mL) was added p-loluenesul Ionic acid (2.2 g, 1.0 equiv), and the reaction was stirred at 65 °C for 24 h. The reaction mixture was concentrated, dilutedwith DCM, washed with brine, dried over Na2SC>4, and concentrated under reduced pressure to remove the solvent. The residue was purified by flash column chromatography (0-100% EtOAc / zr -hexane) to give l-(3-iodo-l-(tetrahydro-2H-pyran-2- yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyndin-5-yl)ethan-l-one and l-(3-iodo-2- (tetrahydro-2H-pyran-2-yl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l- one (Intermediate 30) as a white solid (3.6 g, 76% yield): LC-MS m / z [M+H]+376.14;XH NMR (400 MHz, DMSO-&) 55.33 (dd, J= 9.7, 2.6 Hz, 1H), 4.34-4.09 (m, 2H), 3.89- 3.81 (m, 1H), 3.80-3.53 (m. 3H), 2.91-2.55 (m, 2H), 2.23-2.04 (m, 4H), 2.01-1.90 (m, 1H), 1.89-1.78 (m, 1H), 1.71-1.57 (m, 1H). 1.57-1.44 (m, 2H).l-(3-(7-(difluoromethyl)-3,4-dihydroquinolin-l(2H)-yl)-2-(tetrahydro-2H-pyran-2-yl)- 2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one and l-(3-(7- (difhioromethyl)-3,4-dihydroquinolin-l(2H)-yl)-l-(tetrahydro-2H-pyran-2-yl)-l,4,6,7- tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 31a)
[0781] A mixture of Intermediate 30 (2.0 g, 1.0 equiv), 7-(difluoromethyl)-l,2,3,4- tetrahydroquinoline 5 (1.4 g, 1.2 equiv), RuPhos Pd G2 (828 mg, 0.2 equiv), RuPhos (500 mg, 0.2 equiv), and r-BuONa (2.3 g, 4.5 equiv) in dioxane (40 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 110 °C for 12 h. LC-MS showed Intermediate 30 was completely consumed, and a main peak with desired MS was formed. The mixture was cooled, diluted with DCM, filtered through Celite, the filter cake was washed with DCM, and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (0-100% EtOAc / n-hexane) to give l-(3-(7-(difhioromethyI)-3,4-dihydroquinolin-l(2H)-yl)-I-(tetrahydro-2H-pyran-2- yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one and l-(3-(7- (difhioromethyl)-3,4-dihydroquinolin- I(2H)-yl)-2-(tetrahydro-2H-pyran-2-yl)-2, 4,6,7- tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 31a) as a light yellow foam (1.7 g, yield = 74%); LC-MS mlz [M+H]+431.28; ’ll NMR (400 MHz, Chloroform-^) 57.12-7.00 (m, HI), 6.84-6.74 (m, HI), 6.67 (s, III), 6.61-6.28 (m, III), 5.26-5.16 (m, 1H), 4.26-4.13 (m, 1H), 4.09-3.98 (m, 2H), 3.94-3.81 (m, 1H), 3.77-3.59 (m, 4H), 2.94-2.75 (m, 4H), 2.41-2.28 (m, 1H), 2.17-1.92 (m, 7H), 1.70-1.56 (m,3H);13C NMR (101 MHz, CDCh) 5 169.79, 169.13, 149.54, 149.01, 143.00, 138.94, 137.29, 133.16, 132.98, 132.76, 132.73, 132.55, 129.52, 129.36, 126.64, 126.63, 126.42, 117.52, 117.39, 115.38, 115.32, 115.26, 115.15, 115.11, 115.02, 114.99, 112.78, 112.66, 111.20. 111.14, 111.08, 110.99, 110.93, 110.87, 108.01, 107.18, 85.34, 85.30, 67.88, 67.61, 49.49, 49.35, 43.28, 43.00, 38.87, 38.61, 29.44, 29.40, 27.59, 24.98, 24.94, 23.10, 22.69, 22.55, 22.47, 22.37, 22.01, 21.80, 21.53.l-(3-(6-bromo-7-(difluoromethyl)-3,4-dihydroquinolin-l(2H)-yl)-l-(tetrahydro-2H- pyran-2-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one and l-(3-(6- bromo-7-(difluoromethyl)-3,4-dihydroquinolin-l(2H)-yl)-2-(tetrahydro-2H-pyran-2-yl)- 2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 32a)
[0782] To a solution of Intermediate 31a (1.7 g, 1.0 equiv) in DCM (30 mL) was added NBS (667 mg, 0.95 equiv) in portions under ice bath condition. 2 h later, the reaction mixture was diluted with DCM, washed with aq. Na2S2O3 followed by brine, dried over Na2$O4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by flash column chromatography (0-5% MeOH / DCM) to give l-(3- (6-bromo-7-(difluoromethyl)-3,4-dihydroquinolin-l(2H)-yl)-l-(tetrahydro-2H-pyran-2- yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one and l-(3-(6-bromo-7- (difluoromethyl)-3,4-dihydroquinolin- l(2H)-yl)-2-(tetrahydro-2H-pyran-2-yl)-2, 4,6,7- tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 32a) as a white foam (1.75 g, yield = 87%): LC-MS m [M+H]+509.16;NMR (400 MHz, Chloroform-^ 57.20 (d,. / = 15.9 Hz, 1H), 6.94-6.57 (m, 2H), 5.27-5.17 (m, 1H), 4.27- 4.13 (m, 1H), 4.10-3.98 (m, 2H), 3.95-3.80 (m, 1H), 3.78-3.59 (m, 4H), 2.95-2.77 (m, 4H), 2.40-2.28 (m, 1H), 2.13-1.90 (m, 6H), 1.72-1.55 (m, 5H).l-(3-(6-bromo-7-(difhioromethyl)-3,4-dihydroquinolin-l(2H)-yl)-l,4,6,7-tetrahydro-5H- pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 33a)
[0783] To a solution of Intermediate 32a (1.0 g) in 3 M HCl / MeOH (30 mL) the reaction mixture was stirred at 110 °C for 6 h. LC-MS showed Intermediate 32 was completely consumed. Then the solvent was removed under reduced pressure, and the residue was dissolved in DCM and water (1:3), neutralized with aq. NaOH to PH 7-8. The resulting mixture was extracted with DCM, washed with brine, dried over Na2SO4, and concentrated under reduced pressure to remove the solvent to give the crude product Intermediate 33a, LC-MS m / z [M+H]+ 425.10.Intermediate EXAMPLE 7General procedure for Intermediates 36, 39 and 41
[0784] Reagents and conditions: (a) 3 M HCl / MeOH, rt; (b) Pd(OAc)2, Pph3, K2CO3, Dioxan: H2O (5:2), 100 °C, N2, 3h; (c) Cs2CO3, DMF, 70-80°C, 8h; (d) DIBAL-H (25% in toluene). DCM, -78 °C, 40% yield; (e) Pd / C, H2, MeOH; reflux, overnight; (f Xphos pd G3, Dioxane, t-BuONa, 100°C. N2. overnight.l-(3-(7-(difluoromethyl)-6-(l -methyl- lH-pyrazol-4-yl)-3,4-dihydroquinolin-l(2H)-yl)- l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 36a)
[0785] A solution of Intermediate 33a (426 mg, 1.0 eq), l-methyl-4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-lH-pyrazole (250 mg, 1.2 eq), Pd(OAc)2 (22.4 mg, 0.1 eq), Pphs (52 mg, 0.2 eq), and K2CO3 (276 mg, 2 eq), in Dioxan: H2O (5:2, 30 mL). The mixture was evacuated and backfilled with argon (3 cycles). The reaction mixture was then heated at 100 °C for 8 h. Monitor the reaction through TLC until the reaction was completed. Then the reaction solvent was evaporated under reduced pressure and purified by flash column chromatography (0-5% MeOH / DCM) to give to give Intermediate 36a as a light yellow solid (80%): LC-MS m / z [M+H]+427.43; ’ll NMR (400 MHz, Methanol-da) 5 7.67-7.61 (m, 1H), 7.51 (s, 1H), 7.15-7.06 (m, 1H), 6.76-6.40 (m, 2H), 4.30-4.17 (m, 2H), 3.96-3.90 (m, 3H), 3.89-3.76 (m, 2H), 3.72-3.62 (m, 2H), 2.94-2.74 (m, 4H), 2.21-2.00 (m, 5H);13C NMR (101 MHz, MeOD) 5 172.48, 172.38, 148.28, 148.17. 143.92, 143.62, 141.83, 141.47, 139.27, 132.39, 132.27, 131.52, 131.32, 131.11, 130.90, 130.00, 129.75, 124.70, 124.37, 120.54, 118.31, 117.26, 117.20, 115.49, 114.86, 113.67, 112.96, 112.57, 112.52, 106.09, 50.89, 50.79, 44.19, 43.76, 39.84, 39.54, 38.97, 27.95, 27.91, 23.54, 23.45, 22.67, 21.64, 21.35.methyl trms-4-(5-acetyl-3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin-l(2H)-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-cJpyridin-l- yl)cyclohexane-l -carboxylate (Intermediate 38a)
[0786] To a solution of l-(3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin-l(2H)-yl)- 1,4,6, 7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l- one (Intermediate 36a) (300 mg, 0.70 mmol) and 37 (658 mg, 2.1 mmol) in DMF (4 mL) was added CS2CO3 (917 mg, 2.8 mmol). The mixture was stirred at 70 °C for 7 h, and then directly purified by pre-HPLC: acetonitrile / H2O from 45% to 100% in 55 min, flow rate (60 ml / min). The desired product started coming out when acelomlrile / IbO = 52%.The title compound Intermediate 38a was obtained as a white solid (169 mg, yield = 42%). LC-MS: m / z [ M+H]+= 567.25. ’ll NMR (400 MHz, Chloroform- ) b 7.64 (s, 1H), 7.46 (s, 1H), 7.08 - 6.97 (m, 1H), 6.83 (s, 1H), 6.47 (td, J = 55.5, 11.6 Hz, 1H), 4.25 (s, 1H), 4.13 (s, 1H), 4.05 - 3.99 (m, 3H), 3.97 - 3.89 (m. 2H), 3.82 - 3.75 (m, 1H), 3.74 - 3.66 (m, 5H), 2.92 - 2.81 (m, 3H), 2.80 - 2.73 (m, 1H), 2.47 - 2.35 (m, 1H), 2.24 - 2.01 (m, 11H), 1.69 - 1.52 (m, 2H).methyl (lr,4r)-4-(5-acetyl-3-(7-(difluoromethyl)-6-morpholino-3,4-dihydroquinolin- l(2H)-yl)-4,5,6,7-tetrahydro- lH-pyrazolo[4,3-c]pyridin- 1 -yl)cyclohexane- 1 -carboxylate (Intermediate 38b)
[0787] Intermediate 38b was synthesized with a similar procedure to that of Intermediate 38a. LC-MS mlz [M+H]+572.29.methyl (lr,4r)-4-(5-acetyl-3-(6-bromo-7-(difluoromethyl)-3,4-dihydroquinolin-l(2H)-yl)- 4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l-yl)cyclohexane-l-carboxylate (Intermediate 38c)
[0788] Intermediate 38c was synthesized with a similar procedure to that of Intermediate 38a. LC-MS m / z [M+H]+567.15.Zran.s-4-(5-acetyl-3-(7 -(difluoromethyl)-6-( 1 -methyl- 1 H-pyrazol-4-yl)-3,4- dihydroquinolin-l(2H)-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l- yl)cyclohexane-l-carbaldehyde (Intermediate 39a)
[0789] Intermediate 38a (223 mg, 0.39 mmol) was dissolved in anhydrous DCM (15 mL) and the solution was degassed and charged with N2 3 time. DIBAL (25% in toluene, 1.06 mL, 1.56 mmol) was added dropwise at -78 °C over 1 h and the reaction mixture was stirred at -78 °C for additional 2 h. Then the reaction was quenched with aqueous ammonium chloride. The result mixture was extracted with DCM, and the organic layers were washed with brine, dried over anhydrous Na2SC>4, filtered, and concentrated under reduce pressure. The crude residue was purified by pre-HPLC: acclonilrilc / lbO from 35% to 100% in 65 min, flow rate (60 ml / min). The desired product started coming out when acelonilrilc / IbO = 52%. The title compound Intermediate 39a was obtained as a white solid (146 mg, yield = 69%). LC-MS: mz [M+H]+= 537.24. ’H NMR (400 MHz, Chloroform-ri) 87.56 - 7.51 (m, 1H), 7.43 - 7.37 (m, 1H), 7.07 - 6.96 (m, 1H), 6.89 - 6.83 (m, 1H), 6.51 (td, J = 55.6, 10.9 Hz, 1H), 4.25 (s, 1H), 4.12 (s, 1H), 3.98 - 3.93 (m, 3H), 3.93 - 3.82 (m, 2H), 3.78 - 3.64 (m, 3H), 2.91 - 2.82 (m, 2H), 2.81 - 2.69 (m, 2H), 2.40 - 2.28 (m, III), 2.24 - 2.00 (m, 1111), 1.51 - 1.36 (m, 211).(ls,4s)-4-(5-acetyl-3-(7-(difhioromethyl)-6-morpholino-3,4-dihydroquinolin-l(2H)-yl)- 4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l-yl)cyclohexane-l-carbaldehyde (39b)
[0790] Intermediate 39b was synthesized with a similar procedure to that of Intermediate 39a. LC-MS m / z [M+H]+542.29.(lr,4r)-4-(5-acetyl-3-(6-bromo-7-(difluoromethyl)-3,4-dihydroquinolin-l(2H)-yl)- 4,5,6,7-tetrahydro- 1 H-pyrazolo[4,3-c]pyridin- 1 -yl)cyclohexane- 1 -carbaldehyde (Intermediate 39c)
[0791] Intermediate 39c was synthesized with a similar procedure to that of Intermediate 39a. LC-MS m / z [M+H]+537.14.4-(5-acetyl-3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4-dihydroquinolin- l(2H)-yl)-4, 5, 6, 7-tetrahydro- lILpyrazolo[4,3-c]pyridin-l-yl)piperi dine- 1 -carboxylate (Intermediate 40)
[0792] Intermediate 40 was synthesized by following a similar procedure as that of Intermediate 38 (yield, 45%). LC-MS mlz [M+H]+644.28; ’ll NMR (400 MHz, Methanol-A) 57.66 (s, 1H), 7.54 (d, 7= 3.1 Hz, 1H), 7.39-7.26 (m, 5H), 7.10 (d, J= 8.2 Hz, 1H), 6.76-6.40 (m, 2H), 5.13 (s, 2H), 4.34-4.24 (m, 3H), 4.20 (d, J= 6.0 Hz, 2H), 3.94 (s, 3H), 3.88 (t, J= 5.8 Hz, 1H), 3.81 (t, J= 5.8 Hz, 1H), 3.66 (q, J= 6.1 Hz, 2H), 3.10-2.96 (m, 2H), 2.95-2.85 (m, 3H), 2.82 (t, J= 5.7 Hz, 1H), 2.18 (s, 2H), 2.10-1.92 (m, 7H).1 -(3-(7 -(difluoromethyl)-6-( 1 -methyl- 1 H-pyrazol-4-yl)-3,4-dihydroquinolin- 1 (2H)-yl)- 1 - (piperidin-4-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 41)
[0793] To a solution of Intermediate 40 (270 mg, 1.0 equiv) in MeOH (12 mL) was added Pd(OH)2 (54 mg, 0.2 equiv). The mixture was degassed and purged with H2 threetimes, then kept stirred under N2 atmosphere for 8 h. After that, the mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to give product 1 -(3 -(7 -(difluoromethyl)-6-( 1 -methyl- 1 H-pyrazol-4-y l)-3,4-dihydroquinolin- 1 (2H)-yl)- 1 - (piperidin-4-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 41) as a white solid (167 mg, 78% yield). LC-MS mh [M+H]+510.00;JH NMR (400 MHz, MeOH-A) 87.64 (s, 1H), 7.51 (s, 1H), 7.12 (d, J= 8.9 Hz, 1H), 6.80- 6.41 (m, 2H), 4.53-4.42 (m, 1H), 4.22 (d, J= 6.4 Hz, 2H), 3.93 (s, 3H), 3.90 (t, J= 5.8 Hz, 1H), 3.83 (t, J = 5.8 Hz, 1H), 3.67 (q, 7= 6.0 Hz, 2H), 3.63-3.54 (m, 2H), 3.27-3.16 (m. 2H), 2.97-2.87 (m, 3H), 2.84 (t, J= 5.8 Hz, 1H), 2.38-2.15 (m, 6H), 2.12-2.01 (m, 3H);13C NMR (101 MHz, MeOD) 8 172.22, 150.88, 150.38, 143.59, 140.16, 139.53, 139.37, 132.24, 132.11, 131.12, 130.99, 130.58, 130.51, 129.42, 127.82, 127.67, 126.52, 120.83, 117.34, 115.00, 112.66, 111.51, 111.07, 107.85, 107.81, 53.26, 53.21, 50.94, 50.86, 44.54. 44.30, 44.25, 43.93, 40.09, 39.91. 39.68, 38.92, 38.75, 35.58, 30.42, 29.76, 28.42, 28.09, 23.37, 23.35, 23.27, 22.46, 21.65, 21.42, 21.34, 21.01.Intermediate EXAMPLE 8General procedure for Intermediates 44 and 47
[0794] Reagents and conditions: (a) DMF, NaH, 0 °C to it, 4 h; (b) DCM, TFA, reflux; (c) HATU, DCM, ELN, rt.4-((( lr,4r)-4-aminocyclohexyl)oxy)-2-chlorobenzonitrile (Intermediate 44a)Intermediate 44a
[0795] Intermediate 43 (2.15 g, 10 mmol) was dissolved in anhydrous THF (30 mL) in an ice bath. NaH (60% in mineral oil, 0.9 g, 22.5 mmol) was added in portions, and after 0.5 h the reaction mixture was warmed up to room temperature (rt) for 0.5 h. The reaction was placed in an ice bath and compound 42a (2.30 g, 15 mmol) was added and warmed up to rt for 4 h. After that the reaction mixture was quenched with H2O at 0 °C, extracted with EtOAc, dried, and concentrated. The above crude product was dissolved in DCM: TFA (4:1) was added at rt. After 0.5 h, all volatile materials were removed in a rotary evaporator to afford Intermediate 44a in 95% yield, ’ll NMR (MeCN-dg): 5 7.71 (d, J = 8.0 Hz, 1H), 7.21 (d, J= 2.4 Hz, 1H), 7.02 (dd, J= 8.0 Hz, 2.4 Hz, 1H), 6.79 (br, 3H, NH2TFA), 4.43 (m, 1H), 3.27 (m, 1H), 2.22 (m, 2H), 2.14 (m, 2H), 1.62 (m, 2H), 1.52 (m, 2H).N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(piperazin-l-yl)benzamide (Intermediate 47a)
[0796] Intermediate 44a (75 mg, 1.0 eq.) was dissolved in DCM (2 mL), HAITI (119 mg, 1.1 eq) and EtsN (2.5 eq.) was added. The mixture was stirred at for 5 min, then compound 45a (74 mg, 1.0 eq.) was added in to the mixture. The result mixture was stirred at rt for additional 15 min, after that the mixture was diluted with water and extracted with DCM, dried, and concentrated to give the crude product of Intermediate 46a. Compound Intermediate 46a (0.27 g, 0.5 mmol) was dissolved in DCM (2 mL) and TFA (0.5 mL) was added at rt. After 4 h, all volatile materials were removed in a rotary evaporator and purified by silica gel column chromatography to afford Intermediate 47a in 95% yield. II NMR (MeCN-d ): 5 7.77 (d, J= 8.8 Hz, 2H), 7.71 (d, J= 8.4 Hz, 1H), 7.21 (d, J= 2.4 Hz, 1H), 7.03 (m, 3H), 6.84 (d, J= 8.0 Hz, 1H, CONH), 5.13 (br, 2H, NH TFA), 4.46 (m, 1H), 3.95 (m, 1H), 3.53 (m, 4H), 3.35 (m, 4H), 2.17 (m, 2H), 2.07 (m, 2H), 1.59 (m, 4H).N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(piperazin-l-yl)pyridazine-3- carboxamide (Intermediate 47b)
[0797] Intermediate 47b was synthesized with a similar procedure to that of Intermediate 47a. ’ll NMR (400 MHz, DMSO-cfe) 5 8.68 (d, J = 8.3 Hz, HI), 7.89 (dd, J = 17.4, 9.1 Hz, 2H), 7.43 (d, J = 9.6 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 8.8, 2.5 Hz, 1H), 4.53 (td, J= 10.1, 5.0 Hz, 1H), 3.86 (t, J= 5.2 Hz, 4H), 3.74 (s, 1H), 3.21 - 3.09 (m, 3H), 2.18 - 2.06 (m, 2H), 1.95 - 1.85 (m, 2H), 1.72 - 1.59 (m, 2H), 1.59 - 1.45 (m, 2H). N-((lr,4r)-4-(4-cyano-3-methoxyphenoxy)cyclohexyl)-6-(piperazin-l-yl)pyridazine-3- carboxamide (Intermediate 47c)
[0798] Intermediate 47c was synthesized with a similar procedure to that of Intermediate 47a. ’ll NMR (400 MHz, DMS0-rf6) 58.69 (d, J = 8.2 Hz, 1H), 8.05 (s, 1H), 7.93 (d, J = 9.5 Hz, 1H), 7.66 - 7.59 (m, 1H), 7.46 (d, J = 9.6 Hz, 1H), 6.74 - 6.72 (m, 1H), 4.54 - 4.44 (m, 1H), 3.94 (t, J = 5.3 Hz, 4H), 3.89 (s, 3H), 3.88 - 3.82 (m, 1H), 3.26 (t, J = 5.3 Hz, 4H), 2.13 (d, J = 11.9 Hz, 2H), 1.91 (d, J = 12.2 Hz, 2H), 1.66 (q, J = 12.0 Hz, 2H), 1.52 (q, J= 11.2 Hz, 2H).N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(piperazin-l-yl)pyrimidine-5- carboxamide (Intermediate 47 d)
[0799] Intermediate 47d was synthesized with a similar procedure to that of Intermediate 47a. 'll NMR (400 MHz, DMSO-cfc) 58.76 (s, 2H), 8.14 (d, J = 7.5 Hz, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.40 (d, J= 2.4 Hz, 1H), 7.15 (dd, J = 8.8, 2.4 Hz, 1H), 4.61 - 4.49 (m, 1H), 3.86 - 3.78 (m, 1H), 3.78 - 3.73 (m, 4H), 2.80 - 2.74 (m, 4H), 2.10 (dd, J = 8.2, 3.6 Hz, 2H), 1.96 - 1.88 (m, 2H), 1.58 - 1.43 (m, 4H).N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(piperazin-l-yl)nicotinamide (Intermediate 47e)
[0800] Intermediate 47e was synthesized with a similar procedure to that of Intermediate 47a. ’ll NMR (400 MIIz, DMSO-tfc) 5 8.65 (d, 7= 2.5 Hz, III), 8.15 (d, 7 = 7.5 Hz, III), 8.06 (dt, J = 9.0, 3.1 Hz, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.39 (d, J = 2.4 Hz, 1H), 7.15 (dd, J = 8.8, 2.5 Hz, 1H), 6.96 (d, J = 9.2 Hz, 1H), 4.60 - 4.49 (m, 1H), 3.90 - 3.75 (m, 5H), 3.20 (s, 4H), 2.15 - 2.06 (m, 2H), 1.91 (d, 7= 9.8 Hz, 2H), 1.53 (p, J = 11.4 Hz, 4H).N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-3-fluoro-4-(piperazin-l- yl)benzamide (Intermediate 47f)
[0801] Intermediate 47f was synthesized with a similar procedure to that of Intermediate 47a. ’ll NMR (400 MHz, DMSO-tfc) 5 8.25 (d, 7 = 7.6 Hz, IH), 7.87 (d, 7 = 8.8 Hz, IH), 7.73 - 7.70 (m, IH), 7.68 (s, IH), 7.40 (d, 7 = 2.4 Hz, IH), 7.19 - 7.12 (m, 2H), 4.62 - 4.49 (m, IH), 3.81 (d, J = 8.0 Hz, 2H), 2.18 - 2.04 (m, 2H), 1.90 (d, J = 10.3 Hz, 2H), 1.66 - 1.43 (m, 4H).N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(piperazin-l-yl)picolinamide (Intermediate 47g)
[0802] Intermediate 47g was synthesized with a similar procedure to that of Intermediate 47a. LC-MS mlz [M+H]+440.18.N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-fluoro-4-(piperazin-l- yl)benzamide (Intermediate 47h)
[0803] Intermediate 47g was synthesized with a similar procedure to that of Intermediate a. LC-MS mlz [M+H]+457.18.Intermediate EXAMPLE 9General procedure for Intermediates 50a-h
[0804] Reagents and conditions: (a) HATU, DCM, EtsN, rt; (b) DCM, TFA, reflux.N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)isoindoline-5-carboxamide (Intermediate 50a)
[0805] Intermediate 48a (75 mg, 1.0 eq.) was dissolved in DCM (2 mb), HATU (119 mg, 1.1 eq) and EtsN (2.5 eq.) was added. The mixture was stirred at for 5 min, thencompound 44a (71 mg, 1.0 eq.) was added in to the mixture. The resulting mixture was stirred at rt for additional 15 min, after that the mixture was diluted with water and extracted with DCM, dried, and concentrated to give the crude product of Intermediate 49a. The crude product was dissolved in DCM: TFA (4:1) at rt. The reaction mixture was stirred at rt for additional 4 h, after Intermediate 49a was completely deprotected. Then the reaction solvent was evaporated under reduced pressure and purified by silica gel column chromatography to afford Intermediate 50a as a white solid. 1H NMR (400 MHz, DMSO-6 / 6) 58.39 (d, J = 7.6 Hz, 1H), 7.90 - 7.83 (m, 3H), 7.49 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.16 (dd, J = 8.8, 2.4 Hz, 1H), 4.63 - 4.51 (m, 5H), 3.88 - 3.78 (m, 1H), 2.12 (d,.7 = 9.9 Hz, 2H), 1.92 (d, J= 10.3 Hz, 2H), 1.55 (p,.7 = 11.8 Hz, 4H).N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-fluoroisoindoline-5-carboxamide (Intermediate 50c)
[0806] Intermediate 50c was synthesized with a similar procedure to that of Intermediate 50a. 'll NMR (400 MHz, Chloroform-^ / ) 5 8.04 (t, J = 7.4 Hz, 1H), 7.58 (d, J = 8.7 Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.02 (d, J = 2.4 Hz, 1H), 6.87 (dd, J = 8.8, 2.4 Hz, 1H), 6.66 (dd, J = 9.9, 7.6 Hz. 1H), 4.74 (d. J = 5.2 Hz, 4H), 4.35 (td, J = 9.8, 8.0, 4.9 Hz, 1H), 4.10 (d, J = 9.6 Hz, 1H). 2.28 - 2.14 (m, 4H), 1.78 - 1.64 (m, 2H), 1.57 - 1.44 (m. 3H).
[0807] Intermediates 50b and 50d-50h were synthesized with similar procedures to that of Intermediate 50a.Intermediate EXAMPLE 10General procedure for Intermediates 51 and 52
[0808] Reagents and conditions: (a) HATU, DCM, Et3N, rt; (b) DCM, TFA, reflux.4-amino-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide (Int 52a)Intermediate 52a
[0809] Intermediate 52a was synthesized with a similar procedure to that of Intermediate 50a. 'll NMR (400 MHz, DMSO-rf6) 58.30 (d, J = 7.5 Hz, 1H), 7.88 (dd, J= 9.9, 7.8 Hz, 3H), 7.39 (d, J = 2.4 Hz, 1H), 7.31 - 7.24 (m, 2H), 7.15 (dd, J = 8.8, 2.4 Hz, 1H), 4.55 (dt, J = 10.3, 5.3 Hz, 1H), 3.81 (d, J = 10.4 Hz, 1H). 2.11 (q, J = 5.7, 4.7 Hz, 2H), 1.91 (q, J = 4.9, 3.0 Hz, 2H), 1.61 - 1.43 (m, 4H).
[0810] Intermediates 52b-52g were synthesized with similar procedures to that of Intermediate 50a.4-bromo-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide (Intermediate
[0811] Intermediate 51h was synthesized with a similar procedure to that of Intermediate 49a. 4l NMR (400 MHz, DMSO-76) 5 8.40 (d, J = 7.6 IIz, III), 7.83 - 7.78 (m, 211), 7.70 - 7.65 (m, 2H), 7.40 (d, 7= 2.4 Hz, 1H), 7.15 (dd, J = 8.8, 2.5 Hz, 1H), 4.55 (dt, J = 10.0, 5.2 Hz, 1H), 3.89 - 3.75 (m, 1H), 2.20 - 2.05 (m, 2H), 1.92 (d, J = 10.5 Hz, 2H), 1.64 - 1.42 (m, 4H).Phenyl (4-(((lr,4r)-4-(3-chloro-4- cyanophenoxy)cyclohexyl)carbamoyl)phenyl)carbamate (Intermediate 5 Iq)
[0812] 'll NMR (400 MHz, DMSO-d6) 5 10.47 (s, 1H), 8.17 (d, J = 7.6 Hz. 1H), 7.85 (dd, J = 10.0, 8.1 Hz, 3H), 7.61 - 7.55 (m, 2H), 7.49 - 7.42 (m, 2H), 7.40 (d, J = 2.4 Hz, 1H), 7.32 - 7.22 (m, 3H), 7.15 (dd, J= 8.8, 2.5 Hz, 1H), 4.61 - 4.48 (m, 1H), 3.89 - 3.74 (m, 1H), 2.12 (d, 7= 9.8 Hz, 2H), 1.92 (d, 7= 10.0 Hz, 2H), 1.54 (p, 7= 11.0 Hz, 4H).
[0813] Intermediates 51i-51p and 51r-51s were synthesized with similar procedures to that of Intermediate 49a.Intermediate 52h
[0814] To a solution of Intermediate 51o (100 mg, 0.2 mmol), PdCh(dppf) (15 mg, 0.02 mmol), KOAc (39.2 mg, 0.4 mmol), and 4,4,4',4’,5,5,5',5'-octamethyl-2,2'-bi(l,3,2- dioxaborolane) (76 mg, 0.3 mmol) were added in 1,4-dioxane (7 mL). The mixture was heated to 110 °C for 3 h. After cooling to rt, the mixture was concentrated in vacuo. EtOAc (50 mL) was added, and the mixture was washed with water (40 mL x 2). The organic layer was dried over anhydrous Na2SC>4, filtered, and concentrated in vacuo.The crude residue was purified by silica gel flash chromatography to give Intermediate 52h.Intermediate EXAMPLE 11General procedure for Intermediates 54 and 57
[0815] Reagents and conditions: (a) DMF, Cs2CO3, 90 °C, 12 h; (b) DCM, TFA, reflux; (c) HATU, DCM, Et3N, rt; (d) piperazine, DIPEA, DMF, 75 °C.4-(((lr,4r)-4-aminocyclohexyl)(methyl)amino)-2-chlorobenzonitrile (Intermediate 54a)
[0816] ' / 'ran.s-t -riiclhylaminocyclohexybcarbamale t-butyl ester 53 (2.28 g, 10 mmol) was dissolved in DMF (30 mL), CS2CO3 (2.30 g, 15 mmol) and compound 42a (2.30 g, 15 mmol) was added. The reaction was stirred at 90 °C for 12 h. After that the reaction mixture was diluted with H2O, extracted with EtOAc, dried, and concentrated. The above crude product was dissolved in DCM MFA (4:1) was added at rt. After 0.5 h, all volatile materials were removed in a rotary evaporator to afford Intermediate 54a in 95% yield. ’ll NMR (MeCN-ri3): 5 7.52 (d, J= 8.0 Hz, 1H). 7.39 (br, 3H, NH2-TFA), 6.92 (d, J= 2.4 Hz, 1H), 6.80 (dd, J = 8.0 Hz, 2.4 Hz, 1H), 3.79 (m, 1H), 3.19 (m, 1H), 2.83 (s, 3H), 2.58 (m, 4H), 2.18 (m, 2H), 1.80 (m, 1H), 1.70 (m, 1H).4-(((lr,4r)-4-aminocyclohexyl)(methyl)amino)-2-methoxybenzonitrile (Intermediate 54b)Intermediate 54b
[0817] Intermediate 54b was synthesized with a similar procedure to that of Intermediate 54a. ’ll NMR (400 MHz, DMSO-tfc) 57.38 (d, J = 8.8 Hz, 1H), 6.46 (dd, J = 9.0, 2.3 Hz, 1H), 6.30 (d, J = 2.3 Hz, 1H), 3.87 (s, 3H), 3.80 - 3.69 (m, 1H), 3.03 (q, J = 9.1, 6.0 Hz, 1H), 2.83 (s, 3H), 2.04 - 1.93 (m, 2H), 1.69 (h, J = 3.3 Hz, 4H), 1.53 (qd, J = 11.7, 7.5 Hz, 2H).Intermediate 57a
[0818] Intermediate 57a was synthesized with a similar procedure to that of Intermediate 47a. ’ll NMR (400 MHz, DMSO-tfc) 6 8.59 (d, 7= 8.3 Hz, HI), 7.94 (d, 7 = 9.5 Hz, III), 7.62 (d, J = 9.0 Hz, 1H). 7.46 (d, J = 9.6 Hz, 1H), 6.95 (d, J = 2.5 Hz, 1H), 6.83 (dd, J = 9.1, 2.6 Hz, 1H), 3.96 (t, J = 5.3 Hz, 4H), 3.91 - 3.84 (m, 1H), 3.83 - 3.71 (m, 1H), 3.60 (q, J= 4.7 Hz, 1H), 3.23 (t, J = 5.3 Hz, 4H), 2.86 (s, 3H), 1.92 (d, J = 10.6 Hz, 2H), 1.82 - 1.63 (m, 6H).
[0819] N-((lr,4r)-4-((4-cyano-3-methoxyphenyl)(methyl)amino)cyclohexyl)-6- (piperazin-l-yl)pyridazine-3-carboxamide (Intermediate 57b)
[0820] Intermediate 57b was synthesized with a similar procedure to that of Intermediate 47a. ’H NMR (400 MHz, DMSO-tfe) 5 8.53 (d, J= 8.3 Hz, 1H), 7.85 (d, J= 9.5 Hz, 1H), 7.38 (d, J = 8.9 Hz, 1H). 7.34 (d, J = 9.6 Hz, 1H), 6.45 (dd, J = 9.0, 2.2 Hz, 1H), 6.31 (d, 7 = 2.2 Hz, 1H), 3.88 (s, 3H), 3.88 - 3.82 (m, 1H), 3.82 - 3.72 (m, 2H), 3.68 (t,.7 = 5.1 Hz, 4H), 2.89 (t, 7 = 5.1 Hz, 4H), 2.87 (s, 3H), 1.93 (dd, 7 = 11.8, 3.0 Hz, 2H), 1.70 (dtd, 7= 24.7, 12.6, 3.3 Hz, 611).Intermediate EXAMPLE 12General procedure for Intermediates 58 and 59
[0821] Reagents and conditions: (a) DMF, NaH, 0 °C to rt, 4 h; (b) DCM, TFA, reflux; (c) HATU, DCM, Et3N, rt; (d) DCM, TFA, reflux.4-((lr,3r)-3-amino-2,2,4,4-tetramethylcyclobutoxy)-2-chlorobenzonitrile (Intermediate
[0822] Intermediate 59 was synthesized from commercially available 42a with a similar procedure to that of Intermediate 44a. 'll NMR (400 MHz, DMSO-rf6) 5 7.87 (d, J = 8.7 Hz, 1H), 7.19 (d, J= 2.3 Hz, 1H), 6.99 (dd, J= 8.8, 2.3 Hz, 1H), 4.37 (s, 1H), 3.76 (s, 1H), 3.11 (s, 1H), 1.29 (s, 6H), 1.08 (s, 6H). UPLC-MS calculated for C15H20CIN2O [M + H]+: 279.13, found: 279.07. UPLC-retention time: 2.0 min, purity >95%.N-((lr,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(piperazin-l- yl)benzamide (Intermediate 60a)
[0823] Intermediate 60a was synthesized with a similar procedure to that of Intermediate9.08 (s, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.81 (s, 1H), 7.60 (d, J= 9.2 Hz, 1H), 7.18 (d, J = 2.3 Hz, 1H), 7.05 (d. J = 8.9 Hz, 2H), 7.01- 6.98 (m, 1H), 4.33 (s, 1H), 4.07 (d, J= 9.1 Hz, 1H), 3.54-3.44 (m, 4H), 3.26 (s, 4H), 1.23 (s, 6H), 1.13 (s, 6H). UPLC-MS calculated for C26H32CIN4O2 [M + H]+: 467.22, found: 467.24. UPLC -retention time: 4.1 min, purity >95%.
[0824] Intermediates 60b-60d were synthesized with a similar procedure to that of Intermediate 47 a.Intermediate EXAMPLE 13General procedure for Intermediates 65 and 66
[0825] Reaction conditions: (a) DMF, CS2CO3, 110 °C, 16 h; (b) DCM, TEA; (c) dioxane, tert-butyl 4-iodobenzoate, Pd2(dba)3, Xphos, CS2CO3, 100 °C, 12 h; (d) DCM, TFA; (e) DIPEA, DMF, 75°C.(S)-2-chloro-4-(3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile (Intermediate 62)Intermediate 62
[0826] 2-Chloro-4-fluorobenzonitrile 42a (1.55 g, 10 mmol, 1.0 equiv) and the tert-butyl (S)-3-methyL2,8-diazaspiro[4.5]decane-8-carboxylate 61 (2.03 g, 8 mmol, 0.8 equiv) were dissolved in DMF (15 mL), and CS2CO3 (9.78 g, 3.0 equiv) was added. The mixture was stirred at 120 °C overnight. The reaction mixture was cooled and partitioned between EtOAc and water. The organic layer was separated, washed with brine, dried, and purified with hexane and EtOAc using Combiflash to afford a white solid, which was dissolved in DCM (10 mL) and TEA (3 mL). The mixture was stirred at rt for 0.5 h. All the volatiles were removed by a rotary evaporator to provide a light-yellow solid with a 70% yield. UPLC-MS: 4.0 min, purity > 95%, MS [M + H]+; found, 290.10, calcd, 290.13. 'll NMR (MeOD): 5 8.98 (br, 2H), 7.52 (d, J= 8.8 Hz, 1H), 6.75 (d, J= 2.4 Hz, 1H), 6.61 (dd, J= 8.8 Hz, 2.4 Hz, 1H), 4.04 (m, 1H), 3.42 (m, 2H), 3.14 (m, 4H), 2.34 (m, 1H), 2.16 (m, 2H), 1.76 (m, 2H), 1.68 (m, 1H), 1.25 (d, J = 6.0 Hz, 3H).(S)-4-(2-(3-chloro-4-cyanophenyl)-3-methyl-2,8-diazaspiro[4.5]decan-8-yl)benzoic acid (Intermediate 65b)Intermediate 65b
[0827] A solution of 62 (1.0 equiv), Xantphos (0.2 equiv), Pd(dba)3 (0.1 equiv), 63b (1.5 equiv) and t-BuONa (2.0 equiv), anhydrous 1,4-di oxane. The mixture was evacuated and backfilled with argon (3 cycles). The reaction mixture was then heated at 100 °C for 8 h before being filtered through celite. The reaction solvent was evaporated under reduced pressure. After that water was added, the reaction mixture was extracted with EtOAc and washed with water, and the organic phase was dried over Na2SO4. Intermediate 65b was obtained by removing the solvent under vacuum and purified by flash column with further subsequent deprotection by TFA (81% yield two steps). ’ll NMR (400 MHz, DMSO- e): 87.78 (d, J = 8.9 Hz, 2H), 7.57 (d, J = 8.8 Hz, 1H), 6.97 (d, 7= 9.0 Hz, 2H), 6.78 (d, 7 = 2.2 Hz, 1H), 6.63 (dd, 7= 8.9, 2.2 Hz, 1H), 4.00 (dt, 7= 12.7, 6.3 Hz, 1H),3.41 (t, J= 9.6 Hz, 3H), 3.34-3.22 (m, 3H), 2.22 (dd, J= 12.7, 7.7 Hz, 1H), 1.76-1.63 (m, 2H), 1.56 (dd, J= 12.8, 6.5 Hz, 1H), 1.47 (s, 2H), 1.19 (d, J= 6.0 Hz, 3H). UPLC- MS calculated for C23H25CIN3O2 [M + H]+, 410.17; found, 410.22. UPLC-retention time: 5.5 min, purity >95%.(S)-2-chloro-4-(3-methyl-8-(6-(piperazin-l-yl)pyridazin-3-yl)-2,8-diazaspiro[4.5]decan- 2-yl)benzonitrile (Intermediate 66a)
[0828] A solution of Intermediate 62 (1.0 eq) in DMF, and DIPEA (2.5 eq), 64 (1.5, eq) at rt was prepared. The mixture was stirred at 70°C for 4h. Monitored the reaction through TLC until the reaction was completed. Then the reaction solvent mixture was diluted with water and extracted with DCM, dried, and concentrated. The crude material was dissolved in DCM (2 mL) and TFA (0.5 mL) was added at rt. After 2 h, all volatile materials were removed in a rotary evaporator and purified by silica gel column chromatography to afford Intermediate 66a.JH NMR (400 MHz, DMSO-rfc) 5 8.03 - 7.85 (m, 2H), 7.62 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 2.3 Hz, 1H), 6.66 (dd, J = 8.9, 2.3 Hz, 1H), 3.80 - 3.70 (m, 2H), 3.68 (t, J = 5.2 Hz, 5H), 3.64 - 3.54 (m, 2H), 3.48 (d, J = 10.8 Hz, 1H), 3.36 (d, J = 10.7 Hz, 1H), 3.25(s, 4H), 2.27 (dd, J = 12.9, 7.7 Hz, 1H), 1.80 - 1.67 (m, 2H), 1.60 (dd, J = 12.9, 6.7 Hz, 1H), 1.52 (t, J = 5.0 Hz, 2H), 1.21 (d, J = 6.0 Hz, 3H).(S)-2-chloro-4-(3-methyl-8-(6-(piperidin-4-yloxy)pyridazin-3-yl)-2,8- diazaspiro[4.5]decan-2-yl)benzonitrile (Intermediate 66b)
[0829] Intermediate 66b was synthesized with a similar procedure to that of Intermediate 66a. LC / MS [M+H]+: 467.16.(S)-2-chloro-4-(3-methyl-8-(2-(piperidin-4-yloxy)pyrimidin-5-yl)-2,8- diazaspiro[4.5]decan-2-yl)benzonitrile (Intermediate 65c)
[0830] Intermediate 65c was synthesized with a similar procedure to that of Intermediate 66a. LC / MS [M+II]+: 467.19Intermediate EXAMPLE 14General procedure for Intermediate 70
[0831] Reagents and conditions: (a) RuPhos Pd G2, RuPhos, t-BuONa, N2,1.4-dioxane, 100 °C; (b) NBS, DCM, 0°C; (c) Pd(OAc)2, Pph3, K2CO3, Dioxan: H2O (5:2), 100 °C, N2, 3h; (d) TFA, DCM.1 -(3-(7 -fluoro-3,4-dihydroquinolin- 1 (2H)-yl)- 1 -(tetrahydro-2H-pyran-4-yl)- 1,4,6,7 - tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan- 1 -one (Intermediate 68)
[0832] Intermediate 68 was synthesized with a similar procedure to that of intermediate 6. LC-MS m / z [M+H]+399.21.l-(3-(6-bromo-7-fluoro-3,4-dihydroquinolin-l(2H)-yl)-l-(tetrahydro-2H-pyran-4-yl)- l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 69)
[0833] Intermediate 69 was synthesized with a similar procedure to that of Intermediate 7. LC-MS m / z [M+H]+477.12.5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-fluoro-l,2,3,4-tetrahydroquinolin-6-yl)picolinic acid (Intermediate 70)
[0834] Intermediate 70 was synthesized with a similar procedure to that of Intermediate 10a. LC-MS m / z [M+H]+520.23.Intermediate EXAMPLE 15General Procedure for Synthesis of Intermediates 71 and 73a-e
[0835] Reagents and conditions: (a) HATU, DMF, Et3N, rt, 15 min; (b) K2CO3, DMF, 65 °C, 3 h. (c) Et3N, Sodium triacetoxyborohydride, DCM, rt, 3 h; (d) DCM, TFA, 40 °C, 3 h; (e) K2CO3, DMF, 65 °C, 3 h.
[0836] Intermediates 41 and 44a were prepared as described above.6-chloro-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)pyridazine-3-carboxamide (Intermediate 71)Intermediate 71
[0837] Step a: 6-chloropyridazine-3-carboxylic acid (5.0 g, 31.54 mmol) was dissolved in DMF (100 mL), HATU (12.0 g, 31.54) and Et3N (4.8 g, 47.31 mmol) was added. The mixture was stirred at room temperature for 2 min, then intermediate 44a (7.9 g, 31.54 mmol) was added in to the mixture. The resulting mixture was stirred at room temperature for an additional 13 min. After that, the mixture was diluted with water and extracted with DCM. The organic phases were combined and concentrated under reduced pressure. The residue was purified by flash column chromatography (0-50% EtOAc / n- hexane) to give Intermediate 71 (5.5 g, yield: 45%) as yellow solid. ’ll NMR (400 MHz, DMSO-ffc) 89.17 (d, 7 = 8.1 Hz, 1H), 8.23 (d, J = 8.8 Hz, 1H), 8.11 (d, 7= 8.8 Hz, 1H), 7.86 (d, 7 = 8.8 Hz, 1H), 7.40 (d, 7 = 2.4 Hz, 1H), 7.15 (dd, 7 = 8.8, 2.4 Hz, 1H), 4.54 (tt, 7 = 10.4, 4.2 Hz, 1H), 3.92 (tdq, 7 = 11.7, 8.0, 3.9 Hz, 1H), 2.12 (d, 7 = 13.8 Hz, 2H), 1.90 (d, 7 = 14.2 Hz, 2H), 1.71 (q, 7 = 13.2 Hz, 2H), 1.52 (q, 7 = 12.9 Hz, 2H). LC- MS m / z [M+H]+391.11.1 -(1 -( 1 -(azetidin-3-yl)piperidin-4-yl)-3-(7 -(difluoromethyl)-6-( 1 -methyl- 1 H-pyrazol-4- yl)-3,4-dihydroquinolin-l(2H)-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5- yl)ethan-l-one (Intermediate 73a)Intermediate 73a
[0838] Step c: To a solution of Intermediates 41 (51.0 mg, 0.1 mmol) and 72a (34.2 mg, 0.2 mmol) in DCM at room temperature, was added Et3N (20.2 mg, 0.2 mmol). The mixture was stirred at room temperature for 30 min. Then sodium triacetoxyborohydride (31.8 mg, 0.15 mmol) was added to the reaction, and the mixture was stirred at room temperature for 3 h. The reaction was monitored through LC / MS until Intermediate 41was completely consumed, and then the mixture was concentrated under reduced pressure. The crude residue was purified by pre-HPLC (25-100% MeCN / HzO in 70 min, the desired product started eluting at ~ 38% MeCN).
[0839] Step d: The product obtained above in step c was dissolved in 6 mL of DCM:TFA (5:1) and stirred at 40 °C for an additional 3 h. The reaction was monitored through LC / MS until the reaction was completed. Then the mixture was concentrated and purified by pre-HPLC (10-100% MeCN / HzO in 90 min the desired product started eluting at ~ 20% MeCN), to give Intermediate 73a (34 mg, yield: 60%, two steps) as a clear, gel-like solid. ’ll NMR (400 MHz, DMSO-tfe) 5 7.77 (s, 1H), 7.51 (d, J = 0.8 Hz, 1H), 7.13 (s, 1H), 6.80 (td,. / = 55.2, 6.8 Hz, 1H), 6.79 (d,.7= 3.0 Hz, 1H), 4.44 - 4.24 (m, 3H), 4.23 - 4.03 (m, 5H), 3.87 (s, 3H), 3.79 - 3.67 (m, 2H), 3.59 (t, J = 6.0 Hz, 2H), 3.51 - 3.36 (m,2H), 3.03 - 2.79 (m, 5H), 2.76 (s, 1H), 2.28 - 2.02 (m, 6H), 2.01 - 1.92 (m, 3H). LC- MS m / z [M+H]+565.35.l-(l-([l,4'-bipiperidin]-4-yl)-3-(7-(difhioromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin-l(2H)-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-l- one (Intermediate 73b)Intermediate 73b
[0840] Intermediate 73b was synthesized from Intermediates 41 and 72b following a similar procedure to that of Intermediate 73a. ’ll NMR (400 MHz, DMSO-rfe) 5 7.77 (s, 1H), 7.51 (s, 1H), 7.13 (s, 1H), 6.81 (td, 7 = 55.2, 7.0 Hz, 1H), 6.77 (d, J = 3.0 Hz, 1H), 4.51 - 4.39 (s, 1H), 4.14 (d, J = 23.0 Hz, 2H), 3.87 (s, 3H), 3.80 - 3.69 (m, 2H), 3.67 - 3.53 m, 4H), 3.53 - 3.37 (m, 6H), 3.22 (q, J = 11.0 Hz, 2H), 2.95 (q, J = 11.9 Hz, 2H), 2.89 - 2.81 (d, J = 5.8 Hz, 3H). 2.79 - 2.72 (m, 1H), 2.37 - 2.13 (m, 6H). 2.08 (d, J = 2.5 Hz, 2H), 1.91 - 1.78 (m, 2H). LC-MS mJz [M+H]+593.41.l-(l-(l-(azetidin-3-ylmethyl)piperidin-4-yl)-3-(7-(difluoromethyl)-6-(l-methyl-lH- pyrazol-4-yl)-3,4-dihydroquinolin-l(2H)-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3- c]pyridin-5-yl)ethan-l-one (Intermediate 73c)Intermediate 73c
[0841] Intermediate 73c was synthesized from Intermediates 41 and 72c following a similar procedure to that of Intermediate 73a.JH NMR (400 MHz, DMSO-r / e) 8 7.76 (s, 1H), 7.51 (s, 1H), 7.13 (s, 1H), 6.80 (td, J = 55.2, 6.8 Hz, 1H), 6.77 (d, J = 3.8 Hz, 1H), 4.44 > 4.33 (m, 1H), 4.14 (d, J = 22.3 Hz, 2H), 4.09 - 3.97 (m, 2H), 3.94 - 3.80 (s, 5H), 3.81 - 3.67 (m, 2H), 3.66 - 3.49 (m, 4H). 3.41 (s, 2H), 3.36 - 3.26 (m, 1H), 3.12 (s, 2H), 2.92 - 2.79 (m, 3H), 2.74 (t, J = 6.9 Hz, 1H), 2.32 - 2.17 (m, 2H), 2.17 - 2.05 (m, 4H), 2.04 - 1.90 (m, 3H).l-(l-(l-(3-azaspiro[5.5]undecan-9-yl)piperidin-4-yl)-3-(7-(difluoroinethyl)-6-(l -methyl- lH-pyrazol-4-yl)-3,4-dihydroquinolin-l(2H)-yl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3- c]pyridin-5-yl)ethan-l-one (Intermediate 73d)Intermediate 73d
[0842] Intermediate 73d was synthesized from Intermediates 41 and 72d following a similar procedure to that of Intermediate 73a. ’ll NMR (400 MHz, CD3OD) 67.65 (s, 1H), 7.52 (s, 1H), 7.11 (d, J = 8.5 Hz. 1H), 6.86 - 6.37 (m, 2H). 4.68 - 4.40 (m. 1H), 4.25 (dd, 7= 23.5, 7.2 Hz, 2H), 3.93 (d, 7 = 1.0 Hz, 3H), 3.86 (dt, 7= 25.9, 5.8 Hz, 2H), 3.73 - 3.62 (m, 4H), 3.49 - 3.23 (m, 3H), 3.23 - 3.10 (m, 4H), 2.92 (d, 7 = 13.3 Hz, 3H), 2.87 - 2.78 (m, 1H), 2.52 - 2.15 (m, 6H), 2.12 - 1.90 (m, 7H), 1.88 - 1.66 (m, 4H), 1.65 - 1.54 (m, 2H), 1.46 - 1.27 (m, 2H). LC-MS m / z [M+H]+661.29.l-(l-(l-((3-azaspiro[5.5]undecan-9-yl)methyl)piperidin-4-yl)-3-(7-(difluoromethyl)-6-(l- methyl- 1 H-pyrazol-4-yl)-3,4-dihydroquinolin- 1 (2H)-yl)- 1,4,6,7 -tetrahydro-5H- pyrazolo[4,3-c]pyridin-5-yl)ethan-l-one (Intermediate 73e)
[0843] Intermediate 73e was synthesized from Intermediates 41 and 72e following a similar procedure to that of Intermediate 73a.!H NMR (400 MHz, CD3OD) 87.65 (s, 1H), 7.51 (d, J = 0.8 Hz, 1H), 7.12 (d, J = 8.6 Hz, 1H), 6.88 - 6.35 (m, 2H), 4.66 - 4.38 (m, 1H), 4.24 (dd, J = 20.8, 7.3 Hz, 2H), 3.93 (d, J = 1.3 Hz, 3H), 3.86 (dt, J = 25.7, 5.8 Hz, 2H), 3.80 - 3.61 (m, 4H), 3.26 - 3.04 (m, 8H), 2.99 - 2.79 (m, 4H), 2.56 - 2.15 (m, 6H), 2.13 - 2.00 (m, 3H), 1.96 - 1.65 (m, 7H), 1.64 - 1.54 (m, 2H), 1.39 - 1.19 (m, 4H). LC-MS m / z [M+H]+675.33.EXAMPLE 14-(4-(5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)picolinoyl)piperazin- l-yl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide
[0844] Intermediate 10a (12 mg, 1.0 eq.) was dissolved in DMF (2 niL), HATU (10 mg, 1.2 eq) and EhN (2.5 eq.) was added. The mixture was stirred at for 5 min, then compound 47a (10.3 mg, 1.1 eq.) was added in to the mixture. The result mixture was stirred at rt for additional 15 min, after that the mixture was diluted with water and extracted with DCM, dried, and concentrated under reduced pressure to remove the solvent. The resulting crude product was purified by flash column chromatography to give the title compound as a white solid. 'll NMR (400 MHz, DMSO-rfc) 8 8.55 (d, J =2.4 Hz, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.91 - 7.84 (m, 2H), 7.77 (d, J = 8.6 Hz, 2H), 7.74 - 7.67 (m, 1H), 7.40 (d, 7 = 2.4 Hz, 1H), 7.19 - 7.12 (m, 2H), 7.00 (d, J = 8.8 Hz, 2H), 6.95 - 6.88 (m, 1H), 6.78 (td, 7= 54.6, 7.5 Hz, 1H), 4.60 - 4.49 (m, 1H), 4.37 - 4.27 (m, 1H), 4.21 (d, 7= 16.6 Hz, 2H), 4.00 - 3.93 (m, 2H), 3.88 - 3.60 (m, 9H), 3.47 (t. 7= 11.6 Hz, 2H), 3.43 - 3.37 (m, 2H), 3.32 - 3.26 (m, 2H), 2.96 - 2.74 (m, 4H), 2.15 - 2.06 (m, 4H), 2.06 - 1.94 (m, 5H), 1.94- 1.80 (m, 4H), 1.53 (p, 7= 11.4, 10.3 Hz, 4H).
[0845] The following compounds were prepared in a similar procedure to that of Example 1.EXAMPLE 44-((l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difhioromethyl)- 1,2,3, 4-tetrahydroquinolin-6-yl)amino)-N-((lr,4r)-4- (3-chloro-4-cyanophenoxy)cyclohexyl)benz amide
[0846] To a solution of intermediate 7 (60 mg, 1.0 equiv), intermediate 52a (87 mg, 2.0 equiv), Xphos pd G3 (10 mg, 0.10 equiv), and t-BuONa (22.5 mg, 2.0 equiv) in dioxane was degassed and purged 3 times with N2, and then the mixture was stirred at 100 °C for 8 h. Then the reaction mixture being filtered through celite and the solvent was evaporated under reduced pressure, purified by pre-HPLC to give Cpd. No. 4. LC- MS m / z [M+H]+797.98.EXAMPLE 54-((4-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)piperazin-l- yl)methyl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide
[0847] To a solution of intermediate 12 (60 mg, 1.0 equiv), intermediate 51k (62 mg, 1.2 equiv), DIPEA (2.5 equiv) in DMF (4 mL), and then the mixture was stirred at 65 °C for 2 h. Then the reaction mixture was evaporated under reduced pressure, purified by pre- HPLC to give Cpd. No. 5. LC-MS m / z [M+H]+881.40.
[0848] The following compounds were prepared in a similar procedure to that of Example 5.EXAMPLE 64-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)-N-(4-(((lr,4r)-4-(3- chloro-4-cyanophenoxy)cyclohexyl)carbamoyl)phenyl)piperazine-l -carboxamide
[0849] To a solution of intermediate 12 (60 mg, 1.0 equiv), intermediate 51q (85 mg, 1.5 equiv), DIPEA (2.5 equiv) in DMF (4 mL), and then the mixture was stirred at 65 °C for 2 h. Then the reaction mixture was evaporated under reduced pressure, purified by pre- HPLC to give Cpd. No. 6. LC-MS m / z [M+H]+909.90.EXAMPLE 94-(4-(4-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)piperazin-l- yl)piperidin-l-yl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide
[0850] To a solution of intermediate 12 (60 mg, 1.0 equiv), intermediate 51p (79 mg, 1.5 equiv), EtjN (2.5 equiv) in DCM (4 mL), and then the mixture was stirred at rt for 1 h Then NaBH(OAc)3 (2.5 eq) was added to this reaction, and the mixture was stirred at rt for overnight. Monitor the reaction through LC / MS until the reaction was completed. The mixture was concentrated under reduced pressure. The crude residue was purified by pre- HPLC to give Cpd. No. 9. LC-MS m / z [M+H]+949.99.
[0851] The following compounds were prepared in a similar procedure to that of Example 9.EXAMPLE 104-((l-(5-acetyLl-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)ethynyl)-N-((lr,4r)-4- (3-chloro-4-cyanophenoxy)cyclohexyl)benzamide
[0852] To a solution of intermediate 7 (60 mg, 1.0 equiv), intermediate 51j (67 mg, 1.5 equiv), DIPEA (30 mg, 2.0 equiv), PdCh(PPh3)2 (4.1 mg, 0.05 equiv), Cui (1.8 mg, 0.08 equiv) in anhydrous DMF (3 mL) were added to a 100 mL round-bottom flask. The flask was evacuated and backfilled with argon (3 cycles). After stirring at 100 °C overnight, the mixture was then filtered and the solvent removed under vacuum. The crude material was purified by column chromatography to give Cpd. No. 10. LC- MS m / z [M+H]+807.02.EXAMPLE 174-(4-(4-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyri din-3-yl)-7-(di fluoromethyl)-!, 2, 3, 4-tetrahydroquinolin-6-yl)phenyl)piperazin-l- yl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide
[0853] To a solution of intermediate 10g (60 mg, 1.0 equiv), intermediate 5 Ih (61 mg, 1.2 equiv), IHddbap (11 mg, 0.1 equiv), xantphos (13.6 mg, 0.2 equiv) and z-BuONa (22.6 mg, 2.0 equiv) and anhydrous 1,4-dioxane (10 mL) were added to a 100 mL roundbottom flask. The flask was evacuated and backfilled with argon (3 cycles). After stirring at 100 °C overnight, the mixture was then filtered and the solvent removed undervacuum. The crude material was purified by column chromatography to give Cpd. No.17. LC-MS m / z [M+H]+943.42.
[0854] The following compounds were prepared in a similar procedure to that of Example 17.EXAMPLE 392-(4-(l-(5-acetyl-l-(tetrahydro-2II-pyran-4-yl)-4,5,6,7-tetrahydro-lII-pyrazolo[4,3- c]pyri din-3-yl)-7-(di fluoromethyl)- 1, 2, 3, 4-tetrahydroquinolin-6-yl)benzoyl)-N-((lr,4r)-4- (3-chloro-4-cyanophenoxy)cyclohexyl)isoindoline-5-carboxamide
[0855] Cpd. No. 39 was synthesized with a similar procedure to that of Example ijH NMR (400 MHz, DMSO-^) 68.31 (dd. J = 23.5, 7.6 IIz, III), 7.92 - 7.74 (m, 311), 7.70 (d, J = 7.8 Hz, 2H), 7.52 - 7.33 (m, 4H), 7.15 (ddd, J = 8.8. 4.2, 2.4 Hz, 1H), 7.10 (s, 1H), 6.91 (d, J= 9.0 Hz, 1H), 6.71 (td, J= 54.9, 5.3 Hz, 1H), 4.92 (d, J= 17.8 Hz, 4H), 4.61 - 4.49 (m, 1H), 4.32 (td, 7= 11.1, 5.6 Hz, 1H), 4.22 (d, J = 16.6 Hz, 2H), 4.02 - 3.91 (m, 2H), 3.83 (s, 1H), 3.75 (dt, J = 19.6, 5.9 Hz, 2H), 3.63 (q, J = 6.0 Hz, 2H), 3.53 - 3.43 (m, 3H), 2.84 (d, J= 48.9 Hz, 4H), 2.10 (s, 4H), 2.01 (d, J= 6.1 Hz, 5H), 1.97 - 1.80 (m, 4H), 1.54 (q, J= 10.7, 9.2 Hz, 4H).EXAMPLE 414-(4-(4-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difhioromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)phenyl)-lH-l,2,3- triazol-l-yl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide
[0856] To a solution of intermediate 9o (60 mg, 1.0 cquiv), intermediate 51n (49 mg, 1.1 equiv), CuSCLAPEO (1.4 mg, 0.05 equiv), and sodium ascorbate (2.2 mg, 0.1 equiv)) in tert-butyl Alcohol: H2O (1:1, 6mL). The mixture was stirred at 100 °C for 2 h, then filtered and the solvent removed under vacuum. The crude material was purified by column chromatography to give Cpd. No. 41. LC-MS m / z [M+H]+926.29.EXAMPLE 424-(l-(5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difhioromethyl)- 1,2,3, 4-tetrahydroquinolin-6-yl)pyridin-2-yl)azetidin- 3-yl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide
[0857] To a solution of intermediate 9j (30 mg, 1.0 equiv), intermediate 52g (49 mg, 1.1 equiv), and DIPEA (2.2 mg, 3.0 equiv) was added in DMF (2 mL). The mixture was stirred at 100 °C for 2 h, then the solvent removed under vacuum. The crude material was purified by column chromatography to give Cpd. No. 42. LC-MS m / z [M+H]+915.38.
[0858] The following compounds were prepared in a similar procedure to that of Example 42.EXAMPLE 482-(5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)- 1,2,3, 4-tetrahydroquinolin-6-yl)picolinoyl)-N-((lr, 4r)- 4- (3 -chloro-4-cy anophenoxy)cy clohexy 1) -4-fluoroi soindoline- 5 -carboxamide
[0859] Cpd. No. 48 was synthesized with a similar procedure to that of Example l / H NMR (400 MHz, DMSO-Je) 58.64 (dd, J = 13.7, 2.2 Hz, 1H), 8.34 (t, J = 8.2 Hz, 1H), 8.00 - 7.90 (m, 211), 7.86 (dd, J = 8.8, 2.4 Hz, III), 7.51 (q, J = 6.8 Hz, HI), 7.40 (t, J = 2.6 Hz, 1H), 7.29 (dd, J = 29.5, 7.8 Hz, 1H), 7.20 - 7.10 (m, 2H), 6.93 (d, J = 11.0 Hz, 1H), 6.80 (tt, J = 54.4, 6.9 Hz, 1H), 5.29 (d, J = 8.9 Hz, 2H), 5.01 (s, 2H), 4.57 (s, 1H), 4.37 - 4.27 (m, 1H), 4.22 (d, J = 16.8 Hz, 2H), 4.04 - 3.93 (m, 2H), 3.87 - 3.69 (m, 3H), 3.68 - 3.59 (m, 2H), 3.51 - 3.43 (m, 2H), 2.96 - 2.74 (m, 4H), 2.10 (s, 4H), 2.01 (d, J = 5.7 Hz, 5H), 1.97 - 1.89 (m, 2H), 1.84 (d, 7= 12.6 Hz, 2H). 1.51 (d, 7 = 7.1 Hz, 4H).EXAMPLE 496-(5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)picolinoyl)-N-((lr,4r)- 4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3- carboxamide
[0860] Cpd. No. 49 was synthesized with a similar procedure to that of Example I.1! I NMR (400 MHz, DMSO-Je) 88.92 (d, J = 6.5 Hz, 2H), 8.66 - 8.61 (m, 1H), 8.53 (dd, J = 15.4, 7.5 Hz, 1H), 8.28 - 8.12 (m, 1H), 7.99 - 7.90 (m, 2H), 7.87 (dd, J = 8.8, 1.7 Hz, 1H), 7.41 (t, J = 2.6 Hz, 1H), 7.19-7.13 (m, 2H), 6.96 - 6.90 (dm, 1H), 6.79 (t, J = 55.1, 1H), 5.28 (d, J = 16.6 Hz, 2H), 4.99 (d, J = 27.3 Hz, 2H), 4.57 (s, 1H), 4.38 - 4.27 (m, 1H), 4.22 (d, J = 16.8 Hz, 2H), 3.97 (d, J = 11.3 Hz, 2H), 3.91 - 3.80 (m, 1H), 3.80 - 3.69 (m, 2H), 3.68 - 3.60 (m, 2H), 3.47 (t, J = 11.6 Hz, 4H), 2.96 - 2.74 (m, 4H), 2.15 - 2.07 (m, 4H), 1.97 (d, J = 26.1 Hz, 7H), 1.84 (d, 7= 12.8 Hz, 2H), 1.54 (q, 7 = 11.3 Hz, 4H).EXAMPLE 512-(5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)picolinoyl)-N-((lr,4r)- 4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2,3-dihydro-lH-pyrrolo[3,4-c]pyridine-6- carboxamide
[0861] Cpd. No. 51 was synthesized with a similar procedure to that of Example 1.1H NMR (400 MHz, DMSO- e) 88.69 (d, 7 = 24.9 Hz, 1H), 8.65 - 8.61 (m, 1H), 8.57 (t, J = 8.9 Hz, 1H), 8.08 (d, 7 = 37.9 Hz, 1H), 8.00 - 7.89 (m, 2H), 7.87 (d, 7 = 8.8 Hz, 1H), 7.39 (d, 7= 2.4 Hz, 1H), 7.18 - 7.09 (m, 2H), 6.93 (d, 7= 11.0 Hz, 1H), 6.80 (td.7 = 54.4, 7.1 Hz, 1H), 5.32 (d, 7= 10.6 Hz, 2H), 5.04 (d, 7 = 7.2 Hz, 2H), 4.54 (tt, 7= 9.6, 4.1 Hz, 1H), 4.32 (tt, 7= 11.3, 4.0 Hz, 1H), 4.22 (d, 7 = 16.2 Hz, 2H), 3.97 (dd, 7 = 10.7, 4.7 Hz, 2H), 3.92 - 3.81 (m, 1H), 3.81 - 3.69 (m, 2H), 3.64 (t, 7= 5.7 Hz, 2H), 3.47 (t, 7= 11.7 Hz, 2H), 2.84 (dt, 7 = 50.2, 6.0 Hz, 4H), 2.16 - 2.06 (m, 4H), 2.05 - 1.96 (m, 5H), 1.91 (d, 7= 10.6 Hz, 2H). 1.85 (d, 7= 12.5 Hz, 2H), 1.65 (q, 7= 12.3 Hz, 2H), 1.59 - 1.45 (m, 2H).EXAMPLE 522-(5-(l-(5-acetyl-l-(piperidin-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-3-yl)- 7-(difluoromethyl)- 1,2,3, 4-tetrahydroquinolin-6-yl)picolinoyl)-N-((lr, 4r)-4-(3-chloro-4- cyanophenoxy)cyclohexyl)isoindoline-5-carboxamide
[0862] CS2CO3 (96 mg, 2.5 equiv) and Cpd. No. 68 (100 mg, 1.0 equiv) were added to a solution of tert-butyl 4-((methylsulfonyl)oxy)piperidine-l -carboxylate (66 mg, 2.0 equiv) in DMF (10 mL). The mixture was heated to 80 °C for 6 h. Monitor the reaction through LC / MS until the reaction was completed. Then the reaction solvent mixture was diluted with water and extracted with DCM, dried, concentrated and purified by pre-HPLC to give the Boc protected intermediate. (One of the main peaks which has less polarity is the desired product). The above Boc protected intermediate was dissolved in DCM (2 mL) and TFA (0.5 mL) was added at rt. After 2 h, all volatile materials were removed in a rotary evaporator and purified by pre-HPLC to afford Cpd. No. 52. LC- MS m / z [M+H]+928.38.
[0863] The following compounds were prepared in a similar procedure to that of Example 52.EXAMPLE 532-(5-(l-(5-acetyl-l-(piperidin-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-3-yl)- 7-(difluoromcthyl)-l,2,3,4-tetrahydroquinolin-6-yl)picolinoyl)-N-((lr,4r)-4-(4- cyanophenoxy)cyclohexyl)isoindoline-5-carboxamide
[0864] CS2CO3 (96 mg, 2.5 equiv) and Cpd. No. 68 (100 mg, 1.0 equiv) were added to a solution of l-(benzylcarbamoyl)piperidin-4-yl methanesulfonate (73 mg, 2.0 equiv) in DMF (10 mL). The mixture was heated to 80 °C for 6 h. Monitor the reaction through LC / MS until the reaction was completed. Then the reaction solvent mixture was diluted with water and extracted with DCM, dried, concentrated and purified by pre-HPLC to give the Cbz protected intermediate. (One of the main peaks which has less polarity is the desired product). The above Cbz protected intermediate was dissolved in MeOH (6 mL) and Pd / C 5% (20 mg) was added. The reaction mixture was stirred at 50 °C under hydrogen atmosphere for overnight. Monitor the reaction through LC-MS until the reaction was completed. The reaction solvent was filtered through celite and evaporated under reduced pressure and purified by pre-HPLC to afford Cpd. No. 53. LC- MS m / z [M+H]+894.40.EXAMPLE 582-(5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)- 1,2,3, 4-tetrahydroquinolin-6-yl)picolinoyl)-N-((lr, 4r)- 4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-fluoroisoindoline-5-carboxamide
[0865] Cpd. No. 58 was synthesized with a similar procedure to that of Example 1. ’ll NMR (400 MHz, DMSO-d6) 8 8.62 (s, 1H), 8.32 (dd, 7= 12.0, 7.6 Hz, 1H), 7.93 (s, 2H), 7.86 (dd, J = 8.8, 1.9 Hz, 1H), 7.55 (dd, 7 = 35.2, 6.4 Hz, 1H), 7.40 (t, J = 2.6 Hz, 1H), 7.34 (dd, 7 = 26.3, 10.1 Hz, 1H), 7.14 (dt, 7= 8.9, 2.5 Hz, 2H), 6.93 (d, 7 = 11.2 Hz. 1H), 6.73 (td, 7= 54.6, 7.2 Hz, 1H), 5.20 (d, 7 = 21.4 Hz, 2H), 4.94 (d, 7 = 16.1 Hz, 2H), 4.56(s, 1H), 4.37 - 4.27 (m, 1H), 4.22 (d, J = 16.8 Hz, 2H), 3.97 (d, J = 11.2 Hz, 2H), 3.88 - 3.68 (m, 3H), 3.64 (t, J = 5.7 Hz, 2H), 3.49 (d, J = 11.6 Hz, 2H), 2.84 (d, J = 47.2 Hz, 4H), 2.15 - 2.05 (m, 4H), 2.05 - 1.96 (m, 5H), 1.96 - 1.79 (m, 4H), 1.58 - 1.45 (m, 4H).EXAMPLE 596-(5-( 1 -(5-acetyl- 1 -(piperidin-4-yl)-4,5,6,7 -tetrahydro- 1 H-pyrazolo[4,3-c]pyridin-3-yl)- 7-(di fluoromethyl)-!, 2,3, 4-tetrahydroquinolin-6-yl)picolinoyl)-N-((lr, 4r)-4-(3-chloro-4- cyanophenoxy)cyclohexyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxamide
[0866] Cpd. No. 59 was synthesized with a similar procedure to that of Cpd. No. 52. ’ll NMR (400 MHz, DMSO-< Z6) 58.96 - 8.89 (m, 1H), 8.63 (s, 2H), 8.54 (dd, J = 12.8, 7.5 Hz. 1H), 8.34 (s, 1H), 7.95 (dt, J= 10.1, 7.6 Hz, 2H), 7.87 (dd, J= 8.8, 1.6 Hz, 1H), 7.41 (t, J = 2.5 Hz, 1H), 7.21 - 7.12 (m, 2H), 6.87 (d, J = 8.3 Hz, 1H), 6.80 (tt, J = 54.4, 6.9 Hz, 1H), 5.27 (d, J = 16.1 Hz, 2H), 4.99 (d, J = 26.6 Hz, 2H), 4.57 (s, 1H), 4.43 (s, 1H), 4.22 (d, J = 18.0 Hz, 2H), 3.85 (s, 2H), 3.77 (d, J = 17.0 Hz, 2H), 3.63 (s, 2H), 3.09 (d, J = 12.2 Hz, 2H), 2.97 - 2.82 (m, 3H), 2.10 (s, 7H). 2.01 (s, 2H), 1.95 (d, J= 11.7 Hz, 2H), 1.64- 1.45 (m, 4H).EXAMPLE 606-(5-(l-(5-acetyLl-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoroniethyl)-l,2,3,4-tetrahydroquinolin-6-yl)pyridin-2-yl)-N- ((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-naphthamide
[0867] A solution of Intermediate 52h (1.0 eq), 9r (1.2 eq), Pd(OAc)2 (0.1 eq), PPha (0.2 eq), and K2CO3 (2 eq), in Dioxane: H2O (5:2) was prepared. The mixture was evacuatedand backfilled with argon (3 cycles). The reaction mixture was then heated at 100 °C for 8 h. Monitor the reaction through TLC until the reaction was completed. Then the reaction solvent was evaporated under reduced pressure.
[0868] The crude residue was purified by silica gel flash chromatography to give Cpd.No. 60. LC-MS ml [M+H]+910.36.EXAMPLE 612-(5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)picolinoyl)-N-((lr,4r)- 4-(4-cyano-3-methoxyphenoxy)cyclohexyl)isoindoline-5-carboxamide
[0869] Cpd. No. 61 was synthesized with a similar procedure to that of Cpd. No. 1.JH NMR (400 MHz, DMSO-tfc) 5 8.62 (dt, J = 4.9, 2.6 Hz, 1H), 8.31 (dd, J = 23.5, 7.6 Hz, 1H), 7.97 - 7.76 (m, 4H), 7.62 (dd, J = 8.5, 2.6 Hz, 1H), 7.47 (dd, 7= 32.1, 8.2 Hz, 1H), 7.16 (d, J = 3.0 Hz, 1H), 6.93 (d, J= 11.2 Hz, 1H), 6.80 (td, J= 54.4, 6.9 Hz, 1H), 6.78 - 6.70 (m, 2H), 5.24 (d, J = 4.2 Hz, 2H), 4.98 (s, 2H), 4.51 (s, 1H), 4.39 - 4.27 (m, 1H), 4.22 (d, J = 16.6 Hz. 2H), 3.97 (dd, J = 10.0, 4.6 Hz, 2H), 3.89 (d, J = 2.3 Hz, 3H), 3.87 - 3.81 (m, 1H), 3.75 (dt, J = 18.7, 5.8 Hz, 2H), 3.64 (q, J = 6.0 Hz, 2H), 3.47 (t, J = 13.2 Hz, 2H), 3.03 (d, J = 7.6 Hz, 3H), 2.85 (dt, J = 53.3, 5.9 Hz, 4H), 2.18 - 2.07 (m, 4H), 2.05 - 1.97 (m, 3H), 1.94 (d, J = 11.6 Hz, 2H), 1.85 (d, J = 12.3 Hz, 2H), 1.64- 1.42 (m, 4H).EXAMPLE 682-(5-(l-(5-acetyl-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-3-yl)-7-(difluoromethyl)- l,2,3,4-tetrahydroquinolin-6-yl)picolinoyl)-N-((lr,4r)-4-(3-chloro-4- cyanophenoxy)cyclohexyl)isoindoline-5-carboxamide
[0870] Intermediate 35 (30 mg, 1.0 eq.) was dissolved in DMF (2 mL), HATU (24.5 mg, 1.0 eq), Et₃N (2.5 eq.) and intermediate 50a (25 mg, 1.0 eq.) were added in to the mixture. The result mixture was stirred at rt for additional 15 min, after that the mixture was diluted with water and extracted with DCM, dried, and concentrated under reduced pressure to remove the solvent. The resulting crude product was purified by flash column chromatography to give Cpd. No. 68. LC-MS mlz [M+H]+845.31.EXAMPLE 786-(4-((5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)pyridin-2- yl)methyl)piperazin- 1 -yl)-N-((l r,4r)-4-(3-chloro-4- cyanophenoxy)cyclohexyl)pyridazine-3-carboxamide
[0871] Cpd. No. 78 was synthesized with a similar procedure to that of Cpd. No. 79. ’ll NMR (400 MHz, DMSO-d6) 6 8.72 (d, J = 8.3 Hz, 1H), 8.67 - 8.63 (m, 1H), 7.97 (d, J = 9.5 Hz, 1H), 7.90 (dd, J = 7.9, 2.4 Hz, 1H), 7.87 (d, J = 8.8 Hz, 1H). 7.60 (d, J = 8.2 Hz, 1H), 7.49 (d, J = 9.6 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 8.8, 2.4 Hz, 1H), 7.11 (s, 1H), 6.95 - 6.88 (m, 1H), 6.76(td, J = 54.7, 5.9 Hz, 1H), 4.61 (s, 2H), 4.59 - 4.49 (m, 1H), 4.38 - 4.27 (m, 1H), 4.21 (d, J= 19.4 Hz, 2H), 4.15 - 3.82 (m, 7H), 3.80 - 3.70 (m, 2H), 3.68 - 3.59 (m. 2H), 3.54 - 3.37 (m, 6H), 2.93 - 2.74 (m, 4H), 2.17 - 2.06 (m, 4H), 2.06 - 1.94 (m, 5H), 1.94 - 1.79 (m, 4H), 1.66 (q, J = 12.0 Hz, 2H), 1.52 (q, J = 11.2 Hz, 2H).EXAMPLE 796-(4-((5-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-l,2,3,4-tetrahydro-l,7-naphthyridin-6-yl)pyridin-2-yl)methyl)piperazin-l- yl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)pyridazine-3-carboxamide
[0872] To a solution of Intermediate 18 (25 mg, 1.1 eq) and 47b (25 mg, 1.0 eq) in dry DCM at it, was added Et₃N (10 mg, 2.0 eq). The mixture was stirred at rt for 3 h. Then NaBH(OAc)3 (27 mg, 2.5 eq) was added to this reaction, and the mixture was stirred at rt for overnight. The reaction was monitored through LC / MS until the reaction was completed. The mixture was concentrated under reduced pressure. The crude residue was purified by pre-HPLC to give Cpd. No. 79 (35 mg).JH NMR (400 MHz, DMSO-d6) 5 9.20 (s, 1H), 8.67 (d, J = 8.2 Hz, 1H), 8.39 (d, J = 7.6 Hz, 1H), 7.96 - 7.88 (m, 2H), 7.86 (d, J = 8.8 Hz, 1H), 7.77 (s, 1H), 7.56 (d, J = 8.2 Hz, 1H), 7.43 (d, J = 9.7 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 8.9, 2.4 Hz, 1H), 4.59 - 4.48 (m, 1H), 4.38 - 4.28 (m, 1H), 4.24 (d, J= 13.5 Hz, 2H), 4.05 - 3.82 (m, 6H), 3.76 (dt, J= 19.4, 5.8 Hz, 2H), 3.67 - 3.58 (m, 2H), 3.53 - 3.42 (m, 3H), 2.95 - 2.73 (m, 4H), 2.15 - 2.06 (m, 4H), 2.06 - 1.94 (m, 5H), 1.94 - 1.80 (m, 4H), 1.65 (q, 7 = 11.5 Hz, 2H), 1.52 (q, 7 = 10.9, 10.3 Hz, 211).
[0873] The following compounds were prepared in a similar procedure to that of Example 79.EXAMPLE 846-(4-(((lr,4r)-4-(5-acetyl-3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin- 1 (2H)-yl)-4,5,6,7-tetrahydro- 1 H-pyrazolo[4,3 -c]py ridin- 1 -yl)cyclohexyl)methyl)piperazin-l-yl)-N-((lr,4r)-4-(3-chloro-4- cyanophenoxy)cyclohexyl)pyridazine-3-carboxamide
[0874] To a solution of Intermediate 39a (25 mg, 1.1 eq) and 47b (23 mg, 1.0 eq) in dry DCM at rt, was added Et₃N (10 mg, 2.0 eq). The mixture was stirred at rt for 3 h. Then NaBH(OAc)3 (27 mg, 2.5 eq) was added to this reaction, and the mixture was stirred at rt for overnight. Monitor the reaction through LC / MS until the reaction was completed. The mixture was concentrated under reduced pressure. The crude residue was purified by pre- HPLC to give Cpd. No. 84 (35 mg).8.70 (d, J = 8.1 Hz, III), 7.96 (d, J = 9.5 Hz, III), 7.87 (d, J = 8.8 Hz, III), 7.76 (s, III), 7.52 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 8.8, 2.5 Hz, 1H), 7.11 (s, 1H), 6.81 (td, J = 54.8, 7.1 Hz, 1H). 6.79 (d, J = 2.4 Hz. 1H), 4.63 - 4.44 (m, 4H), 4.16 (d, J = 17.9 Hz, 2H), 4.10 - 4.00 (m, 1H), 3.94 - 3.80 (m, 4H), 3.78 - 3.64 (m, 4H), 3.58 (t, J = 5.7 Hz, 2H), 3.45 (t, J = 12.7 Hz, 2H), 3.24 - 2.97 (m, 4H), 2.89 - 2.72 (m, 4H), 2.09 (s, 4H), 2.01 - 1.84 (m, 11H), 1.66 (q. J = 12.2, 11.8 Hz, 2H), 1.52 (q, J = 11.3 Hz, 2H), 1.29 - 1.13 (m, 2H).EXAMPLE 856-(4-(((lr,4r)-4-(5-acetyl-3-(7-(difluoromethyl)-6-(l -methyl- lH-pyrazol-4-yl)-3, 4- dihydroquinolin- l(2H)-yl)-4, 5, 6, 7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l- yl)cyclohexyl)methyl)piperazin-l-yl)-N-((lr,4r)-4-((3-chloro-4- cyanophenyl)(methyl)amino)cyclohexyl)pyridazine-3-carboxamide
[0875] Cpd. No. 85 was synthesized with a similar procedure to that of Cpd. No. 84.!H NMR (400 MHz, DMSO-d6) 5 8.59 (d, J = 8.3 Hz, 1H), 7.97 (d, J = 9.4 Hz, 1H), 7.76 (s, 1H), 7.62 (d, J = 9.0 Hz, 1H), 7.52 (d, J = 9.1 Hz, 2H), 7.11 (s, 1H), 6.95 (d, J = 2.6 Hz, 1H), 6.83 (dd, J = 9.1, 2.5 Hz, 1H), 6.80(t, J = 55.2 Hz, 1H), 6.79 (d, J = 2.8 Hz, 1H), 4.59 (d,.1 = 14.0 Hz, 2H), 4.16 (d, J = 17.9 Hz, 2H), 4.05 (s, 1H), 3.87 (s, 3H), 3.80 - 3.73 (m, 1H), 3.73 - 3.63 (m, 3H), 3.62 - 3.54 (m, 2H), 3.2 - 3.0 (m, 4H), 3.45 (t, J = 12.5 Hz, 2H), 2.86 (s, 6H), 2.78 - 2.72 (m, 1H), 2.09 (s, 2H), 2.02 - 1.83 (m, 11H), 1.83 - 1.60 (m, 8H). 1.29 - 1.16 (m, 2H).EXAMPLE 935-(8-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)isoquinolin-3-yl)-N-(4-(((lr,4r)-4-(3-chloro-4- cyanophenoxy)cyclohexyl)carbamoyl)phenyl)picolinamide
[0876] Cpd. No. 93 was synthesized with a similar procedure to that of intermediate 1.’ll NMR (400 MHz, DMSO-d6) 5 10.93 (s, 1H), 10.04 (s, 1H), 9.56 (s, 1H), 8.87 (d, J = 8.7 Hz, 1H), 8.76 (s, 1H), 8.32 (d. J = 8.1 Hz, 1H), 8.25 (d, J = 7.6 Hz, 1H), 8.09 (dd, J = 21.8, 8.3 Hz, 3H), 7.91 (ddd, J= 21.6, 14.2, 8.2 Hz, 4H), 7.74 (dd, 7= 27.2, 7.2 Hz, 1H), 7.40 (d, 7 = 2.4 Hz, 1H), 7.15 (dd, 7 = 8.8, 2.4 Hz, 1H), 4.60 (d, J = 3.6 Hz, 2H), 4.58 - 4.43 (m, 2H), 4.14 - 4.0 (m, 5H), 3.54 (t, 7 = 11.8 Hz, 3H), 3.00 - 2.83 (in, 2H), 2.24 - 2.07 (m, 7H), 1.96 (ddd, 7= 18.3, 12.1, 4.1 Hz, 4H), 1.64- 1.44 (m, 4H).EXAMPLE 1024-(3-((4-(l-(5-acetyl-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3- c]pyridin-3-yl)-7-(difluoromethyl)-l,2,3,4-tetrahydroquinolin-6-yl)-lH-pyrazol-l- yl)methyl)azetidin-l-yl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide
[0877] A solution of Intermediate 9k (50 mg, 1.0 eq), 51s (53 mg, 1.2 eq) and (tributylphosphoranylidene)acetonitrile (29 mg, 1.2 eq) in toluene (5 mL). The mixture was evacuated and backfilled with argon (3 cycles). The reaction mixture was then heated at 110 °C for 8 h. The reaction was monitored through TLC until the reaction was completed. Then the reaction solvent was evaporated under reduced pressure. The crude residue was purified by silica gel flash chromatography to give Cpd. No. 102. LC- MS m / z [M+H]+918.40.
[0878] The following compounds were prepared in a similar procedure to that of Example 102.EX AMPLE 1084-(4-((4-(5-acetyl-3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin-l(2H)-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l-yl)piperidin- l-yl)methyl)piperidin-l-yl)-N-((lr,4r)-4-(3-chloro-4- cyanophenoxy )cyclohexyl)benzamide
[0879] A solution of Intermediate 5 It (100 mg, 1.0 eq) in DCM, and EtsN (32 mg, 1.5 eq) at 0°C. Methanesulfonyl chloride (27 mg, 1.1 eq) was added dropwise. The mixture was stirred at 0°C for 0.5 h. The reaction was monitored through TLC until the reaction was completed. Then the reaction mixture was diluted with H2O, extracted with DCM, dried, and concentrated. The above crude product was dissolved in DMF, and Intermediate 41 (109 mg, 1.0 eq), CS2CO3 (104 mg, 1.5 eq) was added. The reaction mixture was then heated at 70 °C for 4 h. The reaction was monitored through TLC until the reaction was completed. Then the reaction solvent was evaporated under reduced pressure. The crude residue was purified by silica gel flash chromatography to give Cpd. No. 108. LC-MS m / z [M+H]+959.46.
[0880] The following compounds were prepared in a similar procedure to that of Example 108.EXAMPLE 1134-(3-(4-(5-acetyl-3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin-l(2II)-yl)-4,5,6,7-tetrahydro-HI-pyrazolo[4,3-c]pyridin-l-yl)piperidine- l-carbonyl)azetidin-l-yl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide
[0881] Intermediate 52i (75 mg, 1.0 eq.) was dissolved in DCM (4 mL), HATU (69 mg, 1.1 eq) and EhN (2.5 eq.) was added. The mixture was stirred at for 5 min, then Intermediate 41 (84 mg, 1.0 eq.) was added in to the mixture. The result mixture was stirred at rt for additional 15 min, after that the mixture was diluted with water andextracted with DCM, dried, concentrated and purified buy pre-HPLC to give Cpd. No.113. LC-MS mlz [M+H]+945.40.
[0882] The following compounds were prepared in a similar procedure to that of Example 113.EXAMPLE 1306-(4-(((lr,4r)-4-(5-acetyl-3-(7-(difluoromethyl)-6-(l -methyl- lH-pyrazol-4-yl)-3, 4- dihydroquinolin-l(2H)-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l- yl)cyclohexyl)methyl)piperazin-l-yl)-N-((lr,4r)-4-(4-cyano-3- methoxyphenoxy)cyclohexyl)pyridazine-3-carboxamide
[0883] Cpd. No. 130 was synthesized with a similar procedure to that of Cpd. No. 84.JH NMR (400 MHz. DMSO-rf6) 68.69 (d, J = 8.3 Hz, 1H), 7.96 (d, J = 9.4 Hz, 1H), 7.76 (s, 1H), 7.62 (d, J = 9.2 Hz, 1H), 7.54 - 7.48 (m, 2H), 7.11 (s, 1H), 6.82 - 6.77 (m, 1H), 6.79 (td, J = 54.8, 7.1 Hz, 1H), 6.75 - 6.70 (m, 2H), 4.58 (d, J = 13.9 Hz, 2H), 4.53 - 4.45 (m, 1H), 4.22 - 4.11 (m, 2H), 4.11 - 3.99 (s, 1H), 3.88 (d, 7= 8.6 Hz, 6H), 3.79 - 3.63 (m, 4H). 3.62 - 3.55 (m, 2H), 3.45 (t, 7 = 12.4 Hz, 2H), 3.23 - 3.04 (m, 4H), 2.90 - 2.71 (m, 4H), 2.13 (d, 7= 11.6 Hz, 2H), 2.09 (s, 2H), 2.02 - 1.75 (d, 7= 16.1 Hz, 11H), 1.66 (q, 7 = 12.5, 11.9 Hz, 2H), 1.52 (q, 7= 12.3, 11.8 Hz, 2H), 1.22 (q, 7= 13.6 Hz, 2H).EXAMPLE 1324-(4-(((lr,4r)-4-(5-acetyl-3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin-l(2H)-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l-yl)cyclohexyl)methyl)piperazin-l-yl)-N-((lr,4r)-4-(3-chloro-4- cyanophenoxy)cyclohexyl)-3-fluorobenzamide
[0884] Cpd. No. 132 was synthesized with a similar procedure to that of Cpd. No. 84.:H NMR (400 MHz, DMSO-&) 8 8.25 (d, J = 7.5 Hz, 1H), 7.87 (dd, J = 8.7, 1.1 Hz, 1H), 7.76 (s, 1H), 7.72 (d, J= 5.8 Hz, 1H), 7.69 (s, 1H), 7.50 (s, 1H), 7.40 (d, J= 2.4 Hz, 1H), 7.21 - 7.13 (m, 2H), 7.11 (s, 1H), 6.79 (m, 2H), 4.60 - 4.68(m, 1H), 4.16 (d, J= 17.8 Hz, 2H), 4.10 - 3.98 (m, 1H), 3.87 (s, 3H), 3.84 - 3.52 (m, 10H), 3.30 - 3.03 (m, 6H), 2.91 - 2.71 (m, 4H), 2.15 - 2.04 (m, 4H), 2.03 - 1.82 (m, 12H), 1.52 (q, J = 10.7 Hz, 4H), 1.22 (q, 7= 13.2 Hz, 3H).
[0885] The following compounds were prepared in a similar procedure to that of Example 84.
[0886] EXAMPLE 1536-(4-(((lr,4r)-4-(5-acetyl-3-(6-cyano-7-(difluoromethyl)-3,4-dihydroquinolin-l(2H)-yl)- 4,5,6,7-tetrahydro- 1 H-pyrazolo [4,3 -c]pyridin- 1 -y l)cy clohexy l)methy l)piperazin- 1 -yl)-N - ((lr,4r)-4-(4-cyano-3-methoxyphenoxy)cyclohexyl)pyridazine-3-carboxamide
[0887] A solution of Cpd. No. 155 (15 mg, 1.0 eq) in DMF, and Zn(CN)2 (3 mg, 1.5 eq), Pd(pphs)4 (4 mg, 0.2 eq) were added. The mixture was evacuated and backfilled with argon (3 cycles). Then the reaction mixture was heated at 110 °C for 12 h. Monitor the reaction through LC / MS. After that the mixture was concentrated under reduced pressure. The crude residue was purified by pre-HPLC to give Cpd. No. 153. LC- MS m / z [M+H]+902.46.
[0888] The following compounds were prepared in a similar procedure to that of Example 153.EXAMPLE 1686-(4-(5-acetyl-3-(7-(difhioromethyl)-6-(l -methyl- lH-pyrazol-4-yl)-3,4-dihydroquinolin- l(2H)-yl)-4, 5,6, 7-tetrahydro-lH-pyrazolo[4, 3-c]pyridin-l-yl)piperidin-1 -yl)-N-((lr,4r)-4- (3-chloro-4-cyanophenoxy)cyclohexyl)pyridazine-3-carboxamide
[0889] To a solution of Intermediate 71 (46.9 mg, 0.12 mmol) and Intermediate 41 (51.0 mg, 0.1 mmol) in DMF (5 mL), was added K2CO3 (27.6 mg, 0.2 mmol). The mixture was stirred at 65 °C for 3 h. Monitor the reaction through LC / MS until Intermediate 41 was completely consumed, and then the mixture was concentrated under reduced pressure. The crude residue was purified by pre-HPLC (25-100% MeCN / H2O in 70 min, the desired product started eluting at ~ 46% MeCN) to give Compound 168 (64.8 mg, yield: 75%) as yellow solid. ’ll NMR (400 MHz, DMSO-d6) 5 8.63 (d, J = 8.2 Hz, 1H), 7.89 -7.81 (m, 2H), 7.75 (s, 1H), 7.49 (s, 1H), 7.46 (d, J = 9.9 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.14 (dd, 7 = 8.7, 2.5 Hz, 1H), 7.09 (s, 1H), 6.78 (td, 7 = 51.6, 6.8 Hz, 1H), 6.77 (s,lH), 4.61 (d, 7= 13.1 Hz, 2H), 4.57 - 4.44 (m, 2H), 4.39 - 4.22 (m, 1H), 4.15 (d, 7 = 20.4 Hz, 2H), 3.86 (s, 3H), 3.80 - 3.69 (m, 2H), 3.55 (q, 7 = 5.8 Hz, 2H), 3.24 (t, 7 = 25.7 Hz, 2H), 2.95 - 2.74 (m, 4H), 2.17 - 2.04 (m, 4H), 2.04 - 1.81 (m, 9H), 1.64 (q, 7 = 12.3 Hz, 2H), 1.51 (q, 7= 11.7 Hz, 2H). LC-MS m / z [M+H]+864.36.EXAMPLE 1696-(3-(4-(5-acetyl-3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin- 1 (2H)-yl)-4,5,6,7-tetrahydro- 1 H-pyrazolo[4,3-c]pyridin- 1 -yl)piperidin- l-yl)azetidin-l-yl)-N-((lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)pyridazine-3- carboxamide
[0890] To a solution of Intermediate 73a (28.3 mg, 0.05 mmol) and Intermediate 71 (23.4 mg, 0.06 mmol) in DMF (5 mL), was added K2CO3 (13.8 mg, 0.1 mmol). The mixture was stirred at 65 °C for 3 h. Monitored the reaction through LC / MS until Intermediate 73a was completely consumed, and then the mixture was concentrated under reduced pressure. The crude residue was purified by pre-HPLC (25-100% MeCN / FhO in 70 min, the desired product started eluting at ~ 40% MeCN) to give Compound 169 (36.5 mg, yield: 80%) as yellow solid. 'll NMR (400 MHz, DMSO- / 6) 5 8.65 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 9.2 Hz, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.76 (s, 1H), 7.50 (s, 1H), 7.39 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 8.8, 2.4 Hz, 2H), 7.00 (d, J = 9.2 Hz, 1H), 6.81 (td, J = 51.6, 6.8 Hz, 1H), 6.79 (d, J = 3.1 Hz, 1H), 4.61 - 4.25 (m, 7H), 4.15 (d, 7 = 21.6 Hz, 2H), 3.93 - 3.80 (m, 4H), 3.81 - 3.40 (m, 6H), 3.23 - 3.05 (m, 2H), 2.95 - 2.73 (m, 4H), 2.34 - 2.15 (m, 4H), 2.15 - 2.05 (m, 4H), 2.02 - 1.93 (m, 3H), 1.90 (d, 7 = 13.1 Hz, 2H), 1.65 (q, J= 12.2 Hz, 2H), 1.52 (q, J = 11.5 Hz, 2H). LC-MS mlz [M+H]+919.59.
[0891] Compounds 170-173 were prepared from Intermediates 73b-73e and Intermediate 71 following a similar procedure to the one used to prepare Compound 169.EXAMPLE 174N-((lr,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohexyl)-6-(4-(((lr,4r)-4-(3-(7- (difluoromethyl)-6-(l -methyl- lH-pyrazol-4-yl)-3,4-dihydroquinolin-l(2H)-yl)-5-isopropyl-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l- yl)cyclohexyl)methyl)piperazin- 1 -yl)pyridazine-3-carboxamide (Compound Nl)General procedure for Compound N 1aReagents and conditions: (a) 2-(Trimethylsilyl)ethoxymethyl chloride, NaH, DMF, 0 °C to rt, 3 h; (b) 1,4-Dioxane, Ruphos pd G2, Ruphos, Sodium tert-butoxide, 100 °C, N2, overnight; (c) NBS, DCM, 0 °C, 30 min; (d) Pd(OAc)2, Pphs, K2CC>3, 1,4-Dioxane: H2O (5:2), 100 °C, N2, 3 h; (e) Formic acid, rt, 4 h; (f) Acetone, Sodium triacetoxyborohydride, DCM, rt, 30 min; (g) Tetrabutylammonium fluoride solution (1 M, in THF), THF, reflux, overnight; (h) CS2CO3, DMF, 80 °C, overnight, (i) Diisobutylaluminium hydride (25% in toluene), DCM, -78 °C, 40% yield; (j) EtaN, Sodium triacetoxyborohydride, DCM, rt, 2 h.tert-butyl 3-iodo-l-((2-(trimethylsilyl)ethoxy)methyl)-l,4,6,7-tetrahydro-5H- pyrazolo[4,3-c]pyridine-5-carboxylate (74)A solution of tert-butyl 3-iodo-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate 1 (25.0 g, 71.6 mmol) in anhydrous DMF (300 mL) at 0 °C, was added NaH (3.4 g, 85.9 mmol) in portions. After stirring at 0 °C for 30 min, 2-(Trimethylsilyl)ethoxymethyl chloride (14.3 g, 85.9 mmol) was slowly added into the mixture. After that, the mixture was warmed to room temperature and stirred for an additional 2.5 h. Monitor the reaction through LC / MS until the intermediate 1 was completely consumed, and then the mixture was quenched with ice water and extracted with EtOAc. The organic phases were combined and concentrated under reduced pressure. The residue was purified by flash column chromatography (0-60% EtOAc / n-hcxanc) to give intermediate 74 (27.5 g, yield: 80%) as white solid.rH NMR (400 MHz, DMSO-de) 55.35 (d, J = 16.3 Hz, 2H), 4.16 (d, J = 26.6 Hz, 2H), 3.61 (t, J = 5.8 Hz, 2H), 3.58 - 3.46 (m, 2H). 2.65 (dt, J = 37.0, 5.8 Hz, 2H), 1.42 (d, J = 1.3 Hz, 9H), 0.89 - 0.75 (m, 2H), -0.04 (d, J = 5.2 Hz, 9H).tert-butyl 3-(7-(difhioromethyl)-3,4-dihydroquinolin-l(2H)-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)- 1,4,6, 7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5- carboxylate (75)A mixture of Intermediate 74 (4.8 g, 10 mmol), 7-(difluoromethyl)-l,2,3,4-tetrahydroquinoline 5a (2.2 g. 12 mmol), RuPhos Pd G2 (777 mg, 1.0 mmol), RuPhos (447 mg, 1.0 mmol), and Sodium tert-butoxide (2.4 g, 25 mmol) in 1,4-dioxane (120 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 100 °C for 12 h. After that, the mixture was cooled, diluted with DCM, filtered through Celite, the filter cake was washed with DCM, and the filtrate was concentrated under reducedpressure. The residue was purified by flash column chromatography (0-5% MeOH / DCM) to give intermediate 75 (3.4 g, yield: 64%) as yellow solid.JH NMR (400 MHz, DMSO-de) 5 7.14 (d, J = 7.7 Hz, 1H), 6.83 (d, J = 7.3 Hz, 2H), 6.80 (td, J = 55.2, 6.8 Hz, 2H), 6.60 (s, 1H), 5.30 (s, 2H), 3.98 (s, 2H), 3.65 - 3.52 (m, 6H), 2.79 (dt, J = 28.3, 6.1 Hz, 4H), 1.95 (p, J = 6.2 Hz, 2H), 1.36 (s, 9H), 0.83 (t, J = 7.2 Hz, 2H), -0.06 (s, 9H).tert-butyl 3-(6-bromo-7-(difluoromethyl)-3,4-dihydroquinolin-l(2H)-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5- carboxylate (76)To a solution of intermediate 75 (3.0 g, 5.6 mmol) in DCM (80 mL) was added NBS (997 mg, 5.6 mmol) in portions under ice-bath condition. After 30 min, the reaction mixture was diluted with DCM, washed with aqueous Na2S20 followed by brine, and the organic layers were concentrated under reduced pressure. The resulting residue was purified by Hash column chromatography (0-5% MeOH / DCM) to give intermediate 76 (2.8 g, yield: 82%) as a yellow solid. ’ll NMR (400 MHz, DMSO-d6) 57.37 (s, 1H), 6.92 (t,.1 = 54.2 Hz, 1H), 6.73 (s, 1H), 5.31 (s, 2H), 4.02 (s, 2H), 3.64 - 3.53 (m, 6H), 2.87 -2.73 (dt, J = 28.3, 6.1 Hz, 4H), 1.94 (p, J = 6.2 Hz, 2H), 1.37 (s, 9H), 0.82 (t, J = 7.2, 2H), -0.06 (s, 9H).tert-butyl 3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4-dihydroquinolin-l(2H)-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-l,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (77)A mixture of intermediate 76 (1.4 g, 2.28 mmol), l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole 9s (570.0 mg, 2.74 mmol), Pd(OAc)2 (51.1 mg, 0.23 mmol), Pphj (119.5 mg, 0.46) and K2CO3 (629.3 mg, 4.56 mmol) were added into 50 mL of 1,4-Dioxane: H2O (5:2). The mixture was degassed and purged 3 times with N2, then stirred at 100 °C for 3 h. After that, the mixture was cooled, filtered through Celite, the filter cake was washed with DCM, and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (0-5% MeOH / DCM) to give intermediate 77 as white solid (1.1 g, yield: 80%). ’ll NMR (400 MHz, DMSO-d6) 5 9.06 (s, 1H), 7.79 - 7.74 (m, 1H), 7.53 - 7.48 (m, 1H), 7.17 - 7.11 (m, 1H), 6.83 - 6.78 (m, 1H), 6.76 (td, J = 55.2, 6.8 Hz, 1H) 5.34 (d, J = 24.6 Hz, 2H), 4.02 (s, 2H), 3.88 (d, J = 2.1 Hz, 3H), 3.64 - 3.53 (m, 6H), 2.81 (dt, J = 30.9, 6.1 Hz, 4H), 1.97 (t, J = 5.8 Hz, 2H), 1.36 (s, 9H), 0.90 - 0.79 (m. 2H), -0.01 - -0.06 (m, 9H).7 -(difluoromethyl) - 6- ( 1 -methyl- 1 H-py razol-4-y 1) - 1 - ( 1 - (( 2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (78)Intermediate 77 (1.0 g, 1.63 mmol) was added into formic acid (8 mL). The mixture was stirred at rt for 4 h. The reaction was monitored by LC-MS until completion. The mixture was concentrated and purified by pre-HPLC to give intermediate 78 (587 mg, yield: 70%). ’ll NMR (400 MHz, DMSO-d6) 57.78 (s, 1H), 7.51 (t, J = 1.7 Hz, 1H), 7.16 (s, 1H), 6.96 - 6.66 (m, 2H), 5.37 (s, 2H), 3.84 (s, 2H), 3.63 - 3.56 (m, 4H), 3.47 - 3.37 (m, 2H), 3.03 (t, J = 6.0 Hz, 2H), 2.85 (t, J = 6.4 Hz, 2H), 1.98 (q, J = 5.9 Hz, 2H), 0.87 (t, J = 8,6, 2H), -0.015 (s, 9H).7-(difluoromethyl)-l-(5-isopropyl-l-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-lH-pyrazolo[4, 3-c]pyridin-3-yl)-6-(l -methyl-1 H-pyrazol-4-yl)-l, 2,3,4-tetrahydroquinoline (79)A solution of intermediate 78 (514 mg, 1.0 mmol) in DCM (5 mL) at room temperature was added acetone (580 mg, 10.0 mmol). The mixture was stirred at room temperature for 30 min. Then sodium triacet oxyborohydride (318 mg, 1.5 mmol) was added to this reaction, and the mixture was stirred at room temperature for 3 h. Monitor the reaction through LC / MS until the intermediate 78 was completely consumed and then the mixture was concentrated under reduced pressure. The crude residue was purified by pre-HPLC to give intermediate 79 (456 mg, yield: 82%). ’ll NMR (400 MHz, DMSO-d6) 57.78 (s, 1H), 7.52 (d, J = 0.8 Hz, 1H), 7.16 (s, 1H), 6.87 (s, 1H), 6.82 (td, J = 55.1 Hz, 6.8 Hz, 1H), 5.46 - 5.31 (m, 2H), 4.01 - 3.95 (m, 2H), 3.94 - 3.89 (m, 1H), 3.88 (s, 3H), 3.81 - 3.73 (m, 1H), 3.72 - 3.52 (m, 4H), 3.40 - 3.28 (m, 1H), 3.23 - 3.15 (m, 1H), 3.12 - 3.00 (m, 1H), 2.86 (t, J = 6.4 Hz, 2H), 1.99 (p, J = 6.1 Hz, 2H), 1.27 (dd, J = 10.6, 6.5 Hz, 6H), 0.88 (dt, J = 8.9, 6.6 Hz, 2H), -0.06 (s,9H).7-(difluoromethyl)-l-(5-isopropyl-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-3- yl)-6-(l-methyl-lH-pyrazol-4-yl)-l,2,3,4-tetrahydroquinoline (80)Intermediate 79 (400 mg, 0.72 mmol) was dissolved in THF (8 mL). Followed by 1 mL of tetrabutylammonium fluoride solution (1 M, in THF) was added into the mixture. The mixture was stirred and refluxed at 66 °C overnight. Monitor the reaction through LC / MS until the intermediate 79 was completely consumed, and then the mixture was concentrated under reduced pressure. The crude residue was purified by pre-HPLC to give intermediate 80 (159 mg, yield: 52%) as white solid.NMR (400 MIIz, DMSO-d6) 5 7.77 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 0.8 Hz, 1H), 7.14 (s, 1H), 6.87 (s, 1H), 6.81 (td, J = 55.2 Hz, 6.8 Hz, 1H), 3.95 - 3.90 (m, 2H), 3.87 (s, 3H), 3.70 - 3.53 (m, 4H), 3.37 - 3.25 (m, 1H), 3.21 - 3.09 (m, 1H), 3.01 (dd, J = 16.9, 4.4 Hz, 1H), 2.85 (t, J = 6.4 Hz, 2H), 1.99 (p, J = 6.5 Hz, 2H), 1.29 (dd, J = 8.0, 6.6 Hz, 6H).methyl (lr,4r)-4-(3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4-dihydroquinolin-l(2H)-yl)-5-isopropyl-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l-yl)cyclohexane- 1 -carboxylate (81)Step h: A solution of Intermediate 80 (150 mg, 0.35 mmol), CS2CO3 (287.8 mg, 0.88 mmol) and methyl (ls,4s)-4-((methylsulfonyl)oxy)cyclohexane-l -carboxylate 37 (181.7 mg, 0.77 mmol) in DMF (5 mL). The mixture was stirred at 80 °C for overnight. Monitor the reaction through LC / MS until the intermediate 80 was completely consumed. Then the mixture was concentrated under reduced pressure. The crude residue was purified by pre-HPLC to give intermediate 81 (69 mg, yield: 35%) as yellow solid. (Two isomers are generated by substitution at the two nitrogen atoms of the pyrazole. In Cl 8 reversed-phase chromatography, the desired compound has a slightly longer retention time than the other isomer). 'll NMR (400 MHz, DMSO-d6) 57.75 (d, J = 0.8 Hz, 1H), 7.49 (d, J = 0.8 Hz, 1H), 7.07 (s, 1H), 6.78 (s, 1H), 6.78 (td, J = 55.2 Hz, 6.8 Hz, 1H), 4.05 - 3.95 (m, 1H), 3.87 (s. 3H), 3.61 (s, 3H), 3.59 - 3.53 (m, 2H), 3.16 (s, 2H), 2.88 - 2.78 (m. 3H), 2.72 (s, 4H), 2.38 (tt, J = 12.4, 8.8, 3.6 Hz, 1H), 2.06 - 1.76 (m, 8H), 1.53 (qd, J = 13.0, 3.8 Hz, 2H), 0.97 (d, J = 6.5 Hz, 6H).(lr,4r)-4-(3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4-dihydroquinolin- l(2H)-yl)-5-isopropyl-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l-yl)cyclohexane-l- carbaldehyde (82)Intermediate 81 (60 mg, 0.10 mmol) was dissolved in anhydrous DCM (15 mL) and the solution was degassed and charged with N2 3 times. The mixture was stirred at -78 °C for 5 min followed by diisobutylaluminum hydride (25% in toluene, 0.24 mL, 0.42 mmol) was added dropwise into the mixture. The reaction mixture was stirred at -78 °C for an additional 1.5 h. The reaction was then quenched with aqueous potassium sodium tartrate, after which the mixture was warmed to room temperature and stirred for an additional 30 minutes. The resulting mixture was diluted with DCM and filtered through Celite, and the filter cake was washed with DCM. The combined organic layers were concentrated under reduced pressure. The crude residue was used directly in the next step without further purification. LC-MS m / z [M+H]+537.31.N-((lr,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohexyl)-6-(4-(((lr,4r)-4-(3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4-dihydroquinolin-l(2H)-yl)-5-isopropyl-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l-yl)cyclohexyl)methyl)piperazin- 1 -yl)pyridazine-3-carboxamide (Compound Nl)Compound Nl was synthesized from intermediate 82 and intermediate 57a following a similar procedure to that of EXAMPLE 84 (yield 30%, two steps). ’ll NMR (400 MHz, DMSO-de) 5 8.50 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 9.3 Hz, 1H), 7.76 (s, 1H), 7.61 (d, J = 8.9 Hz, 1H), 7.51 (s, 1H), 7.36 (d, J = 9.7 Hz, 1H), 7.12 (s, 1H), 6.99 - 6.58 (m, 4H), 4.20- 3.47 (m, 14H), 3.27 - 3.10 (m, 1H), 3.10 - 2.97 (m, 1H), 2.86 (s, 5H), 2.76 - 2.65 (m, 1H), 2.60 - 2.53 (m, 1H), 2.19 (s, 2H), 2.05 - 1.53 (m, 18H), 1.52 - 0.68 (m, 12H). LC-MS m / z [M+H]+974.45.EXAMPLE 1756-(4-(((lr,4r)-4-(5-acetyl-3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin-l(2H)-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l- yl)cyclohexyl)methyl)piperazin-l-yl)-N-((lr,4r)-4-phenoxycyclohexyl)pyridazine-3- carboxamide (Compound N2)General procedure for Compound N2Reagents and conditions: (a) K2CO3, DMF, 70°C, 4 h; (b) DCM, TFA, reflux; (c) HATU, DMF, Et3N, rt; (d) TFA, DCM, rt; (e) Et3N, Sodium triacetoxyborohydride, DCM, rt.(lr,4r)-4-phenoxycyclohexan-l -amine (85)A solution of phenol 83 (420.0 mg, 4.4 mmol), K2CO3 (924.9 mg, 6.7 mmol) and compound 84 (943.0 mg, 4.4 mmol) in DMF (12 mL). The mixture was stirred at 70 °C for 4 h. After complete conversion, the mixture was diluted with H2O, extracted with EtOAc, dried, and concentrated.The above crude product was dissolved in 10 mL of DCM: TFA (4:1) and stirred at room temperature for an additional 4 h. Monitor the reaction through LC / MS until the reaction was completed. Then the mixture was concentrated and purified by flash column chromatography (0-20% MeOH / DCM) to give intermediate 85 (337 mg, yield: 40%) as white solid. ’ll NMR (400 MHz, DMSO-d6) 57.31 - 7.23 (m, 2H), 6.99 - 6.88 (m, 3H), 4.34 - 4.12 (m. III), 3.16 - 3.00 (m, III), 2.15 - 2.04 (m, 211), 2.04 - 1.94 (m, 211), 1.56 - 1.35 (m, 4H).N-((lr,4r)-4-phenoxycyclohexyl)-6-(piperazin-l-yl)pyridazine-3-carboxamide (87)Intermediate 87 was synthesized from intermediates 85 and 86 following a similar procedure to that of intermediate 47b (yield 30%, two steps).JH NMR (400 MHz, DMSO-ds) 58.61 (d,.1 = 8.3 Hz, 1H), 7.91 (d,.1 = 9.5 Hz, 1H), 7.42 (d, J = 9.6 Hz, 1H), 7.33 - 7.22 (m, 2H), 6.97 - 6.93 (m, 2H), 6.93 - 6.89 (m, 1H), 4.29 (tt, J = 10.2, 4.1 Hz, 1H), 3.94 - 3.80 (m, 5H), 3.14 (t, J = 5.1 Hz, 4H), 2.09 (d, J = 5.9 Hz, 2H), 1.91 (d, J = 13.0 Hz, 2H), 1.62 (q, J = 12.9 Hz, 2H), 1.49 (q, J = 10.9, 9.3 Hz, 2H).6-(4-(((lr,4r)-4-(5-acetyl-3-(7-(difhioromethyl)-6-(l -methyl- HI-pyrazol-4-yl)-3, 4-dihydroquinolin- l(2H)-yl)-4, 5, 6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridin-l-yl)cyclohexyl)methyl)piperazin- 1 -yl)-N -((1 r,4r)-4-phenoxycyclohexy l)pyridazine-3 -carboxamide (Compound N2)Compound N2 was synthesized from intermediate 39a and intermediate 87 following a similar procedure to that of EXAMPLE 84 (yield 65%). 'll NMR (400 MHz, DMSO-d6) 5 8.56 (dd, J = 8.3, 2.3 Hz, 1H), 7.83 (dd, J = 9.5, 1.9 Hz, 1H), 7.76 (s, 1H), 7.50 (s, 1H), 7.35 (dd, J = 9.7, 3.6 Hz, 1H), 7.31 - 7.24 (m, 2H), 7.11 (d, J = 3.0 Hz, 1H), 6.98 - 6.88 (m, 4H), 6.82 - 6.77 (m, 1H), 4.29 (tt, J = 10.4, 4.2 Hz, 1H), 4.23 - 4.07 (m, 2H), 4.07 - 3.95 (m, 1H), 3.87 (s, 4H), 3.79 - 3.63 (m, 5H), 3.63 - 3.55 (m, 2H), 2.89 -2.81 (m, 3H), 2.49 - 2.44 (m. 2H), 2.34 (d, J = 7.6 Hz, 1H), 2.18 (dd, J = 7.4, 3.8 Hz, 1H), 2.15 - 2.05 (m, 4H), 2.01 - 1.86 (m, 8H), 1.86 - 1.69 (m, 3H). 1.62 (q, J = 12.7, 3H), 1.54 - 1.42 (m, 3H), 1.33 - 1.18 (m, 5H). LC-MS m / z [M+H]+902.63.EXAMPLE 176Synthesis of Compound ARi.Reagents and conditions: (a) HATU, DMF, EtsN, rt, 15 min.N-((lr,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohexyl)pyridazine-3-carboxamide (ARi)ARi was synthesized with a similar procedure to that of Intermediate 47a.rH NMR (400 MHz, DMSO-de) 59.41 (dd, J = 5.0, 1.7 Hz, 1H), 9.01 (d, J = 8.3 Hz, 1H), 8.21 (dd, J =8.4, 1.7 Hz, 1H), 7.91 (dd, J = 8.4, 5.1 Hz, 1H), 7.62 (d, J = 9.0 Hz, 1H), 6.95 (d, J = 2.5 Hz, 1H), 6.84 (dd, J = 9.1, 2.5 Hz, 1H), 3.99 - 3.86 (m, 1H), 3.84 - 3.73 (m, 1H), 2.86 (s,3H), 2.00 - 1.88 (m, 2H), 1.84 - 1.65 (m, 6H).Intermediate EXAMPLE 177General Procedure for Synthesis of Intermediates 92a-c and 93a-f
[0892] Reagents and conditions: (a) HATU, DMF, EtaN, it; (b) DMF, EtjN, 65 °C; (c) DMF, NaH, 0 °C to rt; (d)DCM, TFA, reflux.(S)-N-(l-(3-(3-chloro-4-cyanophenyl)-lH-pyrazol-l-yl)propan-2-yl)-6-(piperazin-l- yl)pyridazine-3 -carboxamide (Intermediate 93a)
[0893] Intermediate 93a was synthesized with a similar procedure to that of Intermediate 47a. LC-MS m / z [M+H]+451.13.Intermediate 93b
[0894] tert-butyl 4-hydroxypiperidine-l -carboxylate (500 mg, 1.0 eq.) was dissolved in anhydrous DMF (30 mL) in an ice bath. NaH (60% in mineral oil, 1.2 eq.) was added in portions, and after 0.5 h the reaction mixture was warmed up to room temperature (rt) for 0.5 h. After that Intermediate 92c (500 mg, 1.2 eq.) was added to the reaction mixture. And the mixture was stirred at rt for additional 1 h. Followed by quenched with H2O at 0 °C, extracted with EtOAc, dried, and concentrated. The above crude product was dissolved in DCM: TFA (4:1) was added at rt. After 0.5 h, all volatile materials were removed in a rotary evaporator to afford Intermediate 93B in 65% yield. LC- MS m / z [M+H]+466.13.(S)-N-(l-(3-(3-chloro-4-cyanophenyl)-lH-pyrazol-l-yl)propan-2-yl)-2-(piperidin-4- yloxy)pyrimidine-5-carboxamide (Intermediate 93d)93d
[0895] Intermediate 93d was synthesized with a similar procedure to that of Intermediate 93b. LC-MS m / z [M+H]+466.10.EXAMPLE 1786-(4-(((lr,4R)-4-(5-acetyl-3-(7-(difluoromethyl)-6-(l-methyl-lH-pyrazol-4-yl)-3,4- dihydroquinolin- 1 (2H)-yl)-4,5,6,7-tetrahydro- 1 H-pyrazolo[4,3 -c]py ridin- 1 - yl)cyclohexyl)methyl)piperazin-l-yl)-N-((R)-l-(3-(3-...
Claims
1. What is claimed is:
1. A compound having Formula (I):CPBi— L-ARi (i).or a pharmaceutically acceptable salt thereof, wherein:CBPi is a monovalent radical of a CBP / p300 protein inhibitor;ARi is a monovalent radical of an androgen receptor inhibitor; andL is a covalent linker comprising 1-50 non-hydrogen atoms selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
2. A compound having Formula (II):(II), or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of C1-C4 alkoxy, C1-C4 haloalkyl, and halo;W is selected from the group consisting of =N- and =CH-;R2is selected from the group consisting of hydrogen and C1-C4 alkyl;m is 0, 1, 2, 3, or 4;R3is selected from the group consisting of:n = 0, 1 or 2;X is selected from the group consisting of O, -NCH3and -CH2-;U is selected from the group consisting of O, -NR3aand -CHR3a-;R3aat each occurrence is independently selected from the group consisting of hydrogen and C1-C4 alkyl;Rbis selected from the group consisting of hydrogen, optionally substituted Ci-Ce alkyl, optionally substituted C3-C6 cycloalkyl, and optionally substituted 4- to 8-membered heterocyclo;R3Cis selected from the group consisting of hydrogen and optionally substituted Ci-C6alkyl; orR3band R3ctaken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered heterocyclo;R4is selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, and optionally substituted 4- to 8-membered heterocyclo;V and Y are selected from the group consisting of -N= and -C(R5)=;R5is selected from the group consisting of hydrogen, halo, cyano, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;R6is selected from the group consisting of hydrogen, halo, cyano, optionally substituted Ci-Ce alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted 4-to 8-membered heterocyclo, optionally substituted 5- to 9-membered heteroaryl, and -ORm;Rmis selected from the group consisting of optionally substituted C1-C4 alkyl and optionally substituted C3-C6 cycloalkyl;R12is selected from the group consisting of -C(=O)R12a, -C(=O)NR12bR12c, and -C(=O)OR12d;R12ais selected from the group consisting of hydrogen C1-C4 alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl;R12bis selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl;R12Cis selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl; orR12band R12ctaken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered heterocyclo;R12dis C1-C4 alkyl;Z is absent; orZ is selected from the group consisting of -O- and -N(Rla)-;Ring A is -Cs cycloalkylenyl; and L1is -N(Rlb)-C(=O)-A, wherein the bond marked with an "A" is attached to Ring B; orRing A is 7- to 11 -membered spiroheterocyclenyl; and L1is absent; orRing A is 4- to 8-membered heterocyclenyl; and L1is absent; orRing A is 5- or 6-membered heteroarylenyl; and L1is:wherein the bond marked with an is attached to Ring B;Rlbis selected from the group consisting of hydrogen and C1-C4 alkyl;Ring B is selected from the group consisting of optionally substituted arylenyl and optionally substituted 5- to 10-membered heteroarylenyl;L2is -X1-X2-X3-X4-X5-*;wherein the bond marked with an is attached to R3;X1is absent; orX1is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, C1-C4 alkylenyl, 3- to 8-membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 11 -membered helerocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;X2is absent; orX2is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, Ci-Cs alkylenyl, 3- to 8-membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;X3is absent; orX3is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, Ci-Cs alkylenyl, 3- to 11 -membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;X4is absent; orX4is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, C1-C4 alkylenyl, 3- to 11 -membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;X5is absent; orX5is selected from the group consisting of -O-, -N(Rla)-, -C(=O)-, -CH=CH-, -C=C-, C1-C4 alkylenyl, 3- to 8-membered heteroalkylenyl, Ca-Cs cycloalkylenyl, 4- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl; and each Rlais independently selected from the group consisting of hydrogen and C1-C4 alkyl.
3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, having Formula (III):wherein M1and M2are -C(CH3)2-; or M1and M2are --CH2CH2-.
4. The compound of claims 2 or 3, or a pharmaceutically acceptable salt thereof, wherein Z is -O-.
5. The compound of claims 2 or 3, or a pharmaceutically acceptable salt thereof, wherein Z is -N(Rla)-.
6. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein Rlais hydrogen or methyl.
7. The compound of claim 2, or a pharmaceutically acceptable salt thereof, having Formula (IV):(IV).
8. The compound of claims 2 or 7, or a pharmaceutically acceptable salt thereof, wherein R2is methyl.
9. The compound of claim 2, or a pharmaceutically acceptable salt thereof, having Formula (V):(V).
10. The compound of claim 2, or a pharmaceutically acceptable salt thereof, having Formula (VI):(VI).
11. The compound of claim 2, or a pharmaceutically acceptable salt thereof, having Formula (VIT):
12. The compound of any one of claims 2-11, or a pharmaceutically acceptable salt thereof, wherein R1is selected from the group consisting of chloro, trifluoromethyl, and methoxy.
13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R1is chloro.
14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R1is trifluoromethyl.
15. The compound of any one of claims 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-l.
16. The compound of any one of claims 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-2.
17. The compound of claims 15 or 16, or a pharmaceutically acceptable salt thereof, wherein R4is hydrogen.
18. The compound of claims 15 or 16, or a pharmaceutically acceptable salt thereof, wherein R4is optionally substituted C1-C4 alkyl.
19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R4is selected from the group consisting of methyl, isopropyl, and20. The compound of claims 15 or 16, or a pharmaceutically acceptable salt thereof, wherein R4is optionally substituted 4- to 8-membered heterocyclo.
21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein R4is selected from the group consisting of:
22. The compound of any one of claims 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-3.
23. The compound of any one of claims 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-4.
24. The compound of any one of claims 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-5.
25. The compound of any one of claims 2-14, or a pharmaceutically acceptable salt thereof, wherein R3is R3-6.
26. The compound of any one of claims 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is hydrogen.
27. The compound of any one of claims 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is halo.
28. The compound of any one of claims 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is cyano.
29. The compound of any one of claims 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is optionally substituted 5- or 6-membered heteroaryl.
30. The compound of claim 29, or a pharmaceutically acceptable salt thereof, wherein R6is:
31. The compound of any one of claims 22-25, or a pharmaceutically acceptable salt thereof, wherein R6is optionally substituted 4 to 8-membered heterocyclo.
32. The compound of claim 31, or a pharmaceutically acceptable salt thereof, wherein R6is:
33. The compound of any one of claims 23-32, or a pharmaceutically acceptable salt thereof, wherein R3aat each occurrence is independently selected from the group consisting of hydrogen and methyl.
34. The compound of claim 33, or a pharmaceutically acceptable salt thereof, wherein R3aat each occurrence is methyl.
35. The compound of any one of claims 15-34, or a pharmaceutically acceptable salt thereof, wherein R12is -C(=O)R12a.
36. The compound of any one of claims 15-34, or a pharmaceutically acceptable salt thereof, wherein R12is -C(=O)NHR12a.
37. The compound of claims 35 or 36, or a pharmaceutically acceptable salt thereof, wherein R12ais C1-C4 alkyl.
38. The compound of claim 37, or a pharmaceutically acceptable salt thereof, wherein R12ais methyl.
39. The compound of any one of claims 15-38, or a pharmaceutically acceptable salt thereof, wherein Y is -N=.
40. The compound of any one of claims 15-38, or a pharmaceutically acceptable salt thereof, wherein Y is -C(R3)=.
41. The compound of claim 40, or a pharmaceutically acceptable salt thereof, wherein R5is -CHF2.
42. The compound of any one of claims 2-41, or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted arylenyl.
43. The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted phenylenyl.
44. The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein Ring B is selected from the group consisting of:wherein bond marked with an is attached to L2.
45. The compound of any one of claims 2-41, or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted 5- to 10-membered heteroarylenyl.
46. The compound of claim 45, or a pharmaceutically acceptable salt thereof, wherein Ring B is selected from the group consisting of:wherein bond marked with an is attached to L2.
47. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is absent.
48. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -O-.
49. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -N(Rla)-.The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -C(=O)-.
51. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -CH=CH-.
52. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is -C=C-.
53. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is C1-C4 alkylenyl.
54. The compound any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is 3- to 8-membered heteroalkylenyl.
55. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is Cb-Cs cycloalkylenyl.
56. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is 4- to 11 -membered heterocyclenyl.
57. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is arylenyl.
58. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein X1is 5- to 9-membered heteroarylenyl.
59. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is absent.
60. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -O-.
61. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -N(Rla)-.
62. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -C(=O)-.
63. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -CH=CH-.
64. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is -C=C-.
65. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is C1-C8 alkylenyl.
66. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is 3- to 8-membered heteroalkylenyl.
67. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is C3-C8 cycloalkylenyl.
68. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is 4- to 8-membered heterocyclenyl.
69. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is arylenyl.
70. The compound of any one of claims 2-58, or a pharmaceutically acceptable salt thereof, wherein X2is 5- to 9-membered heteroarylenyl.
71. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is absent.
72. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is -O-.
73. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is -N(Rla)-74. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X5is -C(=O)-75. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is -CH=CH-.
76. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X5is -C=C-.
77. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is C1-C8 alkylenyl.
78. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is 3- to 11 -membered heteroalkylenyl.
79. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is C3-C8 cycloalkylenyl.
80. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is 4- to 8-membered heterocyclenyl.
81. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X3is arylenyl.
82. The compound of any one of claims 2-70, or a pharmaceutically acceptable salt thereof, wherein X5is 5- to 9-membered heteroarylenyl.
83. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is absent.
84. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -O-.
85. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -N(Rla)-.
86. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -C(=O)-.
87. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -CH=CH-.
88. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is -C=C-.
89. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is C1-C4 alkylenyl.
90. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is 3- to 11 -membered heteroalkylenyl.
91. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is Cr-Cs cycloalkylenyl.
92. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is 4- to 8-membered heterocyclenyl.
93. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is arylenyl.
94. The compound of any one of claims 2-82, or a pharmaceutically acceptable salt thereof, wherein X4is 5- to 9-membered heteroarylenyl.
95. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is absent.
96. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is -O-.
97. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is -N(Rla)-.
98. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is -C(=O)-.
99. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X3is -CH=CH-.
100. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is -C=C-.
101. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is C1-C4 alkylenyl.
102. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X3is 3- to 8-membered heteroalkylenyl.
103. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is C3-C8 cycloalkylenyl.
104. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is 4- to 8-membered heterocyclenyl.
105. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is arylenyl.
106. The compound of any one of claims 2-94, or a pharmaceutically acceptable salt thereof, wherein X5is 5- to 9-membered heteroarylenyl.
107. The compound of any one of claims 2-46, or a pharmaceutically acceptable salt thereof, wherein L2is selected from the group consisting of:
108. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is any one or more of the compounds of Table 1.
109. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
110. A pharmaceutical composition comprising the compound of any one of claims 1-109, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
111. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1-109, or a pharmaceutically acceptable salt or solvate thereof.
112. The method of claim 111, wherein the cancer is prostate cancer.
113. The method of claims 111 or 112 further comprising administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of cancer.
114. A kit comprising the compound of any one of claims 1-109, or a pharmaceutically acceptable salt or solvate thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt or solvate thereof, to a subject having cancer.
115. The kit of claim 114, wherein the cancer is prostate cancer.
116. A method of inhibiting CBP / P300 proteins and androgen receptors within a cell of a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1-109, or a pharmaceutically acceptable salt or solvate thereof.
117. A compound having Formula (VIII):(VIII),or a salt thereof, wherein:R4is selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, optionally substituted (’?-(>> cycloalkyl, and optionally substituted 4- to 8-membered heterocyclo;Y is selected from the group consisting of -N= and -C(R:’)=;R5is selected from the group consisting of hydrogen, halo, cyano, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;R7is:Ring C is selected from the group consisting of Cs-Cs cycloalkylenyl, 3- to 8-membered heterocyclenyl, arylenyl, and 5- to 9-membered heteroarylenyl;R8is selected from the group consisting of hydrogen, halo, hydroxy, amino, -C=CH, -CHO, and -C(=O)OR9;R9is selected from the group consisting of hydrogen and C1-C6alkyl;R12is selected from the group consisting of -C(=O)R12a, -C(=O)NR12bR12c, and -C(=O)OR12d;R12ais selected from the group consisting of hydrogen, C1-C4 alkyl, and C3-C6 cycloalkyl;R12his selected from the group consisting of hydrogen, C1-C4 alkyl, and C3-C6 cycloalkyl;R12Cis selected from the group consisting of hydrogen, C1-C4 alkyl, and C3-C6 cycloalkyl; orR12band R12ctaken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered heterocyclo; andR12dis C1-C4 alkyl.
118. 1'he compound of claim 117, or a salt thereof, wherein R4is hydrogen.
119. The compound of claim 117, or a salt thereof, wherein R4is optionally substituted C1-C4 alkyl.
120. The compound of claim 119, or a salt thereof, wherein R4is selected from the group consisting of methyl, isopropyl, and121. The compound of claim 117, or a salt thereof, wherein R4is optionally substituted 4- to 8-membered heterocyclo.
122. The compound of claim 121, or a salt thereof, wherein R4is selected from the group consisting of:
123. The compound of any one of claims 117-122, or a salt thereof, wherein Y is -N=.
124. The compound of any one of claims 117-122, or a salt thereof, wherein Y is -C(R5)=.
125. The compound of claim 124, or a salt thereof, wherein R3is hydrogen.
126. The compound of claim 124, or a salt thereof, wherein R5is halo.
127. The compound of claim 124, or a salt thereof, wherein R5is cyano.
128. The compound of claim 124, or a salt thereof, wherein R5is -CHF2.
129. The compound of any one of claims 117-128, or a salt thereof, wherein Ring C is C3-C8 cycloalkylenyl.
130. The compound of any one of claims 117-128, or a salt thereof, wherein Ring C is 3- to 8-membered heterocyclenyl.
131. The compound of any one of claims 117-128, or a salt thereof, wherein Ring C is phenylenyl.
132. The compound of any one of claims 117-128, or a salt thereof, wherein Ring C is 5- to 9-membered heteroarylenyl.
133. The compound of any one of claims 117-132, or a salt thereof, wherein R8is hydrogen.
134. The compound of any one of claims 117-132, or a salt thereof, wherein R8is halo.
135. The compound of any one of claims 117-132, or a salt thereof, wherein R8is hydroxy.
136. The compound of any one of claims 117-132, or a salt thereof, wherein R8is amino.
137. The compound of any one of claims 117-132, or a salt thereof, wherein R8is -( =(’11.
138. The compound of any one of claims 117-132, or a salt thereof, wherein R8is -CHO.
139. The compound of any one of claims 117-132, or a salt thereof, wherein R8is -C(=O)OR9.
140. The compound of claim 139, or a salt thereof, wherein R9is hydrogen.
141. The compound of claim 139, or a salt thereof, wherein R9is t-butyl.
142. The compound of claim 117, or a salt thereof, wherein R7is selected from the group consisting of:
143. The compound of claim 117, or a salt thereof, wherein R7is selected from the group consisting of:
144. The compound of any one of claims 117-143, or a salt thereof, wherein R12is -C(=O)R12a.
145. The compound of any one of claims 117-143, or a salt thereof, wherein R12is -C(=O)NHR12a.
146. The compound of claims 144 or 145, of a salt thereof, wherein R12ais Ci- C4 alkyl.
147. The compound of claim 146, or a salt thereof, wherein R12ais methyl.
148. A compound having Formula (IX):or a salt thereof, wherein:R1is selected from the group consisting of C1-C4 alkoxy, C1-C4 haloalkyl, and halo;W is selected from the group consisting of =N- and =CH-;R2is selected from the group consisting of hydrogen and C1-C4 alkyl;m is 0, 1, 2, 3, or 4;Z is absent; orZ is selected from the group consisting of -O- and -N(Rla)-;Ring A is C4-C8 cycloalkylenyl; and L1is -N(Rlb)-C(=O)-A, wherein the bond marked with an "A" is attached to R10; orRing A is 7- to 11 -membered spiroheterocyclenyl; and L1is absent; orRing A is 4- to 8-membered heterocyclenyl; and L1is absent; orRing A is 5- or 6-membered heteroarylenyl; and L1is:wherein the bond marked with an is attached to R10;Rlbis selected from the group consisting of hydrogen and C1-C4 alkyl;R10is:Ring D is selected from the group consisting of optionally substituted aryl, optionally substituted 5- to 10-membered heteroaryl, and optionally substituted 7- to 11-membered spiroheterocyclenyl;R11is absent; orR11is selected from the group consisting of halo, hydroxy, amino, -N3, optionally substituted C1-C4 alkyl, C2-C3 alkynyl, -C(=O)ORlc, -N(Rla)C(=O)Rlc, optionally substituted 4- to 7-membered heterocyclo, -O- (optionally substituted 4- to 7-membered heterocyclo), optionally substituted 7- to 11 -membered spiroheterocyclenyl, and boronic ester;each Rlcis independently selected from the group consisting of hydrogen, C1-C4 alkyl, and optionally substituted C5-C6 aryl; andeach Rlais independently selected from the group consisting of hydrogen and C1-C4 alkyl.
149. The compound of claim 148, or a salt thereof, wherein R1is halo.
150. The compound of claim 149, or a salt thereof, wherein R1is chloro.
151. The compound of claim 148, or a salt thereof, wherein R1is C1-C4 alkoxy.
152. The compound of claim 151, or a salt thereof, wherein R1is methoxy.
153. The compound of claim 148, or a salt thereof, wherein R1is C1-C4 haloalkyl.
154. The compound of any one of claims 148-153, or a salt thereof, wherein W is =N-.
155. The compound of any one of claims 148-153, or a salt thereof, wherein W is =CH-.
156. The compound of any one of claims 148-153, or a salt thereof, wherein Z is absent.
157. The compound of any one of claims 148-153, or a salt thereof, wherein Z is -O-.
158. The compound of any one of claims 148-153, or a salt thereof, wherein Z is -N(Rla)-.
159. The compound of claim 158, wherein Rlais hydrogen or methyl.
160. The compound of any one of claims 148-159, or a salt thereof, wherein m is 0.
161. The compound of any one of claims 148-159, or a salt thereof, wherein m is 1, 2, 3, or 4.
162. The compound of claim 161, or a salt thereof, wherein R2is C1-C4 alkyl.
163. 1'he compound of claim 162, or a salt thereof, wherein R2is methyl.
164. The compound of any one of claims 148-163, or a salt thereof, wherein Ring A is C4-C8 cycloalkylenyl.
165. The compound of any one of claims 148-163, or a salt thereof, wherein Ring A is 7- to 11 -membered spiroheterocyclenyl.
166. The compound of any one of claims 148-163, or a salt thereof, wherein:is selected from the group consisting of:
168. A ternary complex comprising an androgen receptor, the compound of any one of claims 1-109, or a pharmaceutically acceptable salt thereof, and a CBP / p300 protein.
